<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id>
<journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id>
<journal-id journal-id-type="publisher-id">ijms</journal-id>
<journal-title-group>
<journal-title>International Journal of Molecular Sciences</journal-title>
</journal-title-group>
<issn pub-type="epub">1422-0067</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31878022</article-id>
<article-id pub-id-type="pmc">6981491</article-id>
<article-id pub-id-type="doi">10.3390/ijms21010119</article-id>
<article-id pub-id-type="publisher-id">ijms-21-00119</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Amino Acid Transport Defects in Human Inherited Metabolic Disorders</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6789-1563</contrib-id>
<name>
<surname>Yahyaoui</surname>
<given-names>Raquel</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-21-00119">1</xref>
<xref ref-type="aff" rid="af2-ijms-21-00119">2</xref>
<xref ref-type="corresp" rid="c1-ijms-21-00119">*</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5515-3034</contrib-id>
<name>
<surname>Pérez-Frías</surname>
<given-names>Javier</given-names>
</name>
<xref ref-type="aff" rid="af3-ijms-21-00119">3</xref>
<xref ref-type="aff" rid="af4-ijms-21-00119">4</xref>
</contrib>
</contrib-group>
<aff id="af1-ijms-21-00119"><label>1</label>Laboratory of Metabolic Disorders and Newborn Screening Center of Eastern Andalusia, Málaga Regional University Hospital, 29011 Málaga, Spain</aff>
<aff id="af2-ijms-21-00119"><label>2</label>Grupo Endocrinología y Nutrición, Diabetes y Obesidad, Instituto de Investigación Biomédica de Málaga-IBIMA, 29010 Málaga, Spain</aff>
<aff id="af3-ijms-21-00119"><label>3</label>Grupo Multidisciplinar de Investigación Pediátrica, Instituto de Investigación Biomédica de Málaga-IBIMA, 29010 Málaga, Spain; <email>jpf@uma.es</email></aff>
<aff id="af4-ijms-21-00119"><label>4</label>Departamento de Farmacología y Pediatría, Facultad de Medicina, Universidad de Málaga, 29010 Málaga, Spain</aff>
<author-notes>
<corresp id="c1-ijms-21-00119"><label>*</label>Correspondence: <email>raquelyahyaoui@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>23</day>
<month>12</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<month>1</month>
<year>2020</year>
</pub-date>
<volume>21</volume>
<issue>1</issue>
<elocation-id>119</elocation-id>
<history>
<date date-type="received">
<day>26</day>
<month>11</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>12</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© 2019 by the authors.</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Amino acid transporters play very important roles in nutrient uptake, neurotransmitter recycling, protein synthesis, gene expression, cell redox balance, cell signaling, and regulation of cell volume. With regard to transporters that are closely connected to metabolism, amino acid transporter-associated diseases are linked to metabolic disorders, particularly when they involve different organs, cell types, or cell compartments. To date, 65 different human solute carrier (SLC) families and more than 400 transporter genes have been identified, including 11 that are known to include amino acid transporters. This review intends to summarize and update all the conditions in which a strong association has been found between an amino acid transporter and an inherited metabolic disorder. Many of these inherited disorders have been identified in recent years. In this work, the physiological functions of amino acid transporters will be described by the inherited diseases that arise from transporter impairment. The pathogenesis, clinical phenotype, laboratory findings, diagnosis, genetics, and treatment of these disorders are also briefly described. Appropriate clinical and diagnostic characterization of the underlying molecular defect may give patients the opportunity to avail themselves of appropriate therapeutic options in the future.</p>
</abstract>
<kwd-group>
<kwd>SLC</kwd>
<kwd>solute carriers</kwd>
<kwd>membrane transport</kwd>
<kwd>inborn errors of metabolism</kwd>
<kwd>amino acid transporter</kwd>
<kwd>symporter</kwd>
<kwd>inherited metabolic disorders</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-ijms-21-00119" sec-type="intro">
<title>1. Introduction</title>
<p>Amino acids are key metabolites that are vital for cells and organisms. They are used as energy metabolites, are the basic elements for protein synthesis, and are precursors or aid in the biosynthesis of signaling molecules such as neurotransmitters and peptide hormones. Amino acids also play a role in the synthesis of many other molecules, such as nucleotides, polyamines, glucosamines, creatine, and related carbohydrates. In addition, amino acids are the main generators of C1 compounds (one-carbon molecules) [<xref ref-type="bibr" rid="B1-ijms-21-00119">1</xref>]. Amino acid transporters play very important roles in nutrient uptake, neurotransmitter recycling, protein synthesis, gene expression, cell redox balance, cell signaling, and regulation of cell volume [<xref ref-type="bibr" rid="B2-ijms-21-00119">2</xref>].</p>
<p>Amino acids have very diverse chemical natures and structures. In mammalian genomes, amino acid transporters are classified into solute carrier (SLC) families based on sequence similarity [<xref ref-type="bibr" rid="B3-ijms-21-00119">3</xref>]. Members of sequence-related families may share an affinity for a substrate class and/or driving force. It appears that the combination of a certain amino acid and a coupling substrate is not exclusive, e.g., the same amino acid can be transported by different mechanisms. Environmental conditions have an effect on amino acid transport systems. These transport systems adapt to specific conditions by selecting the particular coupling mode that permits them to achieve the affinity necessary for certain physiological conditions [<xref ref-type="bibr" rid="B3-ijms-21-00119">3</xref>,<xref ref-type="bibr" rid="B4-ijms-21-00119">4</xref>].</p>
<p>To date, 65 different SLC families and more than 400 transporter genes have been identified. Eleven families are known to include amino acid transporters [<xref ref-type="bibr" rid="B1-ijms-21-00119">1</xref>]. Despite the fact that most amino acid transporters have already been identified and characterized, there continues to be a substantial number of orphan transporters including in some SLC families. Amino acid transporters have recently been categorized into different systems depending on functional criteria, such as Na<sup>+</sup>-dependence and substrate preference, transport mechanism, and regulatory properties [<xref ref-type="bibr" rid="B5-ijms-21-00119">5</xref>,<xref ref-type="bibr" rid="B6-ijms-21-00119">6</xref>,<xref ref-type="bibr" rid="B7-ijms-21-00119">7</xref>,<xref ref-type="bibr" rid="B8-ijms-21-00119">8</xref>,<xref ref-type="bibr" rid="B9-ijms-21-00119">9</xref>,<xref ref-type="bibr" rid="B10-ijms-21-00119">10</xref>,<xref ref-type="bibr" rid="B11-ijms-21-00119">11</xref>,<xref ref-type="bibr" rid="B12-ijms-21-00119">12</xref>,<xref ref-type="bibr" rid="B13-ijms-21-00119">13</xref>,<xref ref-type="bibr" rid="B14-ijms-21-00119">14</xref>].</p>
<p>In general, intracellular amino acid concentrations are greater than—or at least equal to—the concentrations found in extracellular fluid. In order to concentrate amino acids within the cell, active transport mechanisms are used. Multiple amino acid transporters (e.g., systems A, N, and XAG) combine thermodynamically competent Na<sup>+</sup> influx with amino acid flux to catalyze amino acid uphill transport via secondary active transport [<xref ref-type="bibr" rid="B5-ijms-21-00119">5</xref>,<xref ref-type="bibr" rid="B6-ijms-21-00119">6</xref>,<xref ref-type="bibr" rid="B7-ijms-21-00119">7</xref>,<xref ref-type="bibr" rid="B8-ijms-21-00119">8</xref>]. Na<sup>+</sup>/K<sup>+</sup>-ATPase activity contributes to maintaining the Na<sup>+</sup> transmembrane gradient well out of equilibrium. Furthermore, some transport activities are also linked to gradients of other ions, including K<sup>+</sup>, H<sup>+</sup>, and OH<sup>−</sup> [<xref ref-type="bibr" rid="B6-ijms-21-00119">6</xref>]. In the system y+, the electrical component of the transmembrane potential difference is the driving force for cationic amino acid influx. Several different transport systems may cause uptake of a specific amino acid into a particular cell type [<xref ref-type="bibr" rid="B9-ijms-21-00119">9</xref>,<xref ref-type="bibr" rid="B11-ijms-21-00119">11</xref>,<xref ref-type="bibr" rid="B15-ijms-21-00119">15</xref>,<xref ref-type="bibr" rid="B16-ijms-21-00119">16</xref>]. For example, at least two secondary active transporters, known as system A and system N, as well as the system ASC (Ala/Ser/Cys) exchanger can lead to glutamine being transported into hepatocytes [<xref ref-type="bibr" rid="B11-ijms-21-00119">11</xref>]. Some members of the SLC6 family that transport neurotransmitters are Na<sup>+</sup>/Cl<sup>−</sup> dependent. Other systems related to amino acid transport are systems B<sup>0</sup> (transport for most neutral, branched, and aromatic amino acids), system L (Na<sup>+</sup>-independent transport system for neural amino acids), and system T (Na<sup>+</sup>-dependent taurine uptake).</p>
<p>An association has been found between amino acid transporter-associated diseases and metabolic disorders in instances in which transporters are closely connected to metabolism, particularly when they involve different cell types, organs, or cell compartments [<xref ref-type="bibr" rid="B17-ijms-21-00119">17</xref>,<xref ref-type="bibr" rid="B18-ijms-21-00119">18</xref>,<xref ref-type="bibr" rid="B19-ijms-21-00119">19</xref>]. <xref ref-type="table" rid="ijms-21-00119-t001">Table 1</xref> summarizes the human SLC amino acid transporters that have been identified and their respective transporter genes. In this work, the physiological functions of amino acid transporters will be described by the inherited diseases that arise from transporter impairment. The name of the amino acid transporter, gene/locus, location, phenotype MIM number, inheritance, and main clinical manifestations of these inherited metabolic diseases are summarized in <xref ref-type="table" rid="ijms-21-00119-t002">Table 2</xref>.</p>
<p>This review intends to summarize and update all the conditions in which a strong association has been found between an amino acid transporter and an inherited metabolic disorder. Many of these inherited disorders have been identified in recent years. The pathogenesis, clinical phenotype, laboratory findings, diagnosis, genetics, and treatment of these disorders are also briefly described.</p>
</sec>
<sec id="sec2-ijms-21-00119">
<title>2. Dicarboxylic Aminoaciduria (OMIM #222730)</title>
<p>Dicarboxylic aminoaciduria (DA) involves excess excretion of acidic amino acids (aspartate and glutamate) in the urine due to incomplete anionic amino acid reabsorption from the glomerular filtrate in the kidney [<xref ref-type="bibr" rid="B20-ijms-21-00119">20</xref>]. It is a rare autosomal recessive disorder caused by loss-of-function mutations in the <italic>SLC1A1</italic> gene, which encodes the excitatory amino acid transporter 3 (EAAT3). This affects glutamate and aspartate transport in the intestine, kidney, and brain [<xref ref-type="bibr" rid="B21-ijms-21-00119">21</xref>]. It was first described in 1974 [<xref ref-type="bibr" rid="B22-ijms-21-00119">22</xref>]. EAAT3 is widely expressed in the brain’s cortex, especially in the hippocampus, basal ganglia, cerebellum, and olfactory bulb. It is believed to be involved in the biosynthesis of glutathione and GABA [<xref ref-type="bibr" rid="B20-ijms-21-00119">20</xref>,<xref ref-type="bibr" rid="B23-ijms-21-00119">23</xref>]. Dicarboxylic aminoaciduria has an estimated incidence of 1:36,000, according to the results of the newborn urine-screening program that has been carried out in Québec for more than 30 years [<xref ref-type="bibr" rid="B24-ijms-21-00119">24</xref>,<xref ref-type="bibr" rid="B25-ijms-21-00119">25</xref>].</p>
<p>This disorder’s clinical features have not been widely studied. However, an association with mental retardation has been reported in two cases and with kidney stones in one case [<xref ref-type="bibr" rid="B20-ijms-21-00119">20</xref>,<xref ref-type="bibr" rid="B26-ijms-21-00119">26</xref>]. It was believed to be a mostly asymptomatic condition [<xref ref-type="bibr" rid="B27-ijms-21-00119">27</xref>], but more recent studies have shown that DA may be linked to the pathogenesis of obsessive-compulsive disorder (OCD) and schizophrenia spectrum disorders [<xref ref-type="bibr" rid="B28-ijms-21-00119">28</xref>,<xref ref-type="bibr" rid="B29-ijms-21-00119">29</xref>,<xref ref-type="bibr" rid="B30-ijms-21-00119">30</xref>,<xref ref-type="bibr" rid="B31-ijms-21-00119">31</xref>,<xref ref-type="bibr" rid="B32-ijms-21-00119">32</xref>,<xref ref-type="bibr" rid="B33-ijms-21-00119">33</xref>,<xref ref-type="bibr" rid="B34-ijms-21-00119">34</xref>].</p>
</sec>
<sec id="sec3-ijms-21-00119">
<title>3. Epileptic Encephalopathy SLC1A2-Related (OMIM #617105)</title>
<p>It has recently been reported that heterozygous de novo mutations in <italic>SCL1A2</italic> underlie severe early-onset epileptic encephalopathy [<xref ref-type="bibr" rid="B35-ijms-21-00119">35</xref>]. <italic>SLC1A2</italic> encodes excitatory amino acid transporter 2 (EAAT2), which is one of the major glutamate transporters that are expressed in astroglia. The role of SLC1A2 is to clear glutamate from the extracellular space at the synapse [<xref ref-type="bibr" rid="B36-ijms-21-00119">36</xref>]. Excessive glutamate levels can result in neurotoxicity, which may be a cause of epilepsy [<xref ref-type="bibr" rid="B37-ijms-21-00119">37</xref>]. The few cases that have been described involve an extremely severe phenotype that is characterized by the onset of seizures in the first week after birth and profound impairment of development with no detectable regression. All cases presented with multiple seizure types, including prominent tonic and myoclonic seizures, as well as spasms. One case is presented with profound growth failure and microcephaly [<xref ref-type="bibr" rid="B35-ijms-21-00119">35</xref>,<xref ref-type="bibr" rid="B37-ijms-21-00119">37</xref>,<xref ref-type="bibr" rid="B38-ijms-21-00119">38</xref>].</p>
<p>A recent study has demonstrated that the three known variants involved in this condition are localized in the trimerization domain of SLC1A2. The Leu85Pro variant reduces wild-type SLC1A2 protein localization and function via a dominant negative mechanism [<xref ref-type="bibr" rid="B39-ijms-21-00119">39</xref>]. A recent study suggests that this disorder can be caused not only by de novo mutations, but also by biallelic variants in <italic>SLC1A2</italic>. Furthermore, there is also a recessive mode of inheritance [<xref ref-type="bibr" rid="B37-ijms-21-00119">37</xref>]. Although the β-lactam antibiotic ceftriaxone has been demonstrated to increase expression of EAAT2 [<xref ref-type="bibr" rid="B40-ijms-21-00119">40</xref>] by increasing EAAT2 promoter activation [<xref ref-type="bibr" rid="B41-ijms-21-00119">41</xref>], the efficacy of ceftriaxone continues to be controversial [<xref ref-type="bibr" rid="B37-ijms-21-00119">37</xref>,<xref ref-type="bibr" rid="B42-ijms-21-00119">42</xref>].</p>
</sec>
<sec id="sec4-ijms-21-00119">
<title>4. Episodic Ataxia Type 6 SLC1A3-Related (OMIM #612656)</title>
<p>Episodic ataxia type 6 (EA6) is caused by mutations in <italic>SLC1A3</italic>. This gene encodes excitatory amino acid transporter 1 (EAA1), which is a glial glutamate transporter that clears glutamate from the synaptic cleft and regulates neurotransmitter concentrations at excitatory glutamatergic synapses [<xref ref-type="bibr" rid="B43-ijms-21-00119">43</xref>]. Heterozygous mutations in <italic>SLC1A3</italic> are associated with a broad range of clinical phenotypes. To date, a total of seven patients from four families have been reported to have infantile episodic ataxia and seizures, migraine, dysarthria, intellectual disability, intentional tremor, and, in some cases, alternating hemiplegia [<xref ref-type="bibr" rid="B44-ijms-21-00119">44</xref>,<xref ref-type="bibr" rid="B45-ijms-21-00119">45</xref>,<xref ref-type="bibr" rid="B46-ijms-21-00119">46</xref>,<xref ref-type="bibr" rid="B47-ijms-21-00119">47</xref>]. Onset typically occurs in early childhood. It is common for episodes to be triggered by emotional and physical stress [<xref ref-type="bibr" rid="B48-ijms-21-00119">48</xref>]. The clinical phenotypes differ from each other according to glutamate reuptake ability [<xref ref-type="bibr" rid="B44-ijms-21-00119">44</xref>,<xref ref-type="bibr" rid="B45-ijms-21-00119">45</xref>]. Studies of in vitro functional expression in COS-7 cells have found that mutant EAAT1 leads to a reduction in glutamate uptake compared to the wild-type channel [<xref ref-type="bibr" rid="B45-ijms-21-00119">45</xref>]. It has recently been reported that two affected members of the same family have been showing adult-onset ataxia with dysarthria and jerky ocular pursuit movements. They had a good response to acetazolamide [<xref ref-type="bibr" rid="B43-ijms-21-00119">43</xref>]. Acetazolamide is a carbonic anhydrase inhibitor that is particularly effective in episodic ataxia type 2 caused by <italic>CACNA1A</italic> gene mutations [<xref ref-type="bibr" rid="B48-ijms-21-00119">48</xref>].</p>
</sec>
<sec id="sec5-ijms-21-00119">
<title>5. Spastic Tetraplegia, Thin Corpus Callosum, and Progressive Microcephaly Linked to SLC1A4 (OMIM #616657)</title>
<p><italic>SLC1A4</italic> is a neuronal and glial gene that encodes the alanine/serine/cysteine/threonine and glutamate transporter 1 (ASCT1) [<xref ref-type="bibr" rid="B49-ijms-21-00119">49</xref>]. ASCT1 transports L-serine across the blood-brain barrier from astrocytes to the extracellular space, and, lastly, into neurons [<xref ref-type="bibr" rid="B50-ijms-21-00119">50</xref>,<xref ref-type="bibr" rid="B51-ijms-21-00119">51</xref>]. Biallelic mutations in the <italic>SLC1A4</italic> gene have been implicated as a very rare cause of neurodevelopmental disorders, including congenital microcephaly, epileptic encephalopathy, severe hypotonia, global developmental delay, spasticity that is most prominent in the lower limbs, and thin corpus callosum [<xref ref-type="bibr" rid="B49-ijms-21-00119">49</xref>,<xref ref-type="bibr" rid="B52-ijms-21-00119">52</xref>,<xref ref-type="bibr" rid="B53-ijms-21-00119">53</xref>,<xref ref-type="bibr" rid="B54-ijms-21-00119">54</xref>,<xref ref-type="bibr" rid="B55-ijms-21-00119">55</xref>]. At present, this genetic condition has been diagnosed almost exclusively in a small number of individuals of Ashkenazi Jewish descent. There is a high prevalence of heterozygous healthy carriers in this population [<xref ref-type="bibr" rid="B52-ijms-21-00119">52</xref>].</p>
</sec>
<sec id="sec6-ijms-21-00119">
<title>6. Cystinuria (OMIM #220100)</title>
<p>Cystinuria is a common genetic disorder caused by defective transport of cystine and dibasic amino acids (ornithine, lysine, and arginine) across the apical membrane of epithelial cells in the renal proximal tubules and the gastrointestinal tract mediated by the b<sup>0,+</sup> transporter [<xref ref-type="bibr" rid="B21-ijms-21-00119">21</xref>,<xref ref-type="bibr" rid="B56-ijms-21-00119">56</xref>,<xref ref-type="bibr" rid="B57-ijms-21-00119">57</xref>,<xref ref-type="bibr" rid="B58-ijms-21-00119">58</xref>,<xref ref-type="bibr" rid="B59-ijms-21-00119">59</xref>,<xref ref-type="bibr" rid="B60-ijms-21-00119">60</xref>,<xref ref-type="bibr" rid="B61-ijms-21-00119">61</xref>,<xref ref-type="bibr" rid="B62-ijms-21-00119">62</xref>,<xref ref-type="bibr" rid="B63-ijms-21-00119">63</xref>,<xref ref-type="bibr" rid="B64-ijms-21-00119">64</xref>,<xref ref-type="bibr" rid="B65-ijms-21-00119">65</xref>,<xref ref-type="bibr" rid="B66-ijms-21-00119">66</xref>]. The b<sup>0,+</sup> transporter is a heterodimer comprising rBAT (encoded by <italic>SLC3A1</italic>) and b<sup>0,+</sup> AT (encoded by <italic>SLC7A9</italic>) subunits linked by a disulfide bridge [<xref ref-type="bibr" rid="B67-ijms-21-00119">67</xref>,<xref ref-type="bibr" rid="B68-ijms-21-00119">68</xref>,<xref ref-type="bibr" rid="B69-ijms-21-00119">69</xref>,<xref ref-type="bibr" rid="B70-ijms-21-00119">70</xref>]. Hyperexcretion of cystine and dibasic amino acids in the urine is this disease’s biochemical hallmark [<xref ref-type="bibr" rid="B21-ijms-21-00119">21</xref>]. Global prevalence of cystinuria is estimated to be 1:7000, which ranges from 1:2500 in Libyan Jews (due to the founder effect) to 1:100,000 in Sweden [<xref ref-type="bibr" rid="B59-ijms-21-00119">59</xref>,<xref ref-type="bibr" rid="B61-ijms-21-00119">61</xref>,<xref ref-type="bibr" rid="B71-ijms-21-00119">71</xref>].</p>
<p>Cystine is the least soluble of the four amino acids. As such, it can crystallize in the urinary tract, which results in the formation of cystine stones in the kidney and, less frequently, in the bladder [<xref ref-type="bibr" rid="B71-ijms-21-00119">71</xref>,<xref ref-type="bibr" rid="B72-ijms-21-00119">72</xref>]. It has been estimated that 1–2% and 6–8% of urinary tract stones in adults and children, respectively, are caused by cystinuria and, thus, in the pediatric population, cystinuria is the most common genetic cause of urolithiasis [<xref ref-type="bibr" rid="B73-ijms-21-00119">73</xref>,<xref ref-type="bibr" rid="B74-ijms-21-00119">74</xref>,<xref ref-type="bibr" rid="B75-ijms-21-00119">75</xref>]. Though stones may form at any age, it most commonly occurs in the first two decades of life. Furthermore, 75% of patients develop bilateral stones [<xref ref-type="bibr" rid="B71-ijms-21-00119">71</xref>,<xref ref-type="bibr" rid="B76-ijms-21-00119">76</xref>,<xref ref-type="bibr" rid="B77-ijms-21-00119">77</xref>]. In general, men are affected more severely than women and have a higher number of stones [<xref ref-type="bibr" rid="B61-ijms-21-00119">61</xref>]. A diagnosis is usually established by confirming that stones are composed of cystine [<xref ref-type="bibr" rid="B66-ijms-21-00119">66</xref>]. Cystine stone formation may lead to complications such as obstructive uropathy and pyelonephritis. Up to 70% of patients may develop chronic kidney disease [<xref ref-type="bibr" rid="B76-ijms-21-00119">76</xref>,<xref ref-type="bibr" rid="B78-ijms-21-00119">78</xref>,<xref ref-type="bibr" rid="B79-ijms-21-00119">79</xref>].</p>
<p>Cystinuria is believed to be an autosomal recessive disorder, even if no mutations have been identified or only one mutant allele has been found, which is the case in approximately 5% of patients with cystinuria [<xref ref-type="bibr" rid="B80-ijms-21-00119">80</xref>,<xref ref-type="bibr" rid="B81-ijms-21-00119">81</xref>]. Based on genotyping, cystinuria can be classified as Type A (caused by mutations in <italic>SLC3A1</italic>) or Type B (caused by mutations in <italic>SLC7A9</italic>) [<xref ref-type="bibr" rid="B82-ijms-21-00119">82</xref>]. In cystinuria type A, heterozygous individuals have a normal amino acid urinary pattern. In cystinuria type B, heterozygous individuals usually have increased cystine and dibasic amino acid urinary excretion and may develop nephrolithiasis. Thus, it can be considered an autosomal dominant trait [<xref ref-type="bibr" rid="B83-ijms-21-00119">83</xref>]. Manifesting heterozygous individuals suggest that cystinuria type B can be transmitted in an autosomal dominant inheritance pattern with incomplete penetrance [<xref ref-type="bibr" rid="B84-ijms-21-00119">84</xref>]. Global prevalence and disease severity appear to be the same in cystinuria types A and B [<xref ref-type="bibr" rid="B66-ijms-21-00119">66</xref>]. It is possible that there is a very rare third type of cystinuria caused by a mutation in each of the two previously mentioned genes (cystinuria type AB), but it still needs to be confirmed in order to demonstrate the digenic inheritance of cystinuria [<xref ref-type="bibr" rid="B80-ijms-21-00119">80</xref>]. Molecular analyses in some families have found the co-occurrence of a single gene with two mutations and another gene with one mutation, which is compatible with an AAB or BBA genotype [<xref ref-type="bibr" rid="B85-ijms-21-00119">85</xref>,<xref ref-type="bibr" rid="B86-ijms-21-00119">86</xref>]. To date, 247 mutations have been reported in <italic>SLC3A1</italic> and 160 mutations have been reported in <italic>SLC7A9</italic> in the Human Gene Mutation Database (HBMD<sup>®</sup> Professional 2019, <uri xlink:href="http://www.hgmd.cf.ac.uk/ac/index.php">http://www.hgmd.cf.ac.uk/ac/index.php</uri>, accessed November 15, 2019) [<xref ref-type="bibr" rid="B87-ijms-21-00119">87</xref>]. Newborn urine-screening programs may detect this disorder. Some of the cystinuria patients detected via Québec’s newborn screening program developed cystine stones in their first decade of life [<xref ref-type="bibr" rid="B88-ijms-21-00119">88</xref>,<xref ref-type="bibr" rid="B89-ijms-21-00119">89</xref>].</p>
<p>In order to treat cystinuria, cystine solubility is increased by boosting urine volume and pH. Though it can be difficult to achieve in young children, hyperdiuresis is the most important component in the prevention of cystine stone formation [<xref ref-type="bibr" rid="B60-ijms-21-00119">60</xref>,<xref ref-type="bibr" rid="B61-ijms-21-00119">61</xref>,<xref ref-type="bibr" rid="B90-ijms-21-00119">90</xref>]. For the most severely affected patients, D-penicillamine and tiopronin thiols are treatment options [<xref ref-type="bibr" rid="B60-ijms-21-00119">60</xref>,<xref ref-type="bibr" rid="B91-ijms-21-00119">91</xref>]. These sulfhydryl drugs convert cystine into cysteine-penicillamine or cysteine-tiopronin, respectively, which are more soluble mixed disulfides. However, these drugs are associated with significant side effects [<xref ref-type="bibr" rid="B92-ijms-21-00119">92</xref>,<xref ref-type="bibr" rid="B93-ijms-21-00119">93</xref>].</p>
<p>The association of type A cystinuria with hypotonia and further clinical symptoms (hypotonia-cystinuria syndrome, OMIM #606407) is caused by a homozygous deletion on chromosome 2p21, which disrupts the <italic>SLC3A1</italic> gene [<xref ref-type="bibr" rid="B94-ijms-21-00119">94</xref>,<xref ref-type="bibr" rid="B95-ijms-21-00119">95</xref>,<xref ref-type="bibr" rid="B96-ijms-21-00119">96</xref>,<xref ref-type="bibr" rid="B97-ijms-21-00119">97</xref>,<xref ref-type="bibr" rid="B98-ijms-21-00119">98</xref>,<xref ref-type="bibr" rid="B99-ijms-21-00119">99</xref>]. Recently, aspartate/glutamate transporter 1 (AGT1), encoded by <italic>SLC7A13</italic>, has been identified as the second partner of rBAT. AGT1 is localized on the apical membrane of the S3 segment of the proximal tubules, where it forms a heterodimer with rBAT [<xref ref-type="bibr" rid="B100-ijms-21-00119">100</xref>]. It has yet to be determined if <italic>SLC7A13</italic> mutations could help explain the isolated cystinuria observed in patients who still do not have any detectable mutation in <italic>SLC3A1</italic> and <italic>SLC7A9</italic> [<xref ref-type="bibr" rid="B101-ijms-21-00119">101</xref>].</p>
</sec>
<sec id="sec7-ijms-21-00119">
<title>7. Hyperekplexia 3 (OMIM #614618)</title>
<p>Hyperekplexia is a potentially treatable and rare neurological disorder that is characterized by an exaggerated startle reflex caused by external stimuli (noise or touch) and generalized muscle stiffness. It presents in neonates immediately or soon after birth [<xref ref-type="bibr" rid="B102-ijms-21-00119">102</xref>,<xref ref-type="bibr" rid="B103-ijms-21-00119">103</xref>]. Hyperekplexia has been discovered in genetic screening studies to be genetically heterogeneous. The primary cause has been determined to be several missense and nonsense mutations in the postsynaptic glycine receptor (GlyR) alpha-1 subunit gene (<italic>GLRA1</italic>). More recently, a presynaptic component to this disease has been demonstrating with missense, nonsense, and frameshift mutations identified in the glycine transporter GlyT2 gene, <italic>SLC6A5</italic> (hyperekplexia 3) [<xref ref-type="bibr" rid="B104-ijms-21-00119">104</xref>]. GlyT2 is mainly expressed in glycinergic neurons in the spinal cord, where it is present in the pre-synaptic membrane, which recaptures released neurotransmitters. In order to extend the amount of time glycine remains in the synaptic cleft and, thereby, activate glycine receptors more strongly, this transporter can be blocked. This would, in turn, enhance inhibition, and explain the stiffness observed after being startled [<xref ref-type="bibr" rid="B21-ijms-21-00119">21</xref>,<xref ref-type="bibr" rid="B105-ijms-21-00119">105</xref>]. The transmission pattern is consistent with autosomal recessive inheritance, even though some patients present with an autosomal dominant inheritance pattern [<xref ref-type="bibr" rid="B102-ijms-21-00119">102</xref>].</p>
<p>Although the symptoms of hyperekplexia have been clearly defined, it may be mistaken for neonatal epilepsy and, consequently, diagnosis may be delayed. One aspect that does distinguish this disease from epileptic seizures is the fact that patients with hyperekplexia remain conscious during the tonic-jittery attacks [<xref ref-type="bibr" rid="B103-ijms-21-00119">103</xref>]. Symptoms usually decrease during the first years of life, but the excessive startle response can continue well into adulthood. This can lead to unprotected falls, which may cause serious injuries [<xref ref-type="bibr" rid="B106-ijms-21-00119">106</xref>]. Hyperekplexia can cause serious consequences in some patients, including sudden infant death due to episodes of apnea and/or brain damage [<xref ref-type="bibr" rid="B21-ijms-21-00119">21</xref>]. It is much less likely that patients with hyperekplexia who have a benign phenotype and <italic>SLC6A5</italic> variants will develop recurrent infantile apnea compared to patients who have <italic>GLRA1</italic> variants. On the other hand, developmental delays are more alike in patients with <italic>SLC6A5</italic> variants than in those with <italic>GLRA1</italic> variants [<xref ref-type="bibr" rid="B107-ijms-21-00119">107</xref>]. Hyperekplexia management may include medication with an allosteric potentiator of the inhibitory GABA<sub>A</sub> receptor, clonazepam [<xref ref-type="bibr" rid="B103-ijms-21-00119">103</xref>]. It has also been demonstrated that stimulation of P2X purinergic receptors with βγ-methylene adenosine 5′-triphosphate induces upregulation of GlyT2 transport activity via an increase in total and plasma membrane expression as well as a reduction in transporter ubiquitination [<xref ref-type="bibr" rid="B108-ijms-21-00119">108</xref>]. Another therapeutic strategy is maternal soothing, which has been observed to halt hyperekplexia attacks on numerous occasions [<xref ref-type="bibr" rid="B103-ijms-21-00119">103</xref>].</p>
</sec>
<sec id="sec8-ijms-21-00119">
<title>8. Retinal Dystrophy SLC6A6-Related</title>
<p>The retina is one of the tissues in the body with the greatest amount of taurine because of high concentrations in the photoreceptor layer. Taurine concentration peaks during retina formation and remains high in adulthood, which indicates a role in both photoreceptor development and maintenance [<xref ref-type="bibr" rid="B109-ijms-21-00119">109</xref>]. The transmembrane sodium-dependent taurine transporter (TAUT) transports nutritional taurine into retinal pigment epithelium cells, which supply it to the photoreceptor cells [<xref ref-type="bibr" rid="B110-ijms-21-00119">110</xref>]. A recent study on a consanguineous family reported that a biallelic mutation of human <italic>SLC6A6</italic>, which encodes the TAUT, is linked to early-onset pan-retinal degeneration. Functional studies have demonstrated that <sup>3</sup>H-taurine uptake by peripheral blood mononuclear cells was reduced by 95% and taurine levels were severely reduced in plasma, skeletal muscle, and the brain. Extraocular dysfunctions that were present in <italic>Slc6a6</italic><sup>−/−</sup> mice have not been observed in the studied patients, but significantly increased urinary excretion of 8-oxo-7,8-dihydroguanosine indicated to be generally enhanced oxidative stress and RNA oxidation [<xref ref-type="bibr" rid="B109-ijms-21-00119">109</xref>]. Taurine substitution will likely not be effective because of taurine impaired renal reabsorption, but the use of taurine conjugates taken up into cells could be a promising therapeutic approach [<xref ref-type="bibr" rid="B109-ijms-21-00119">109</xref>].</p>
</sec>
<sec id="sec9-ijms-21-00119">
<title>9. Glycine Encephalopathy with Normal Serum Glycine (OMIM #617301)</title>
<p>In 2016, a new type of nonketotic hyperglycinemia that arises from biallelic mutations in the <italic>SLC6A9</italic> gene, which encodes glycine transporter 1 (GLYT1), was reported [<xref ref-type="bibr" rid="B111-ijms-21-00119">111</xref>]. GLYT1 is mainly located in the caudal regions of the brain (spinal cord, brain stem, and cerebellum), mainly in astrocytes [<xref ref-type="bibr" rid="B112-ijms-21-00119">112</xref>]. It is key for the transport of glycine from the extracellular space and glycinergic transmission termination [<xref ref-type="bibr" rid="B113-ijms-21-00119">113</xref>,<xref ref-type="bibr" rid="B114-ijms-21-00119">114</xref>].</p>
<p>To date, only six cases from three families have been described in the literature [<xref ref-type="bibr" rid="B111-ijms-21-00119">111</xref>,<xref ref-type="bibr" rid="B115-ijms-21-00119">115</xref>]. The first case described was in a patient from Saudi Arabia and the other five were from Israel. All patients reported in the literature had neonatal disease onset, respiratory failure with a requirement for mechanical ventilation, severe hypotonia at birth and subsequent limb hypertonicity, and startle-like responses caused by tactile stimulation and sudden loud sounds. In addition, dysmorphic features, musculoskeletal system abnormalities (joint laxity, hip dislocation, hyperextension of knees, or other musculoskeletal abnormalities), abnormal antenatal findings, abnormal brain magnetic resonance imaging (MRI), high glycine concentrations in cerebrospinal fluid, and a high cerebrospinal fluid to plasma glycine ratio were also found in these patients [<xref ref-type="bibr" rid="B111-ijms-21-00119">111</xref>,<xref ref-type="bibr" rid="B112-ijms-21-00119">112</xref>,<xref ref-type="bibr" rid="B115-ijms-21-00119">115</xref>]. The abnormal antenatal findings were cervical cysts, nuchal translucency, clenched fists, fourth ventriculomegaly, bilateral clubfeet, overriding toes, hyperextension of the knees, joint contractures, arthrogryposis, and hydrops fetalis [<xref ref-type="bibr" rid="B111-ijms-21-00119">111</xref>,<xref ref-type="bibr" rid="B112-ijms-21-00119">112</xref>,<xref ref-type="bibr" rid="B115-ijms-21-00119">115</xref>]. In addition to the previously mentioned clinical findings, a diagnosis can be made based on high cerebrospinal fluid glycine levels, normal plasma glycine levels, an elevated cerebrospinal fluid to plasma glycine ratio, and genetic testing for <italic>SLC6A9</italic> mutations [<xref ref-type="bibr" rid="B112-ijms-21-00119">112</xref>]. There is currently no curative treatment available. Disease management is exclusively supportive.</p>
</sec>
<sec id="sec10-ijms-21-00119">
<title>10. Mental Retardation, Autosomal Recessive 48 (OMIM #616269)</title>
<p>In 2015, a report was published on two families of different ethnic backgrounds with autosomal recessive intellectual disability who were studied via a combination of homozygosity mapping and exome sequencing [<xref ref-type="bibr" rid="B116-ijms-21-00119">116</xref>]. Using these approaches, the authors identified two missense variants in the <italic>SLC6A17</italic> gene that segregated with the phenotype. The in silico and in vitro analysis provided evidence of the causal effects of the identified mutations [<xref ref-type="bibr" rid="B116-ijms-21-00119">116</xref>]. The <italic>SLC6A17</italic> gene encodes a vesicular transporter protein known as XT1 or NTT4 [<xref ref-type="bibr" rid="B117-ijms-21-00119">117</xref>]. This protein, which functions as a selective transporter of four amino acids (Pro, Gly, Leu, Ala) as well as Glu and is involved in regulating glutamatergic synapses, is mainly localized in the nervous system in glutamatergic and some GABAergic neurons [<xref ref-type="bibr" rid="B118-ijms-21-00119">118</xref>,<xref ref-type="bibr" rid="B119-ijms-21-00119">119</xref>,<xref ref-type="bibr" rid="B120-ijms-21-00119">120</xref>,<xref ref-type="bibr" rid="B121-ijms-21-00119">121</xref>].</p>
<p>Based on the two families’ clinical features, the phenotypic spectrum comprises moderate-to-severe intellectual disability with nearly no speech development, progressive tremors, and behavioral problems. Severely impaired motor development that may possibly prevent independent walking has also been observed. No distinctive facial phenotypes have been noted [<xref ref-type="bibr" rid="B116-ijms-21-00119">116</xref>].</p>
</sec>
<sec id="sec11-ijms-21-00119">
<title>11. Hartnup Disorder (OMIM #234500)</title>
<p>The Hartnup disorder is an autosomal recessive inherited disorder caused by mutations in <italic>SLC6A19</italic>, which encodes the neutral amino acid transporter B<sup>0</sup>AT1 [<xref ref-type="bibr" rid="B122-ijms-21-00119">122</xref>,<xref ref-type="bibr" rid="B123-ijms-21-00119">123</xref>]. It affects neutral amino acid transport across the apical brush border membrane of the renal proximal tubule and intestinal epithelium, which leads to impaired intestinal uptake and tubular reabsorption of all neutral amino acids [<xref ref-type="bibr" rid="B124-ijms-21-00119">124</xref>,<xref ref-type="bibr" rid="B125-ijms-21-00119">125</xref>]. The transporter is associated with partner proteins, which are necessary for its expression. These partner proteins are collectrin in the kidney and angiotensin-converting enzyme 2 in the intestine, which are both components of the renin angiotensin system [<xref ref-type="bibr" rid="B126-ijms-21-00119">126</xref>]. The major clinical symptoms of Hartnup disorder are pellagra-like dermatitis, intermittent cerebellar ataxia, and other neurologic and neuropsychiatric symptoms, which closely resemble those of dietary niacin deficiency [<xref ref-type="bibr" rid="B127-ijms-21-00119">127</xref>,<xref ref-type="bibr" rid="B128-ijms-21-00119">128</xref>]. A diagnosis can be made by confirming the characteristic excess of neutral amino acids in the urine and low-normal or normal plasma concentrations. Systemic tryptophan deficiency is key in the development of neuropsychiatric symptoms, given that tryptophan is the precursor of the neurotransmitter serotonin. Most importantly, a tryptophan deficiency leads to decreased niacin and nicotinamide availability, which may explain the pellagra-like dermatitis. This dermatitis responds to niacin supplementation [<xref ref-type="bibr" rid="B21-ijms-21-00119">21</xref>,<xref ref-type="bibr" rid="B125-ijms-21-00119">125</xref>]. The relationship between the physiopathological mechanisms of the disease and the ataxia present in some patients is still unclear [<xref ref-type="bibr" rid="B21-ijms-21-00119">21</xref>].</p>
<p>Since this disease was first described in multiple members of the Hartnup family in 1956 [<xref ref-type="bibr" rid="B128-ijms-21-00119">128</xref>], which is a considerable number of subjects who meet the biochemical diagnostic criteria have been reported. It is most often detected in newborn urine-screening programs [<xref ref-type="bibr" rid="B25-ijms-21-00119">25</xref>]. Nevertheless, most patients are asymptomatic. Symptomatic patients usually develop skin lesions and neurological problems in early childhood. These symptoms tend to improve as the patient grows older [<xref ref-type="bibr" rid="B127-ijms-21-00119">127</xref>]. Symptoms may be precipitated by sun exposure, diarrhea, fever, inadequate diet, or psychological stress. Patients occasionally present with mental retardation, seizures, or psychosis-like symptoms [<xref ref-type="bibr" rid="B129-ijms-21-00119">129</xref>]. In order to prevent these symptoms, sufficient dietary intake of niacin and an adequate amount of tryptophan is necessary. Tryptophan ethyl ester has been used to successfully circumvent the transport defect [<xref ref-type="bibr" rid="B83-ijms-21-00119">83</xref>]. Recently, a novel clinical and biochemical phenotype that mimics Hartnup disorder due to an X-linked <italic>CLTRN</italic> mutation (collectrin deficiency) has been reported [<xref ref-type="bibr" rid="B130-ijms-21-00119">130</xref>].</p>
</sec>
<sec id="sec12-ijms-21-00119">
<title>12. Iminoglycinuria (OMIM #242600) and Hyperglycinuria (OMIM #138500)</title>
<p>The imino acids hydroxyproline and proline use the same renal tubular reabsorption mechanism as glycine. Iminoglycinuria is an autosomal recessive disorder that is expressed in homozygous individuals or individuals with combinations of mutated alleles that is associated with excessive urinary levels of proline, hydroxyproline, and glycine [<xref ref-type="bibr" rid="B21-ijms-21-00119">21</xref>,<xref ref-type="bibr" rid="B131-ijms-21-00119">131</xref>]. Several autosomal alleles including some that are partially expressed in heterozygous individuals cause the disorder. The molecular defect involves three genes: <italic>SLC36A2</italic>, which encodes the proton-dependent amino acid transporter PAT2, <italic>SLC6A20</italic>, which encodes the sodium-dependent imino acid transporter SIT1, and <italic>SLC6A19</italic>, which encodes the transporter B<sup>0</sup>AT1 [<xref ref-type="bibr" rid="B131-ijms-21-00119">131</xref>]. <italic>SLC36A2</italic> appears to be the principal gene implicated in homozygous cases of iminoglycinuria [<xref ref-type="bibr" rid="B21-ijms-21-00119">21</xref>]. Monoallelic or biallelic variants of the putative glycine transporter gene <italic>SLC6A18</italic> are also carried by some individuals (XT2), which denotes that these variants may also contribute to the phenotype [<xref ref-type="bibr" rid="B131-ijms-21-00119">131</xref>].</p>
<p>A variety of clinical symptoms have been described in cases of iminoglycinuria, including hypertension, glycosuria, nephrolithiasis, mental retardation, atypical gyrate atrophy, deafness, and blindness. Given the lack of controlled prospective studies, these associations may be the result of ascertainment bias [<xref ref-type="bibr" rid="B131-ijms-21-00119">131</xref>]. Large urine-screening studies have found iminoglycinuria to be a benign condition, with aminoaciduria only being detected retrospectively [<xref ref-type="bibr" rid="B21-ijms-21-00119">21</xref>,<xref ref-type="bibr" rid="B25-ijms-21-00119">25</xref>,<xref ref-type="bibr" rid="B124-ijms-21-00119">124</xref>]. In newborns and infants less than six months old, iminoglycinuria is a normal finding [<xref ref-type="bibr" rid="B132-ijms-21-00119">132</xref>].</p>
<p>Iminoglycinuria is generally considered to be the recessive phenotype whereas hyperglycinuria seems to be present in many but not all heterozygous individuals, which possibly presents as a dominant trait [<xref ref-type="bibr" rid="B131-ijms-21-00119">131</xref>]. An investigation of intestinal transport indicates further complexity. Intestinal proline (but not glycine) transport is affected in some families whereas, in others, intestinal transport is unaffected [<xref ref-type="bibr" rid="B132-ijms-21-00119">132</xref>].</p>
</sec>
<sec id="sec13-ijms-21-00119">
<title>13. Argininemia SLC7A2-Related</title>
<p>In 2019, the case of a Spanish newborn with high blood arginine levels found during newborn screening and two loss-of-function mutations in the <italic>SLC7A2</italic> gene was reported [<xref ref-type="bibr" rid="B133-ijms-21-00119">133</xref>]. This gene encodes human cationic amino acid transporter 2 (CAT-2) [<xref ref-type="bibr" rid="B134-ijms-21-00119">134</xref>]. Plasma and urinary cationic amino acids (Arg, Lys, and Orn) were high. Plasma and urinary ADMA levels as well as urinary guanidinoacetic acid levels were high at the time of diagnosis, but were normal at the two-year follow-up after following a protein-restricted diet. Currently, the child is five years old and remains asymptomatic, which presents with normal growth and psychomotor development. The disorder’s long-term natural history is not known, even though a low-protein diet is necessary to control amino acid and guanidinoacetic acid levels [<xref ref-type="bibr" rid="B133-ijms-21-00119">133</xref>]. This disorder may potentially be detected in newborn screening while screening for arginase 1 deficiency (OMIM #207800).</p>
</sec>
<sec id="sec14-ijms-21-00119">
<title>14. Lysinuric Protein Intolerance (OMIM #222700)</title>
<p>Lysinuric protein intolerance (LPI) is a rare primary inherited aminoaciduria caused by biallelic mutations in the <italic>SLC7A7</italic> gene, which encodes the HAT light chain y<sup>+</sup>LAT1 [<xref ref-type="bibr" rid="B135-ijms-21-00119">135</xref>]. In this disorder, there is defective transport of the dibasic cationic amino acids lysine, arginine, and ornithine at the basolateral membrane of epithelial cells in the renal tubules and small intestine, where the combination of y<sup>+</sup>LAT1 and 4F2hc generates an active amino acid transporter [<xref ref-type="bibr" rid="B135-ijms-21-00119">135</xref>]. Impairment of intestinal absorption and renal reabsorption of dibasic amino acids causes a metabolic derangement that is characterized by low dibasic amino acid plasma concentrations and increased urinary excretion as well as urea cycle dysfunction, which leads to hyperammonemia and orotic aciduria [<xref ref-type="bibr" rid="B21-ijms-21-00119">21</xref>].</p>
<p>The natural history of LPI has yet to be fully characterized and the clinical symptoms and severity of LPI vary. Breast-fed newborns and infants are usually asymptomatic. When formulas that have a higher protein content or supplementary foods that are high in protein are introduced, postprandial episodes of hyperammonemia usually emerge [<xref ref-type="bibr" rid="B136-ijms-21-00119">136</xref>]. At around one year of age, patients commonly develop a strong aversion to high-protein foods with failure to thrive. In addition, the spleen and liver may be moderately enlarged [<xref ref-type="bibr" rid="B137-ijms-21-00119">137</xref>]. Recurrent fractures occur frequently and rates of high, severe osteoporosis are observed from childhood to adulthood [<xref ref-type="bibr" rid="B138-ijms-21-00119">138</xref>,<xref ref-type="bibr" rid="B139-ijms-21-00119">139</xref>,<xref ref-type="bibr" rid="B140-ijms-21-00119">140</xref>]. After excessive protein intake, patients with hyperammonemia may refuse to eat or vomit and present with stupor and drowsiness, which leads to a coma. These symptoms mimic those of urea cycle deficiencies. In many cases, hyperammonemia may be triggered by starvation, infection, and stress. Some patients only show transient mild hyperammonemia after meals [<xref ref-type="bibr" rid="B137-ijms-21-00119">137</xref>,<xref ref-type="bibr" rid="B141-ijms-21-00119">141</xref>]. Some patients may present with mild normochromic or hypochromic anemia, leukopenia, and thrombocytopenia. Aggravated viral infections, such as severe varicella infection, are frequent in LPI [<xref ref-type="bibr" rid="B142-ijms-21-00119">142</xref>]. The poor growth and skeletal and immunological symptoms of LPI may be partially explained by the reduced availability of lysine, which is an essential amino acid. Renal disease is common in LPI. Disturbed proximal tubular function with mild proteinuria, tubular acidosis, and microhematuria may begin in childhood and often progress to glomerular dysfunction and end-stage renal failure [<xref ref-type="bibr" rid="B143-ijms-21-00119">143</xref>,<xref ref-type="bibr" rid="B144-ijms-21-00119">144</xref>,<xref ref-type="bibr" rid="B145-ijms-21-00119">145</xref>]. Frequent complications include bone marrow involvement with hemophagocytic lymphohistiocytosis and interstitial pulmonary disease with alveolar proteinosis [<xref ref-type="bibr" rid="B137-ijms-21-00119">137</xref>,<xref ref-type="bibr" rid="B146-ijms-21-00119">146</xref>]. A few children and adults have died following a very uniform course of progressive multiple organ failure with interstitial lung involvement, progressive glomerulonephritis, and severe bleeding diathesis [<xref ref-type="bibr" rid="B147-ijms-21-00119">147</xref>].</p>
<p>Diagnosing LPI is based on increased urinary excretion, low cationic amino acid plasma concentrations, especially lysine, and the identification of biallelic pathogenic variants in <italic>SLC7A7</italic> [<xref ref-type="bibr" rid="B148-ijms-21-00119">148</xref>,<xref ref-type="bibr" rid="B149-ijms-21-00119">149</xref>]. Finland has the largest number of patients who share the same founder mutation, c.895-2A &gt; T, which causes a frameshift mutation and leads to a premature stop codon [<xref ref-type="bibr" rid="B150-ijms-21-00119">150</xref>]. The main aims of LPI treatment are to prevent hyperammonemia and achieve normal growth and metabolism by providing a sufficient supply of protein and essential amino acids.</p>
</sec>
<sec id="sec15-ijms-21-00119">
<title>15. Retinitis Pigmentosa 68 (OMIM #615725)</title>
<p>The SLC7A14 transporter is mainly expressed in neural tissue and localized in lysosomes. It has been predicted that it mediates lysosomal uptake of cationic amino acids. <italic>SLC7A14</italic> mutations have been shown to cause autosomal recessive retinitis pigmentosa in Chinese patients [<xref ref-type="bibr" rid="B151-ijms-21-00119">151</xref>]. SLC7A14-deficient mice have been observed to have an abnormal photoreceptor layer in the retina. In this layer, SLC7A14 expression increases as the retina develops and remains high in the mature retina [<xref ref-type="bibr" rid="B151-ijms-21-00119">151</xref>]. Compound heterozygous missense mutations in the <italic>SLC7A14</italic> gene in an autosomal recessive retinitis pigmentosa case and a homozygous mutation in a case of Leber congenital amaurosis have been found in a recent study [<xref ref-type="bibr" rid="B152-ijms-21-00119">152</xref>].</p>
</sec>
<sec id="sec16-ijms-21-00119">
<title>16. Deafness, Autosomal Dominant 25 (OMIM #605583)</title>
<p>In 2001, a large Czech family with nonsyndromic, slowly progressive high-frequency sensorineural hearing loss with postlingual onset and mutations in <italic>SLC17A8</italic> was reported [<xref ref-type="bibr" rid="B153-ijms-21-00119">153</xref>]. The disorder segregated, which showed an autosomal dominant inheritance pattern. A second affected family, which was from the United States of America and of German descent, was described in 2008 [<xref ref-type="bibr" rid="B154-ijms-21-00119">154</xref>] and a Korean family with the same phenotype was described in 2017 [<xref ref-type="bibr" rid="B155-ijms-21-00119">155</xref>]. The <italic>SLC17A8</italic> gene encodes the vesicular glutamate transporter-3 (VGLUT3). This disorder may be produced by a specific defect in vesicular glutamate uptake and release, which is a process that is key in auditory coding at the sensory inner hair cell synapse [<xref ref-type="bibr" rid="B154-ijms-21-00119">154</xref>,<xref ref-type="bibr" rid="B156-ijms-21-00119">156</xref>]. An appropriate etiologic diagnosis of the genetic cause may give patients opportunities for appropriate therapeutic options in the future. In 2012, a study reported that delivering exogenous DNA by adeno-associated virus-mediated gene therapy restored hearing function in VGLUT3 knockout mice [<xref ref-type="bibr" rid="B157-ijms-21-00119">157</xref>].</p>
</sec>
<sec id="sec17-ijms-21-00119">
<title>17. Epileptic Encephalopathy, Early Infantile 39 (OMIM #612949)</title>
<p>The aspartate–glutamate carrier 1 (AGC1) protein transports intramitochondrial aspartate to the cytoplasm in exchange for glutamate and a proton [<xref ref-type="bibr" rid="B158-ijms-21-00119">158</xref>]. AGC1, which is encoded by the <italic>SLC25A12</italic> gene, is mainly expressed in the heart, skeletal muscle, and central nervous system [<xref ref-type="bibr" rid="B158-ijms-21-00119">158</xref>]. It plays a role in the transfer of nicotinamide adenine dinucleotide (NADH)-reducing equivalents from the cytosol to the mitochondria. This transfer is crucial in connecting the glycolytic and oxidative phases of glucose catabolism [<xref ref-type="bibr" rid="B158-ijms-21-00119">158</xref>]. Aspartate, which is produced in the mitochondria and exported to the cytosol, is critical for cell growth, proliferation, and synaptic transmission. Neuronal aspartate is continuously acetylated to form N-acetylaspartate (NAA) in the brain [<xref ref-type="bibr" rid="B159-ijms-21-00119">159</xref>]. NAA is transported to glial cells, especially oligodendrocytes, where it is likely used to synthesize lipids and myelin [<xref ref-type="bibr" rid="B159-ijms-21-00119">159</xref>].</p>
<p>Currently, there are a total of five patients with pathogenic <italic>SLC25A12</italic> variants described in the literature. They presented with a clinical phenotype consisting of arrested progressive encephalopathy, profound developmental delay, hypotonia, microcephaly, and myoclonic epilepsy [<xref ref-type="bibr" rid="B160-ijms-21-00119">160</xref>,<xref ref-type="bibr" rid="B161-ijms-21-00119">161</xref>,<xref ref-type="bibr" rid="B162-ijms-21-00119">162</xref>,<xref ref-type="bibr" rid="B163-ijms-21-00119">163</xref>]. In terms of neural abnormalities, two siblings described in the literature had cerebral atrophy, fluctuating basal ganglia changes, abnormal myelination, and decreased N-acetylaspartate levels, as indicated by magnetic resonance spectroscopy [<xref ref-type="bibr" rid="B160-ijms-21-00119">160</xref>]. In another patient, global cerebral hypomyelination was noted on an MRI with an absence of gray matter, basal ganglia, brainstem, or spectroscopy-measured abnormalities [<xref ref-type="bibr" rid="B161-ijms-21-00119">161</xref>]. One patient improved psychomotor functioning and resumed myelination by following a ketogenic diet [<xref ref-type="bibr" rid="B162-ijms-21-00119">162</xref>]. In the oldest patient, who had MRI results from multiples ages, the clinical presentation was consistent with leukodystrophy of the leuko-axonopathy category instead of with a primary hypo-myelinating disorder [<xref ref-type="bibr" rid="B163-ijms-21-00119">163</xref>].</p>
</sec>
<sec id="sec18-ijms-21-00119">
<title>18. AGC2 Deficiency (OMIM #605814, #603471)</title>
<p>Citrin deficiency is a rare autosomal recessive disorder that arises from a lack of function of the hepatic mitochondrial aspartate/glutamate transporter 2 (AGC2), which supplies aspartate to the cytosol for the argininosuccinate synthetase reaction, in which aspartate and citrulline condense to produce argininosuccinate [<xref ref-type="bibr" rid="B21-ijms-21-00119">21</xref>,<xref ref-type="bibr" rid="B164-ijms-21-00119">164</xref>,<xref ref-type="bibr" rid="B165-ijms-21-00119">165</xref>]. Reduced cytosolic aspartate availability results in citrullinemia and hyperammonemia. This deficiency is caused by a homozygous or compound heterozygous mutation in the <italic>SLC25A13</italic> gene [<xref ref-type="bibr" rid="B165-ijms-21-00119">165</xref>]. There are two principal clinical presentations, which are both age-dependent. Neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD, OMIM #605814) and citrullinemia type II (CTLN2, OMIM #603471), which is present in adolescents and adults [<xref ref-type="bibr" rid="B166-ijms-21-00119">166</xref>]. A third, less common presentation that may occur in childhood is failure to thrive and dyslipidemia caused by citrin deficiency (FTTDCD) [<xref ref-type="bibr" rid="B167-ijms-21-00119">167</xref>].</p>
<p>Neonatal intrahepatic cholestasis with persistent jaundice, failure to thrive, hepatomegaly, and cholestasis has been observed in a large proportion of neonates with citrin deficiency. Anemia, low plasma albumin, and impaired coagulation with prolonged prothrombin time are frequent findings. Plasma citrulline is moderately increased and levels of other amino acids such as methionine, threonine, tyrosine, serine, or phenylalanine may be elevated [<xref ref-type="bibr" rid="B168-ijms-21-00119">168</xref>,<xref ref-type="bibr" rid="B169-ijms-21-00119">169</xref>,<xref ref-type="bibr" rid="B170-ijms-21-00119">170</xref>,<xref ref-type="bibr" rid="B171-ijms-21-00119">171</xref>]. These biochemical abnormalities may be detected via newborn screening [<xref ref-type="bibr" rid="B172-ijms-21-00119">172</xref>].</p>
<p>CLTN2 can follow a period of normal health that lasts several decades. It is characterized by sudden onset of neuropsychiatric symptoms, recurrent ammonia intoxication that may lead to coma and death, and high levels of citrulline in plasma. Steatohepatitis and liver fibrosis are common complications [<xref ref-type="bibr" rid="B173-ijms-21-00119">173</xref>]. Hyperammonemia develops in CTLN2 but not in NICCD due to the fact that liver ASS is significantly decreased in CTLN2 yet is normal in NICCD [<xref ref-type="bibr" rid="B164-ijms-21-00119">164</xref>].</p>
<p>Hyperammonemic episodes in CTLN2 can be treated with IV sodium benzoate and sodium phenylacetate. Arginine should be administered and alcohol must be prohibited. Use of lactose-free or medium-chain triglyceride-enriched formula, a high protein/fat and low carbohydrate diet, and some medications (vitamin K<sub>2</sub>, lipid-soluble vitamins, and ursodeoxycholic acid) are used to treat NICCD. Sodium pyruvate may improve growth. The outcome of NICCD is generally good, with little intervention required by 12 months of age [<xref ref-type="bibr" rid="B174-ijms-21-00119">174</xref>].</p>
</sec>
<sec id="sec19-ijms-21-00119">
<title>19. Hyperornithinemia-Hyperammonemia-Homocitrullinuria (HHH) Syndrome (OMIM #238970)</title>
<p>The HHH syndrome is caused by biallelic mutations in <italic>SLC25A15</italic>, which encodes the mitochondrial ornithine-citrulline carrier 1 (ORC1) [<xref ref-type="bibr" rid="B175-ijms-21-00119">175</xref>]. The disease has a panethnic distribution. It is reported to be more prevalent in Canada, as a result of a founder mutation in Québec [<xref ref-type="bibr" rid="B176-ijms-21-00119">176</xref>] in Italy [<xref ref-type="bibr" rid="B177-ijms-21-00119">177</xref>] and in Japan [<xref ref-type="bibr" rid="B178-ijms-21-00119">178</xref>]. This metabolic compartmentation disorder involves impaired importation of ornithine into mitochondria, which results in functional deficiency of both ornithine carbamoyltransferase (OTC) and ornithine aminotransferase (OAT). The intramitochondrial deficiency of ornithine leads to utilization of carbamoyl phosphate by pathways other than the one catalyzed by OTC, including homocitrulline formation from lysine and orotic acid formation secondary to excess flux down the pyrimidine biosynthetic pathway [<xref ref-type="bibr" rid="B179-ijms-21-00119">179</xref>].</p>
<p>There is a broad spectrum of clinical manifestations that can present at any age, even though it usually manifests in early childhood. The most common symptoms are related to episodic hyperammonemia (confusion, lethargy, and coma) and neurological features such as developmental delay/intellectual disability, learning difficulties, signs of pyramidal tract dysfunction with spastic gait, cerebellar symptoms such as ataxia, and myoclonic seizures. Patients often present with liver dysfunction, which leads to reversible hepatocellular necrosis or acute hepatitis-like attacks and coagulopathy. In particular, there are reports of factor VII and X deficiencies [<xref ref-type="bibr" rid="B21-ijms-21-00119">21</xref>,<xref ref-type="bibr" rid="B179-ijms-21-00119">179</xref>,<xref ref-type="bibr" rid="B180-ijms-21-00119">180</xref>]. The HHH syndrome may also have a more chronic, slowly progressive course with an aversion to high-protein foods, progressive encephalopathy with mental regression, and symptoms of motor dysfunction [<xref ref-type="bibr" rid="B179-ijms-21-00119">179</xref>].</p>
<p>The differential diagnosis between the HHH syndrome and other hyperammonemic syndromes can be determined by the presence of the pathognomonic triad of hyperornithinemia, hyperammonemia, and homocitrullinuria. Treatment consists of preventing ammonia toxicity and a low-protein diet in addition to citrulline or arginine supplementation. Prognosis is variable. Some patients develop pyramidal dysfunction and spastic paraplegia [<xref ref-type="bibr" rid="B179-ijms-21-00119">179</xref>,<xref ref-type="bibr" rid="B181-ijms-21-00119">181</xref>].</p>
</sec>
<sec id="sec20-ijms-21-00119">
<title>20. Epileptic Encephalopathy, Early Infantile, 3 (OMIM #609304)</title>
<p>Biallelic mutations in the <italic>SLC25A22</italic> gene can cause early infantile epileptic encephalopathy-3 (EIEE3) [<xref ref-type="bibr" rid="B182-ijms-21-00119">182</xref>,<xref ref-type="bibr" rid="B183-ijms-21-00119">183</xref>]. <italic>SLC25A22</italic> encodes a glutamate/H<sup>+</sup> symporter (GC1) that is highly expressed in the brain, especially in regions involved in motor coordination (red nuclei, olivary complexes, pontocerebellar fibers, and substantia nigra) [<xref ref-type="bibr" rid="B184-ijms-21-00119">184</xref>]. GC1 is localized in the inner mitochondrial membrane and is more abundant in astrocytes, where it controls the uptake of glutamate. It catalyzes the glutamate/H+ symporter in order to transport glutamate into the mitochondria [<xref ref-type="bibr" rid="B184-ijms-21-00119">184</xref>]. The dysregulation of extracellular glutamate and the activation of the extrasynaptic glutamate receptors would result from an absence of a functional SLC25A22 protein [<xref ref-type="bibr" rid="B185-ijms-21-00119">185</xref>]. To date, 16 patients with EIEE3 have been reported [<xref ref-type="bibr" rid="B182-ijms-21-00119">182</xref>,<xref ref-type="bibr" rid="B183-ijms-21-00119">183</xref>,<xref ref-type="bibr" rid="B184-ijms-21-00119">184</xref>,<xref ref-type="bibr" rid="B186-ijms-21-00119">186</xref>,<xref ref-type="bibr" rid="B187-ijms-21-00119">187</xref>]. Onset occurs in the first months of life and patients present with myoclonic seizures, severe global hypotonia, microcephaly, a “burst suppression” pattern in the interictal electroencephalogram, and an abnormal electroretinogram [<xref ref-type="bibr" rid="B184-ijms-21-00119">184</xref>]. The prognosis of this condition is poor. Most children either die in the first two years of life or survive in a persistent vegetative state [<xref ref-type="bibr" rid="B183-ijms-21-00119">183</xref>]. In addition, <italic>SLC25A22</italic> also plays a role in the epilepsy of infancy with migrating focal seizures (EIMFS), which is a severe developmental and epileptic encephalopathy that also begins in early infancy [<xref ref-type="bibr" rid="B188-ijms-21-00119">188</xref>,<xref ref-type="bibr" rid="B189-ijms-21-00119">189</xref>].</p>
</sec>
<sec id="sec21-ijms-21-00119">
<title>21. Foveal Hypoplasia, 2 (OMIM #609218)</title>
<p>Foveal hypoplasia is characterized by preserved retinal architecture along with the absence of both the retinal foveal pit and the avascular zone. This disorder’s molecular basis is not known. Isolated foveal hypoplasia (in the absence of albinism, aniridia, microphthalmia, or achromatopsia) is exceedingly rare [<xref ref-type="bibr" rid="B190-ijms-21-00119">190</xref>]. <italic>SLC38A8</italic> encodes a sodium-coupled neutral amino acid transporter (SNAT8) that is expressed predominantly in the central nervous system and retina with a preference for glutamate as a substrate [<xref ref-type="bibr" rid="B190-ijms-21-00119">190</xref>]. Biallelic mutations in <italic>SLC38A8</italic> have been linked to a rare autosomal recessive form of foveal hypoplasia (foveal hypoplasia 2, with or without optic nerve misrouting and/or anterior segment dysgenesis). Clinical manifestations are limited to ophthalmologic symptoms, including low vision and secondary nystagmus [<xref ref-type="bibr" rid="B190-ijms-21-00119">190</xref>,<xref ref-type="bibr" rid="B191-ijms-21-00119">191</xref>,<xref ref-type="bibr" rid="B192-ijms-21-00119">192</xref>,<xref ref-type="bibr" rid="B193-ijms-21-00119">193</xref>].</p>
</sec>
<sec id="sec22-ijms-21-00119">
<title>22. Cystinosis (OMIM #219800, #219900, and #219750)</title>
<p>Cystinosis is an autosomal recessive lysosomal storage disease caused by intracellular cystine accumulation due to mutations in the <italic>CTNS</italic> gene. This gene encodes cystinosin, which is a cystine/H<sup>+</sup> symporter that exports cystine out of lysosomes into the cytosol [<xref ref-type="bibr" rid="B19-ijms-21-00119">19</xref>,<xref ref-type="bibr" rid="B194-ijms-21-00119">194</xref>,<xref ref-type="bibr" rid="B195-ijms-21-00119">195</xref>]. A defect in this transporter induces cystine accumulation in many tissues, including the kidney, bone marrow, conjunctiva, thyroid, muscle, brain parenchyma, and others. Cystinosis is classified into three clinical phenotypes: infantile nephropathic cystinosis (#219800), which is the most frequent form, late-onset juvenile nephropathic cystinosis (#219900), and ocular nonnephropathic cystinosis (#219750) [<xref ref-type="bibr" rid="B194-ijms-21-00119">194</xref>,<xref ref-type="bibr" rid="B196-ijms-21-00119">196</xref>,<xref ref-type="bibr" rid="B197-ijms-21-00119">197</xref>,<xref ref-type="bibr" rid="B198-ijms-21-00119">198</xref>,<xref ref-type="bibr" rid="B199-ijms-21-00119">199</xref>,<xref ref-type="bibr" rid="B200-ijms-21-00119">200</xref>].</p>
<p>In infantile nephropathic cystinosis, children are usually asymptomatic at birth and present with the disease between 6–12 months of age. They experience feeding difficulties, vomiting, failure to thrive, and polyuria. Fanconi syndrome is generally present (excessive urinary losses of water, glucose, amino acids, uric acid, phosphate (with hypophosphatemia), sodium, potassium, bicarbonate (leading to hypokalemia, hyponatremia, and metabolic acidosis), and low molecular-weight proteinuria). Hypercalciuria may lead to nephrocalcinosis. Untreated children develop chronic renal failure that progresses to end-stage renal disease in the first decade of life. Involvement of the eye is a primary symptom of cystinosis. Manifestations start with photophobia, which usually appears at two to three years of age [<xref ref-type="bibr" rid="B194-ijms-21-00119">194</xref>,<xref ref-type="bibr" rid="B196-ijms-21-00119">196</xref>,<xref ref-type="bibr" rid="B197-ijms-21-00119">197</xref>]. An ophthalmological examination after one year of life may reveal the presence of corneal cystine crystal deposits [<xref ref-type="bibr" rid="B201-ijms-21-00119">201</xref>].</p>
<p>In addition to the infantile form, the juvenile or intermediate form of cystinosis is usually diagnosed during childhood or adolescence. It is characterized by less severe renal symptoms [<xref ref-type="bibr" rid="B199-ijms-21-00119">199</xref>]. Nonnephropathic cystinosis involves late-onset photophobia due to corneal cystine crystals but there is an absence of renal disease [<xref ref-type="bibr" rid="B200-ijms-21-00119">200</xref>].</p>
<p>Cystinosis should be always suspected in children presenting with Fanconi syndrome since it is the most common inherited cause of Fanconi syndrome. Diagnosis is ascertained by measurement of intra-leucocyte cystine levels and confirmed by molecular analysis of the <italic>CTNS</italic> gene. Most late-onset complications are prevented by oral cysteamine [<xref ref-type="bibr" rid="B202-ijms-21-00119">202</xref>]. Regular measurements of intra-leucocyte cystine levels allow for optimization of this treatment. Corneal cystine crystals do not respond to oral cysteamine and require topical administration of cysteamine hydrochloride. Renal transplantation is the treatment of choice for patients with end-stage renal disease [<xref ref-type="bibr" rid="B202-ijms-21-00119">202</xref>,<xref ref-type="bibr" rid="B203-ijms-21-00119">203</xref>]. Compliance with cysteamine treatment is a major concern in adult patients and could have an impact on the development of neurological and cognitive complications [<xref ref-type="bibr" rid="B204-ijms-21-00119">204</xref>]. Autologous transplantation of gene-modified hematopoietic stem cells (HSCs) may be a curative therapy in the future [<xref ref-type="bibr" rid="B205-ijms-21-00119">205</xref>].</p>
</sec>
<sec id="sec23-ijms-21-00119">
<title>23. Other Possible Inherited Conditions Related to Amino Acid Transporters</title>
<p>A recent study found nine probable pathogenic variants in 11 patients with autism spectrum disorder (ASD) including three in <italic>SLC3A2</italic>, three in <italic>SLC7A5</italic>, and three in <italic>SLC7A8</italic>. <italic>SLC3A2</italic> encodes the heavy subunits and <italic>SLC7A5</italic> and <italic>SLC7A8</italic> of the light subunits of large amino acid transporters (LAT) 1 and 2. LAT1 and LAT2 are responsible for tryptophan and branched-chain amino acids (BCAA) transportation across the blood-brain barrier. They are expressed in both the brain and in blood. Functional studies have been performed, which demonstrate consistently reduced utilization of tryptophan and other large aromatic amino acids. The authors concluded that abnormalities in these transporters are likely to be associated with increased risk of developing ASD [<xref ref-type="bibr" rid="B206-ijms-21-00119">206</xref>].</p>
<p>Some cases of dibasic amino aciduria I (OMIM %222690) have been reported. Patients presented with excessive urinary excretion of lysine, ornithine, and arginine. Plasma levels of the amino acid were normal. The inheritance pattern could be autosomal dominant or recessive. Clinical manifestations include hyperactivity, mental retardation, dysarthria, athetosis, and an adverse reaction to phenothiazines. The molecular defect has yet to be identified [<xref ref-type="bibr" rid="B207-ijms-21-00119">207</xref>,<xref ref-type="bibr" rid="B208-ijms-21-00119">208</xref>,<xref ref-type="bibr" rid="B209-ijms-21-00119">209</xref>].</p>
<p>Major depression is a multifactorial disease that has both genetic and environmental risk factors. Recently, the <italic>SLC6A15</italic> gene was proposed as a new candidate gene for vulnerability to stress and major depression. This gene encodes the neutral amino acid transporter B<sup>0</sup>AT2, which is mainly expressed in neurons [<xref ref-type="bibr" rid="B210-ijms-21-00119">210</xref>]. In a <italic>SLC6A15</italic> regulatory region, risk allele carriers for a single nucleotide polymorphism (SNP) show altered glutamate levels, hippocampal volume, and hypothalamus-pituitary-adrenal axis activity. These markers are all associated with major depression [<xref ref-type="bibr" rid="B210-ijms-21-00119">210</xref>,<xref ref-type="bibr" rid="B211-ijms-21-00119">211</xref>].</p>
<p>It is presumed that the transport of aromatic amino acids, such L-tryptophan and other large neutral amino acids, across the ciliary epithelium and into the lens involves a minimum of two transporters, which include LAT2 (encoded by <italic>SLC7A8</italic>) and TAT1 (encoded by <italic>SLC16A10</italic>). Recently, a homozygous mutation in <italic>SLC7A8</italic> has been identified in a family with congenital cataracts [<xref ref-type="bibr" rid="B212-ijms-21-00119">212</xref>]. The amino acid transporter TAT1 may have a modifying influence on the development of cataracts [<xref ref-type="bibr" rid="B212-ijms-21-00119">212</xref>,<xref ref-type="bibr" rid="B213-ijms-21-00119">213</xref>].</p>
</sec>
<sec id="sec24-ijms-21-00119" sec-type="conclusions">
<title>24. Conclusions</title>
<p>Our work describes different conditions in which a strong association has been found between an amino acid transporter and an inherited metabolic disorder. Many of these inherited disorders have been identified in recent years. Understanding the physiological mechanisms that regulate these transporters, their function, and their distribution will help us better understand the pathophysiology of these diseases. Appropriate clinical and diagnostic characterization of the underlying molecular defect may give patients the opportunity to avail themselves of effective therapeutic options both now and in the future.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>The authors would like to thank Claire Alexandra Conrad for her help with the final English-language version.</p>
</ack>
<notes>
<title>Author Contributions</title>
<p>R.Y. designed, drafted, and revised the manuscript. J.P.-F. critically revised the manuscript. All authors have read and agreed to the published version of the manuscript.</p>
</notes>
<notes>
<title>Funding</title>
<p>This research received no external funding.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflict of interest.</p>
</notes>
<ref-list>
<title>References</title>
<ref id="B1-ijms-21-00119">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bröer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bröer</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Amino acid homeostasis and signalling in mammalian cells and organisms</article-title>
<source/>Biochem. J.
          <year>2017</year>
<volume>474</volume>
<fpage>1935</fpage>
<lpage>1963</lpage>
<pub-id pub-id-type="doi">10.1042/BCJ20160822</pub-id>
<pub-id pub-id-type="pmid">28546457</pub-id>
</element-citation>
</ref>
<ref id="B2-ijms-21-00119">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schweikhard</surname>
<given-names>E.S.</given-names>
</name>
<name>
<surname>Ziegler</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>Amino acid secondary transporters: Toward a common transport mechanism</article-title>
<source/>Curr. Top. Membr.
          <year>2012</year>
<volume>70</volume>
<fpage>1</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="pmid">23177982</pub-id>
</element-citation>
</ref>
<ref id="B3-ijms-21-00119">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wong</surname>
<given-names>F.H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Reddy</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Day</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Shlykov</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Wakabayashi</surname>
<given-names>S.T.</given-names>
</name>
<name>
<surname>Sailer</surname>
<given-names>M.H.</given-names>
<suffix>Jr.</suffix>
</name>
</person-group>
<article-title>The amino Acid-polyamine-organocation superfamily</article-title>
<source/>J. Mol. Microbiol. Biotechnol.
          <year>2012</year>
<volume>22</volume>
<fpage>105</fpage>
<lpage>113</lpage>
<pub-id pub-id-type="doi">10.1159/000338542</pub-id>
<pub-id pub-id-type="pmid">22627175</pub-id>
</element-citation>
</ref>
<ref id="B4-ijms-21-00119">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verrey</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Singer</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ramadan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Vuille-dit-Bille</surname>
<given-names>R.N.</given-names>
</name>
<name>
<surname>Mariotta</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Camargo</surname>
<given-names>S.M.</given-names>
</name>
</person-group>
<article-title>Kidney amino acid transport</article-title>
<source/>Pflugers Arch.
          <year>2009</year>
<volume>458</volume>
<fpage>53</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="doi">10.1007/s00424-009-0638-2</pub-id>
<pub-id pub-id-type="pmid">19184091</pub-id>
</element-citation>
</ref>
<ref id="B5-ijms-21-00119">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palacin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Estevez</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bertran</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zorzano</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Molecular biology of mammalian plasma membrane amino acid transporters</article-title>
<source/>Physiol. Rev.
          <year>1998</year>
<volume>78</volume>
<fpage>969</fpage>
<lpage>1054</lpage>
<pub-id pub-id-type="doi">10.1152/physrev.1998.78.4.969</pub-id>
<pub-id pub-id-type="pmid">9790568</pub-id>
</element-citation>
</ref>
<ref id="B6-ijms-21-00119">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Broer</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Adaptation of plasma membrane amino acid transport mechanisms to physiological demands</article-title>
<source/>Pflugers Arch.
          <year>2002</year>
<volume>444</volume>
<fpage>457</fpage>
<lpage>466</lpage>
<pub-id pub-id-type="doi">10.1007/s00424-002-0840-y</pub-id>
<pub-id pub-id-type="pmid">12136264</pub-id>
</element-citation>
</ref>
<ref id="B7-ijms-21-00119">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bussolati</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Dall’Asta</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Franchi-Gazzola</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sala</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Rotoli</surname>
<given-names>B.M.</given-names>
</name>
<name>
<surname>Visigalli</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Casado</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lopez-Fontanals</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pastor-Anglada</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gazzola</surname>
<given-names>G.C.</given-names>
</name>
</person-group>
<article-title>The role of system A for neutral amino acid transport in the regulation of cell volume</article-title>
<source/>Mol. Membr. Biol.
          <year>2001</year>
<volume>18</volume>
<fpage>27</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="doi">10.1080/09687680110033756</pub-id>
<pub-id pub-id-type="pmid">11396608</pub-id>
</element-citation>
</ref>
<ref id="B8-ijms-21-00119">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Christensen</surname>
<given-names>H.N.</given-names>
</name>
</person-group>
<article-title>Role of amino acid transport and countertransport in nutrition and metabolism</article-title>
<source/>Physiol. Rev.
          <year>1990</year>
<volume>70</volume>
<fpage>43</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="doi">10.1152/physrev.1990.70.1.43</pub-id>
<pub-id pub-id-type="pmid">2404290</pub-id>
</element-citation>
</ref>
<ref id="B9-ijms-21-00119">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hyde</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Hundal</surname>
<given-names>H.S.</given-names>
</name>
</person-group>
<article-title>Amino acid transporters: Roles in amino acid sensing and signalling in animal cells</article-title>
<source/>Biochem. J.
          <year>2003</year>
<volume>373</volume>
<fpage>1</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="doi">10.1042/bj20030405</pub-id>
<pub-id pub-id-type="pmid">12879880</pub-id>
</element-citation>
</ref>
<ref id="B10-ijms-21-00119">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matthews</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>K.J.</given-names>
</name>
</person-group>
<article-title>Recent advances in amino acid transporters and excitatory amino acid receptors</article-title>
<source/>Curr. Opin. Clin. Nutr. Metab. Care
          <year>2002</year>
<volume>5</volume>
<fpage>77</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="doi">10.1097/00075197-200201000-00014</pub-id>
<pub-id pub-id-type="pmid">11790954</pub-id>
</element-citation>
</ref>
<ref id="B11-ijms-21-00119">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bode</surname>
<given-names>B.P.</given-names>
</name>
</person-group>
<article-title>Recent molecular advances in mammalian glutamine transport</article-title>
<source/>J. Nutr.
          <year>2001</year>
<volume>131</volume>
<fpage>2475S</fpage>
<lpage>2485S</lpage>
<pub-id pub-id-type="doi">10.1093/jn/131.9.2475S</pub-id>
<pub-id pub-id-type="pmid">11533296</pub-id>
</element-citation>
</ref>
<ref id="B12-ijms-21-00119">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verrey</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Jack</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Paulsen</surname>
<given-names>I.T.</given-names>
</name>
<name>
<surname>Saier</surname>
<given-names>M.H.J.</given-names>
</name>
<name>
<surname>Pfeiffer</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>New glycoprotein-associated amino acid transporters</article-title>
<source/>J. Membr. Biol.
          <year>1999</year>
<volume>172</volume>
<fpage>181</fpage>
<lpage>192</lpage>
<pub-id pub-id-type="doi">10.1007/s002329900595</pub-id>
<pub-id pub-id-type="pmid">10568788</pub-id>
</element-citation>
</ref>
<ref id="B13-ijms-21-00119">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hediger</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Romero</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Rolfs</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Takanaga</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bruford</surname>
<given-names>E.A.</given-names>
</name>
</person-group>
<article-title>The ABCs of solute carriers: Physiological, pathological and therapeutic implications of human membrane transport proteins</article-title>
<source/>Pflugers Arch.
          <year>2004</year>
<volume>447</volume>
<fpage>465</fpage>
<lpage>468</lpage>
<pub-id pub-id-type="doi">10.1007/s00424-003-1192-y</pub-id>
<pub-id pub-id-type="pmid">14624363</pub-id>
</element-citation>
</ref>
<ref id="B14-ijms-21-00119">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hediger</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Clémençon</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Burrier</surname>
<given-names>R.E.</given-names>
</name>
<name>
<surname>Bruford</surname>
<given-names>E.A.</given-names>
</name>
</person-group>
<article-title>The ABCs of membrane transporters in health and disease (SLC series)</article-title>
<source/>Mol. Asp. Med.
          <year>2013</year>
<volume>34</volume>
<fpage>95</fpage>
<lpage>107</lpage>
<pub-id pub-id-type="doi">10.1016/j.mam.2012.12.009</pub-id>
</element-citation>
</ref>
<ref id="B15-ijms-21-00119">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meier</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ristic</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Klauser</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Verrey</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Activation of system L heterodimeric amino acid exchangers by intracellular substrates</article-title>
<source/>EMBO. J.
          <year>2002</year>
<volume>21</volume>
<fpage>580</fpage>
<lpage>589</lpage>
<pub-id pub-id-type="doi">10.1093/emboj/21.4.580</pub-id>
<pub-id pub-id-type="pmid">11847106</pub-id>
</element-citation>
</ref>
<ref id="B16-ijms-21-00119">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bevington</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Govindji</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Khalid</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sheridan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Impaired system a amino acid transport mimics the catabolic effects of acid in L6 cells</article-title>
<source/>Eur. J. Clin. Investig.
          <year>2002</year>
<volume>32</volume>
<fpage>590</fpage>
<lpage>602</lpage>
<pub-id pub-id-type="doi">10.1046/j.1365-2362.2002.01038.x</pub-id>
<pub-id pub-id-type="pmid">12190959</pub-id>
</element-citation>
</ref>
<ref id="B17-ijms-21-00119">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taylor</surname>
<given-names>P.M.</given-names>
</name>
</person-group>
<article-title>Role of Amino Acid Transporters in Amino Acid Sensing</article-title>
<source/>Am. J. Clin. Nutr.
          <year>2014</year>
<volume>99</volume>
<fpage>223S</fpage>
<lpage>230S</lpage>
<pub-id pub-id-type="doi">10.3945/ajcn.113.070086</pub-id>
<pub-id pub-id-type="pmid">24284439</pub-id>
</element-citation>
</ref>
<ref id="B18-ijms-21-00119">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bröer</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Amino Acid Transporters as Disease Modifiers and Drug Targets</article-title>
<source/>SLAS. Discov.
          <year>2018</year>
<volume>23</volume>
<fpage>303</fpage>
<lpage>320</lpage>
<pub-id pub-id-type="doi">10.1177/2472555218755629</pub-id>
<pub-id pub-id-type="pmid">29557284</pub-id>
</element-citation>
</ref>
<ref id="B19-ijms-21-00119">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kandasamy</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gyimesi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kanai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hediger</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Amino acid transporters revisited: New views in health and disease</article-title>
<source/>Trends Biochem. Sci.
          <year>2018</year>
<volume>43</volume>
<fpage>752</fpage>
<lpage>789</lpage>
<pub-id pub-id-type="doi">10.1016/j.tibs.2018.05.003</pub-id>
<pub-id pub-id-type="pmid">30177408</pub-id>
</element-citation>
</ref>
<ref id="B20-ijms-21-00119">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bailey</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>Ryan</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Thoeng</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>King</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Vanslambrouck</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Auray-Blais</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Vandenberg</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Broer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rasko</surname>
<given-names>J.E.J.</given-names>
</name>
</person-group>
<article-title>Loss-of-function mutations in the glutamate transporter SLC1A1 cause human dicarboxylic aminoaciduria</article-title>
<source/>J. Clin. Investig.
          <year>2011</year>
<volume>121</volume>
<fpage>446</fpage>
<lpage>453</lpage>
<pub-id pub-id-type="doi">10.1172/JCI44474</pub-id>
<pub-id pub-id-type="pmid">21123949</pub-id>
</element-citation>
</ref>
<ref id="B21-ijms-21-00119">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bröer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Palacín</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The role of amino acid transporters in inherited and acquired diseases</article-title>
<source/>Biochem. J.
          <year>2011</year>
<volume>436</volume>
<fpage>193</fpage>
<lpage>211</lpage>
<pub-id pub-id-type="doi">10.1042/BJ20101912</pub-id>
<pub-id pub-id-type="pmid">21568940</pub-id>
</element-citation>
</ref>
<ref id="B22-ijms-21-00119">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teijema</surname>
<given-names>H.L.</given-names>
</name>
<name>
<surname>van Gelderen</surname>
<given-names>H.H.</given-names>
</name>
<name>
<surname>Giesberts</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Laurent de Angulo</surname>
<given-names>M.S.</given-names>
</name>
</person-group>
<article-title>Dicarboxylic aminoaciduria: An inborn error of glutamate and aspartate transport with metabolic implications, in combination with a hyperprolinemia</article-title>
<source/>Metabolism
          <year>1974</year>
<volume>23</volume>
<fpage>115</fpage>
<lpage>123</lpage>
<pub-id pub-id-type="doi">10.1016/0026-0495(74)90108-5</pub-id>
<pub-id pub-id-type="pmid">4810805</pub-id>
</element-citation>
</ref>
<ref id="B23-ijms-21-00119">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Magi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Piccirillo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Amoroso</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lariccia</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Excitatory amino acid transporters (EAATs): Glutamate transport and beyond</article-title>
<source/>Int. J. Mol. Sci.
          <year>2019</year>
<volume>20</volume>
<elocation-id>5674</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms20225674</pub-id>
<pub-id pub-id-type="pmid">31766111</pub-id>
</element-citation>
</ref>
<ref id="B24-ijms-21-00119">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Auray-Blais</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Giguère</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lemieux</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Newborn urine screening programme in the province of Quebec: An update of 30 years’ experience</article-title>
<source/>J. Inherit. Metab. Dis.
          <year>2003</year>
<volume>26</volume>
<fpage>393</fpage>
<lpage>402</lpage>
<pub-id pub-id-type="doi">10.1023/A:1025115405074</pub-id>
<pub-id pub-id-type="pmid">12971427</pub-id>
</element-citation>
</ref>
<ref id="B25-ijms-21-00119">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Auray-Blais</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cyr</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Drouin</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Quebec neonatal mass urinary screening programme: From micromolecules to macromolecules</article-title>
<source/>J. Inherit. Metab. Dis.
          <year>2007</year>
<volume>30</volume>
<fpage>515</fpage>
<lpage>521</lpage>
<pub-id pub-id-type="doi">10.1007/s10545-007-0607-x</pub-id>
<pub-id pub-id-type="pmid">17570073</pub-id>
</element-citation>
</ref>
<ref id="B26-ijms-21-00119">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swarna</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>D.N.</given-names>
</name>
<name>
<surname>Reddy</surname>
<given-names>P.P.</given-names>
</name>
</person-group>
<article-title>Dicarboxylic aminoaciduria associated with mental retardation</article-title>
<source/>Hum. Genet.
          <year>1989</year>
<volume>82</volume>
<fpage>299</fpage>
<lpage>300</lpage>
<pub-id pub-id-type="doi">10.1007/BF00291178</pub-id>
<pub-id pub-id-type="pmid">2567279</pub-id>
</element-citation>
</ref>
<ref id="B27-ijms-21-00119">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Melancon</surname>
<given-names>S.B.</given-names>
</name>
<name>
<surname>Dallaire</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lemieux</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Robitaille</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Potier</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Dicarboxylic aminoaciduria: An inborn error of amino acid conservation</article-title>
<source/>J. Pediatr.
          <year>1977</year>
<volume>91</volume>
<fpage>422</fpage>
<lpage>427</lpage>
<pub-id pub-id-type="doi">10.1016/S0022-3476(77)81312-7</pub-id>
<pub-id pub-id-type="pmid">894411</pub-id>
</element-citation>
</ref>
<ref id="B28-ijms-21-00119">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Adamczyk</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Shugart</surname>
<given-names>Y.Y.</given-names>
</name>
<name>
<surname>Samuels</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Grados</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>B.D.</given-names>
</name>
<name>
<surname>Knowles</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>McCracken</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Rauch</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>D.L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A screen of SLC1A1 for OCD-related alleles</article-title>
<source/>Am. J. Med. Genet. B Neuropsychiatr. Genet.
          <year>2010</year>
<volume>153B</volume>
<fpage>675</fpage>
<lpage>679</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.31001</pub-id>
<pub-id pub-id-type="pmid">19569082</pub-id>
</element-citation>
</ref>
<ref id="B29-ijms-21-00119">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Salles Andrade</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Giori</surname>
<given-names>I.G.</given-names>
</name>
<name>
<surname>Melo-Felippe</surname>
<given-names>F.B.</given-names>
</name>
<name>
<surname>Vieira-Fonseca</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Fontenelle</surname>
<given-names>L.F.</given-names>
</name>
<name>
<surname>Kohlrausch</surname>
<given-names>F.B.</given-names>
</name>
</person-group>
<article-title>Glutamate transporter gene polymorphisms and obsessive-compulsive disorder: A case-control association study</article-title>
<source/>J. Clin. Neurosci.
          <year>2019</year>
<volume>62</volume>
<fpage>53</fpage>
<lpage>59</lpage>
<pub-id pub-id-type="doi">10.1016/j.jocn.2019.01.009</pub-id>
<pub-id pub-id-type="pmid">30661718</pub-id>
</element-citation>
</ref>
<ref id="B30-ijms-21-00119">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arnold</surname>
<given-names>P.D.</given-names>
</name>
<name>
<surname>Sicard</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Burroughs</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Richter</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder</article-title>
<source/>Arch. Gen. Psychiatry
          <year>2006</year>
<volume>63</volume>
<fpage>769</fpage>
<lpage>776</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.63.7.769</pub-id>
<pub-id pub-id-type="pmid">16818866</pub-id>
</element-citation>
</ref>
<ref id="B31-ijms-21-00119">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Demily</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hubert</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Franck</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Poisson</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Munnich</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Besmond</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Somatic mosaicism for SLC1A1 mutation supports threshold effect and familial aggregation in schizophrenia spectrum disorders</article-title>
<source/>Schizophr. Res.
          <year>2018</year>
<volume>197</volume>
<fpage>583</fpage>
<lpage>584</lpage>
<pub-id pub-id-type="doi">10.1016/j.schres.2017.11.028</pub-id>
<pub-id pub-id-type="pmid">29195747</pub-id>
</element-citation>
</ref>
<ref id="B32-ijms-21-00119">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Myles-Worsley</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tiobech</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Browning</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Korn</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Goodman</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gentile</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Melhem</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Byerley</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Faraone</surname>
<given-names>S.V.</given-names>
</name>
<name>
<surname>Middleton</surname>
<given-names>F.A.</given-names>
</name>
</person-group>
<article-title>Deletion at the SLC1A1 glutamate transporter gene co-segregates with schizophrenia and bipolar schizoaffective disorder in a 5-generation family</article-title>
<source/>Am. J. Med. Genet. B Neuropsychiatr. Genet.
          <year>2013</year>
<volume>162B</volume>
<fpage>87</fpage>
<lpage>95</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.32125</pub-id>
<pub-id pub-id-type="pmid">23341099</pub-id>
</element-citation>
</ref>
<ref id="B33-ijms-21-00119">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Afshari</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>W.D.</given-names>
</name>
<name>
<surname>Middleton</surname>
<given-names>F.A.</given-names>
</name>
</person-group>
<article-title>Reduced Slc1a1 expression is associated with neuroinflammation and impaired sensorimotor gating and cognitive performance in mice: Implications for schizophrenia</article-title>
<source/>PLoS ONE
          <year>2017</year>
<volume>12</volume>
<elocation-id>e0183854</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0183854</pub-id>
<pub-id pub-id-type="pmid">28886095</pub-id>
</element-citation>
</ref>
<ref id="B34-ijms-21-00119">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdolhosseinzadeh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sina</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ahmadiani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Asadi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shams</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Genetic and pharmacogenetic study of glutamate transporter (SLC1A1) in Iranian patients with obsessive-compulsive disorder</article-title>
<source/>J. Clin. Pharm. Ther.
          <year>2019</year>
<volume>44</volume>
<fpage>39</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="doi">10.1111/jcpt.12766</pub-id>
<pub-id pub-id-type="pmid">30315580</pub-id>
</element-citation>
</ref>
<ref id="B35-ijms-21-00119">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>Epi4K Consortium</collab>
</person-group>
<article-title>De Novo Mutations in SLC1A2 and CACNA1A are important causes of epileptic encephalopathies</article-title>
<source/>Am. J. Hum. Genet.
          <year>2016</year>
<volume>99</volume>
<fpage>287</fpage>
<lpage>298</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2016.06.003</pub-id>
<pub-id pub-id-type="pmid">27476654</pub-id>
</element-citation>
</ref>
<ref id="B36-ijms-21-00119">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>Kegelman</surname>
<given-names>T.P.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>Z.Z.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Dash</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Dasgupta</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Barral</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Hedvat</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Diaz</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: Opportunities for developing novel therapeutics</article-title>
<source/>J. Cell. Physiol.
          <year>2011</year>
<volume>226</volume>
<fpage>2484</fpage>
<lpage>2493</lpage>
<pub-id pub-id-type="doi">10.1002/jcp.22609</pub-id>
<pub-id pub-id-type="pmid">21792905</pub-id>
</element-citation>
</ref>
<ref id="B37-ijms-21-00119">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wagner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gusic</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Günthner</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Alhaddad</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kovacs-Nagy</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Makowski</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Baumeister</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Strom</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Meitinger</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Prokisch</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Biallelic Mutations in SLC1A2; an Additional Mode of Inheritance for SLC1A2-Related Epilepsy</article-title>
<source/>Neuropediatrics
          <year>2018</year>
<volume>49</volume>
<fpage>59</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="pmid">28915517</pub-id>
</element-citation>
</ref>
<ref id="B38-ijms-21-00119">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guella</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>McKenzie</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Buerki</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Toyota</surname>
<given-names>E.B.</given-names>
</name>
<name>
<surname>Van Allen</surname>
<given-names>M.I.</given-names>
</name>
<collab>Epilepsy Genomics Study</collab>
<name>
<surname>Suri</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Elmslie</surname>
<given-names>F.</given-names>
</name>
<collab>Deciphering Developmental Disorders Study</collab>
<etal></etal>
</person-group>
<article-title>De Novo Mutations in YWHAG Cause Early-Onset Epilepsy</article-title>
<source/>Am. J. Hum. Genet.
          <year>2017</year>
<volume>101</volume>
<fpage>300</fpage>
<lpage>310</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2017.07.004</pub-id>
<pub-id pub-id-type="pmid">28777935</pub-id>
</element-citation>
</ref>
<ref id="B39-ijms-21-00119">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stergachis</surname>
<given-names>A.B.</given-names>
</name>
<name>
<surname>Pujol-Giménez</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gyimesi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Fuster</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Albano</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Troxler</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Picker</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rosenberg</surname>
<given-names>P.A.</given-names>
</name>
<name>
<surname>Bergin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Recurrent SLC1A2 variants cause epilepsy via a dominant negative mechanism</article-title>
<source/>Ann. Neurol.
          <year>2019</year>
<volume>85</volume>
<fpage>921</fpage>
<lpage>926</lpage>
<pub-id pub-id-type="doi">10.1002/ana.25477</pub-id>
<pub-id pub-id-type="pmid">30937933</pub-id>
</element-citation>
</ref>
<ref id="B40-ijms-21-00119">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rothstein</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Regan</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Haenggeli</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Bergles</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dykes Hoberg</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vidensky</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>D.S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression</article-title>
<source/>Nature
          <year>2005</year>
<volume>433</volume>
<fpage>73</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="doi">10.1038/nature03180</pub-id>
<pub-id pub-id-type="pmid">15635412</pub-id>
</element-citation>
</ref>
<ref id="B41-ijms-21-00119">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>Z.Z.</given-names>
</name>
<name>
<surname>Emdad</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sarkar</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Borjabad</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Volsky</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>P.B.</given-names>
</name>
</person-group>
<article-title>Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes</article-title>
<source/>J. Biol. Chem.
          <year>2008</year>
<volume>283</volume>
<fpage>13116</fpage>
<lpage>13123</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M707697200</pub-id>
<pub-id pub-id-type="pmid">18326497</pub-id>
</element-citation>
</ref>
<ref id="B42-ijms-21-00119">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hubbard</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Binder</surname>
<given-names>D.K.</given-names>
</name>
</person-group>
<article-title>Targeting glutamate transporter-1 in neurological diseases</article-title>
<source/>Oncotarget.
          <year>2017</year>
<volume>8</volume>
<fpage>22311</fpage>
<lpage>22312</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.16374</pub-id>
<pub-id pub-id-type="pmid">28423610</pub-id>
</element-citation>
</ref>
<ref id="B43-ijms-21-00119">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname>
<given-names>K.D.</given-names>
</name>
<name>
<surname>Jen</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H.S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>J.H.</given-names>
</name>
</person-group>
<article-title>Late-onset episodic ataxia associated with SLC1A3 mutation</article-title>
<source/>J. Hum. Genet.
          <year>2017</year>
<volume>62</volume>
<fpage>443</fpage>
<lpage>446</lpage>
<pub-id pub-id-type="doi">10.1038/jhg.2016.137</pub-id>
<pub-id pub-id-type="pmid">27829685</pub-id>
</element-citation>
</ref>
<ref id="B44-ijms-21-00119">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jen</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Palos</surname>
<given-names>T.P.</given-names>
</name>
<name>
<surname>Howard</surname>
<given-names>B.D.</given-names>
</name>
<name>
<surname>Baloh</surname>
<given-names>R.W.</given-names>
</name>
</person-group>
<article-title>Mutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia, and seizures</article-title>
<source/>Neurology
          <year>2005</year>
<volume>65</volume>
<fpage>529</fpage>
<lpage>534</lpage>
<pub-id pub-id-type="doi">10.1212/01.WNL.0000172638.58172.5a</pub-id>
<pub-id pub-id-type="pmid">16116111</pub-id>
</element-citation>
</ref>
<ref id="B45-ijms-21-00119">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Vries</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Mamsa</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Stam</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bakker</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Vanmolkot</surname>
<given-names>K.R.</given-names>
</name>
<name>
<surname>Hann</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Terwindt</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Boon</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Howard</surname>
<given-names>B.D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Episodic ataxia associated with EAAT1 mutation C186S affecting glutamate reuptake</article-title>
<source/>Arch. Neurol.
          <year>2009</year>
<volume>66</volume>
<fpage>97</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="doi">10.1001/archneurol.2008.535</pub-id>
<pub-id pub-id-type="pmid">19139306</pub-id>
</element-citation>
</ref>
<ref id="B46-ijms-21-00119">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pyle</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Smertenko</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bargiela</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Griffin</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Duff</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Appleton</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Douroudis</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pfeffer</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Santibanez-Koref</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Eglon</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exome sequencing in undiagnosed inherited and sporadic ataxias</article-title>
<source/>Brain
          <year>2015</year>
<volume>138</volume>
<fpage>276</fpage>
<lpage>283</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awu348</pub-id>
<pub-id pub-id-type="pmid">25497598</pub-id>
</element-citation>
</ref>
<ref id="B47-ijms-21-00119">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iwama</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Iwata</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Shiina</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mitsuhashi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Miyatake</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Takata</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Miyake</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ogata</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mizuguchi</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A novel mutation in SLC1A3 causes episodic ataxia</article-title>
<source/>J. Hum. Genet.
          <year>2018</year>
<volume>63</volume>
<fpage>207</fpage>
<lpage>211</lpage>
<pub-id pub-id-type="doi">10.1038/s10038-017-0365-z</pub-id>
<pub-id pub-id-type="pmid">29208948</pub-id>
</element-citation>
</ref>
<ref id="B48-ijms-21-00119">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jen</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Graves</surname>
<given-names>T.D.</given-names>
</name>
<name>
<surname>Hess</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Hanna</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Griggs</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Baloh</surname>
<given-names>R.W.</given-names>
</name>
<collab>CINCH Investigators</collab>
</person-group>
<article-title>Primary episodic ataxias: Diagnosis, pathogenesis and treatment</article-title>
<source/>Brain
          <year>2007</year>
<volume>130</volume>
<fpage>2484</fpage>
<lpage>2493</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awm126</pub-id>
<pub-id pub-id-type="pmid">17575281</pub-id>
</element-citation>
</ref>
<ref id="B49-ijms-21-00119">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pironti</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Salpietro</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Cucinotta</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Granata</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Mormina</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Efthymiou</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Scuderi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gagliano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Houlden</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Di Rosa</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>A novel SLC1A4 homozygous mutation causing congenital microcephaly, epileptic encephalopathy and spastic tetraparesis: A video-EEG and tractography—Case study</article-title>
<source/>J. Neurogenet.
          <year>2018</year>
<volume>32</volume>
<fpage>316</fpage>
<lpage>321</lpage>
<pub-id pub-id-type="doi">10.1080/01677063.2018.1476510</pub-id>
<pub-id pub-id-type="pmid">29989513</pub-id>
</element-citation>
</ref>
<ref id="B50-ijms-21-00119">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tabatabaie</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Klomp</surname>
<given-names>L.W.</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>de Koning</surname>
<given-names>T.J.</given-names>
</name>
</person-group>
<article-title>L-serine synthesis in the central nervous system: A review on serine deficiency disorders</article-title>
<source/>Mol. Genet. Metab.
          <year>2010</year>
<volume>99</volume>
<fpage>256</fpage>
<lpage>262</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgme.2009.10.012</pub-id>
<pub-id pub-id-type="pmid">19963421</pub-id>
</element-citation>
</ref>
<ref id="B51-ijms-21-00119">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaplan</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Zubedat</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Radzishevsky</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Valenta</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Rechnitz</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Sason</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sajrawi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bodner</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Konno</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Esaki</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>ASCT1 (Slc1a4) transporter is a physiologic regulator of brain d-serine and neurodevelopment</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2018</year>
<volume>115</volume>
<fpage>9628</fpage>
<lpage>9633</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1722677115</pub-id>
<pub-id pub-id-type="pmid">30185558</pub-id>
</element-citation>
</ref>
<ref id="B52-ijms-21-00119">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heimer</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Marek-Yagel</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Eyal</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Barel</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Oz Levi</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hoffmann</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ruzzo</surname>
<given-names>E.K.</given-names>
</name>
<name>
<surname>Ganelin-Cohen</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lancet</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pras</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>SLC1A4 mutations cause a novel disorder of intellectual disability, progressive microcephaly, spasticity and thin corpus callosum</article-title>
<source/>Clin. Genet.
          <year>2015</year>
<volume>88</volume>
<fpage>327</fpage>
<lpage>335</lpage>
<pub-id pub-id-type="doi">10.1111/cge.12637</pub-id>
<pub-id pub-id-type="pmid">26138499</pub-id>
</element-citation>
</ref>
<ref id="B53-ijms-21-00119">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Srour</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hamdan</surname>
<given-names>F.F.</given-names>
</name>
<name>
<surname>Gan-Or</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Labuda</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Nassif</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Oskoui</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gana-Weisz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Orr-Urtreger</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rouleau</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Michaud</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>A homozygous mutation in SLC1A4 in siblings with severe intellectual disability and microcephaly</article-title>
<source/>Clin. Genet.
          <year>2015</year>
<volume>88</volume>
<fpage>e1</fpage>
<lpage>e4</lpage>
<pub-id pub-id-type="doi">10.1111/cge.12605</pub-id>
<pub-id pub-id-type="pmid">25930971</pub-id>
</element-citation>
</ref>
<ref id="B54-ijms-21-00119">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Damseh</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Simonin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jalas</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Picoraro</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Shaag</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Yaacov</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Neidich</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Al-Ashhab</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Juusola</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in SLC1A4, encoding the brain serine transporter, are associated with developmental delay, microcephaly and hypomyelination</article-title>
<source/>J. Med. Genet.
          <year>2015</year>
<volume>52</volume>
<fpage>541</fpage>
<lpage>547</lpage>
<pub-id pub-id-type="doi">10.1136/jmedgenet-2015-103104</pub-id>
<pub-id pub-id-type="pmid">26041762</pub-id>
</element-citation>
</ref>
<ref id="B55-ijms-21-00119">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conroy</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>N.M.</given-names>
</name>
<name>
<surname>Gorman</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>O’Halloran</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Shahwan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Ennis</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>King</surname>
<given-names>M.D.</given-names>
</name>
</person-group>
<article-title>Novel European SLC1A4 variant: Infantile spasms and population ancestry analysis</article-title>
<source/>J. Hum. Genet.
          <year>2016</year>
<volume>61</volume>
<fpage>761</fpage>
<lpage>764</lpage>
<pub-id pub-id-type="doi">10.1038/jhg.2016.44</pub-id>
<pub-id pub-id-type="pmid">27193218</pub-id>
</element-citation>
</ref>
<ref id="B56-ijms-21-00119">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thier</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Segal</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rosenberg</surname>
<given-names>L.E.</given-names>
</name>
</person-group>
<article-title>Cystinuria: In vitro demonstration of an intestinal transport defect</article-title>
<source/>Science
          <year>1964</year>
<volume>143</volume>
<fpage>482</fpage>
<lpage>484</lpage>
<pub-id pub-id-type="doi">10.1126/science.143.3605.482</pub-id>
<pub-id pub-id-type="pmid">14080318</pub-id>
</element-citation>
</ref>
<ref id="B57-ijms-21-00119">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosenberg</surname>
<given-names>L.E.</given-names>
</name>
<name>
<surname>Durant</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Holland</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>Intestinal absorption and renal extraction of cystine and cysteine in cystinuria</article-title>
<source/>N. Engl. J. Med.
          <year>1965</year>
<volume>273</volume>
<fpage>1239</fpage>
<lpage>1245</lpage>
<pub-id pub-id-type="doi">10.1056/NEJM196512022732303</pub-id>
<pub-id pub-id-type="pmid">5841926</pub-id>
</element-citation>
</ref>
<ref id="B58-ijms-21-00119">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thier</surname>
<given-names>S.O.</given-names>
</name>
<name>
<surname>Segal</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Blair</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rosenberg</surname>
<given-names>L.E.</given-names>
</name>
</person-group>
<article-title>Cystinuria: Defective intestinal transport of dibasic amino acids and cystine</article-title>
<source/>J. Clin. Investig.
          <year>1965</year>
<volume>44</volume>
<fpage>442</fpage>
<lpage>448</lpage>
<pub-id pub-id-type="doi">10.1172/JCI105157</pub-id>
<pub-id pub-id-type="pmid">14271303</pub-id>
</element-citation>
</ref>
<ref id="B59-ijms-21-00119">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eggermann</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Venghaus</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zerres</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Cystinuria: An inborn cause of urolithiasis</article-title>
<source/>Orphanet. J. Rare Dis.
          <year>2012</year>
<volume>7</volume>
<fpage>19</fpage>
<pub-id pub-id-type="doi">10.1186/1750-1172-7-19</pub-id>
<pub-id pub-id-type="pmid">22480232</pub-id>
</element-citation>
</ref>
<ref id="B60-ijms-21-00119">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sumorok</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Goldfarb</surname>
<given-names>D.S.</given-names>
</name>
</person-group>
<article-title>Update on cystinuria</article-title>
<source/>Curr. Opin. Nephrol. Hypertens
          <year>2013</year>
<volume>22</volume>
<fpage>427</fpage>
<lpage>431</lpage>
<pub-id pub-id-type="doi">10.1097/MNH.0b013e3283621c5d</pub-id>
<pub-id pub-id-type="pmid">23666417</pub-id>
</element-citation>
</ref>
<ref id="B61-ijms-21-00119">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Edvardsson</surname>
<given-names>V.O.</given-names>
</name>
<name>
<surname>Goldfarb</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Lieske</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Beara-Lasic</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Anglani</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Milliner</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Palsson</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Hereditary causes of kidney stones and chronic kidney disease</article-title>
<source/>Pediatr. Nephrol.
          <year>2013</year>
<volume>28</volume>
<fpage>1923</fpage>
<lpage>1942</lpage>
<pub-id pub-id-type="doi">10.1007/s00467-012-2329-z</pub-id>
<pub-id pub-id-type="pmid">23334384</pub-id>
</element-citation>
</ref>
<ref id="B62-ijms-21-00119">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomas</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Withington</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bultitude</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Doherty</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Cystinuria-a urologist’s perspective</article-title>
<source/>Nat. Rev. Urol.
          <year>2014</year>
<volume>11</volume>
<fpage>270</fpage>
<lpage>277</lpage>
<pub-id pub-id-type="doi">10.1038/nrurol.2014.51</pub-id>
<pub-id pub-id-type="pmid">24662732</pub-id>
</element-citation>
</ref>
<ref id="B63-ijms-21-00119">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pereira</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Schoolwerth</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Pais</surname>
<given-names>V.M.</given-names>
</name>
</person-group>
<article-title>Cystinuria: Current concepts and future directions</article-title>
<source/>Clin. Nephrol.
          <year>2015</year>
<volume>83</volume>
<fpage>138</fpage>
<lpage>146</lpage>
<pub-id pub-id-type="doi">10.5414/CN108514</pub-id>
<pub-id pub-id-type="pmid">25685869</pub-id>
</element-citation>
</ref>
<ref id="B64-ijms-21-00119">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andreassen</surname>
<given-names>K.H.</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>K.V.</given-names>
</name>
<name>
<surname>Osther</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>H.U.</given-names>
</name>
<name>
<surname>Lildal</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Osther</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>How should patients with cystine stone disease be evaluated and treated in the twenty-first century?</article-title>
<source/>Urolithiasis
          <year>2016</year>
<volume>44</volume>
<fpage>65</fpage>
<lpage>76</lpage>
<pub-id pub-id-type="doi">10.1007/s00240-015-0841-x</pub-id>
<pub-id pub-id-type="pmid">26614112</pub-id>
</element-citation>
</ref>
<ref id="B65-ijms-21-00119">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saravakos</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kokkinou</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Giannatos</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Cystinuria: Current diagnosis and management</article-title>
<source/>Urology
          <year>2014</year>
<volume>83</volume>
<fpage>693</fpage>
<lpage>699</lpage>
<pub-id pub-id-type="doi">10.1016/j.urology.2013.10.013</pub-id>
<pub-id pub-id-type="pmid">24246330</pub-id>
</element-citation>
</ref>
<ref id="B66-ijms-21-00119">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sahota</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tischfield</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Goldfarb</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Cystinuria: Genetic aspects, mouse models, and a new approach to therapy</article-title>
<source/>Urolithiasis
          <year>2019</year>
<volume>47</volume>
<fpage>57</fpage>
<lpage>66</lpage>
<pub-id pub-id-type="doi">10.1007/s00240-018-1101-7</pub-id>
<pub-id pub-id-type="pmid">30515543</pub-id>
</element-citation>
</ref>
<ref id="B67-ijms-21-00119">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calonge</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Gasparini</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Chillaron</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chillon</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gallucci</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rousaud</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zelante</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Testar</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Dallapiccola</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Di Silverio</surname>
<given-names>F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cystinuria caused by mutations in rBAT, a gene involved in the transport of cystine</article-title>
<source/>Nat. Genet.
          <year>1994</year>
<volume>6</volume>
<fpage>420</fpage>
<lpage>425</lpage>
<pub-id pub-id-type="doi">10.1038/ng0494-420</pub-id>
<pub-id pub-id-type="pmid">8054986</pub-id>
</element-citation>
</ref>
<ref id="B68-ijms-21-00119">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calonge</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Volpini</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Bisceglia</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rousaud</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>de Sanctis</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Beccia</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Zelante</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Testar</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zorzano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Estivill</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Genetic heterogeneity in cystinuria: The SLC3A1 gene is linked to type I but not to type III cystinuria</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>1995</year>
<volume>92</volume>
<fpage>9667</fpage>
<lpage>9671</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.92.21.9667</pub-id>
<pub-id pub-id-type="pmid">7568194</pub-id>
</element-citation>
</ref>
<ref id="B69-ijms-21-00119">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bisceglia</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Calonge</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Totaro</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Feliubadaló</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Melchionda</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>García</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Testar</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Gallucci</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ponzone</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zelante</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Localization, by linkage analysis, of the cystinuria type III gene to chromosome 19q13.1</article-title>
<source/>Am. J. Hum. Genet.
          <year>1997</year>
<volume>60</volume>
<fpage>611</fpage>
<lpage>616</lpage>
<pub-id pub-id-type="pmid">9042921</pub-id>
</element-citation>
</ref>
<ref id="B70-ijms-21-00119">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feliubadalo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Font</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Purroy</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rousaud</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Estivill</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Nunes</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Golomb</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Centola</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Aksentijevich</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Kreiss</surname>
<given-names>Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Non-type I cystinuria caused by mutations in SLC7A9, encoding a subunit (bo,+AT) of rBAT</article-title>
<source/>Nat. Genet.
          <year>1999</year>
<volume>23</volume>
<fpage>52</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="doi">10.1038/12652</pub-id>
<pub-id pub-id-type="pmid">10471498</pub-id>
</element-citation>
</ref>
<ref id="B71-ijms-21-00119">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Biyani</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Cartledge</surname>
<given-names>J.J.</given-names>
</name>
</person-group>
<article-title>Cystinuria—diagnosis and management</article-title>
<source/>EAU-EBU Update Ser.
          <year>2006</year>
<volume>4</volume>
<fpage>175</fpage>
<lpage>183</lpage>
<pub-id pub-id-type="doi">10.1016/j.eeus.2006.06.001</pub-id>
</element-citation>
</ref>
<ref id="B72-ijms-21-00119">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwentner</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Oswald</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lunacek</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bartsch</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Radmayr</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Giant cystine stone in an infant bladder with no evidence of cystinuria-valence of possible pathomechanisms</article-title>
<source/>Urol. Int.
          <year>2005</year>
<volume>75</volume>
<fpage>285</fpage>
<lpage>287</lpage>
<pub-id pub-id-type="doi">10.1159/000087810</pub-id>
<pub-id pub-id-type="pmid">16215321</pub-id>
</element-citation>
</ref>
<ref id="B73-ijms-21-00119">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Milliner</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>M.E.</given-names>
</name>
</person-group>
<article-title>Urolithiasis in pediatric patients</article-title>
<source/>Mayo Clin. Proc.
          <year>1993</year>
<volume>68</volume>
<fpage>241</fpage>
<lpage>248</lpage>
<pub-id pub-id-type="doi">10.1016/S0025-6196(12)60043-3</pub-id>
<pub-id pub-id-type="pmid">8474265</pub-id>
</element-citation>
</ref>
<ref id="B74-ijms-21-00119">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knoll</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zollner</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wendt-Nordahl</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Michel</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Alken</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Cystinuria in childhood and adolescence: Recommendations for diagnosis, treatment, and follow-up</article-title>
<source/>Pediatr. Nephrol.
          <year>2005</year>
<volume>20</volume>
<fpage>19</fpage>
<lpage>24</lpage>
<pub-id pub-id-type="doi">10.1007/s00467-004-1663-1</pub-id>
<pub-id pub-id-type="pmid">15602663</pub-id>
</element-citation>
</ref>
<ref id="B75-ijms-21-00119">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmed</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Dasgupta</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>M.S.</given-names>
</name>
</person-group>
<article-title>Cystine calculi: Challenging group of stones</article-title>
<source/>Postgrad. Med. J.
          <year>2006</year>
<volume>82</volume>
<fpage>799</fpage>
<lpage>801</lpage>
<pub-id pub-id-type="doi">10.1136/pgmj.2005.044156</pub-id>
<pub-id pub-id-type="pmid">17148700</pub-id>
</element-citation>
</ref>
<ref id="B76-ijms-21-00119">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rhodes</surname>
<given-names>H.L.</given-names>
</name>
<name>
<surname>Yarram-Smith</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rice</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Tabaksert</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Edwards</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hartley</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Woodward</surname>
<given-names>M.N.</given-names>
</name>
<name>
<surname>Smithson</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Tomson</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Welsh</surname>
<given-names>G.I.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical and genetic analysis of patients with cystinuria in the United Kingdom</article-title>
<source/>Clin. J. Am. Soc. Nephrol.
          <year>2015</year>
<volume>10</volume>
<fpage>1235</fpage>
<lpage>1245</lpage>
<pub-id pub-id-type="doi">10.2215/CJN.10981114</pub-id>
<pub-id pub-id-type="pmid">25964309</pub-id>
</element-citation>
</ref>
<ref id="B77-ijms-21-00119">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wong</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Mein</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wass</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Flinter</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Pardy</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bultitude</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>The genetic diversity of cystinuria in a UK population of patients</article-title>
<source/>BJU Int.
          <year>2015</year>
<volume>116</volume>
<fpage>109</fpage>
<lpage>116</lpage>
<pub-id pub-id-type="doi">10.1111/bju.12894</pub-id>
<pub-id pub-id-type="pmid">25109415</pub-id>
</element-citation>
</ref>
<ref id="B78-ijms-21-00119">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barbey</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Joly</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rieu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mejean</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Daudon</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jungers</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Medical treatment of cystinuria: Critical reappraisal of long-term results</article-title>
<source/>J. Urol.
          <year>2000</year>
<volume>163</volume>
<fpage>1419</fpage>
<lpage>1423</lpage>
<pub-id pub-id-type="doi">10.1016/S0022-5347(05)67633-1</pub-id>
<pub-id pub-id-type="pmid">10751848</pub-id>
</element-citation>
</ref>
<ref id="B79-ijms-21-00119">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chillaron</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Font-Llitjos</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fort</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zorzano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Goldfarb</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Nunes</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Palacin</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Pathophysiology and treatment of cystinuria</article-title>
<source/>Nat. Rev. Nephrol.
          <year>2010</year>
<volume>6</volume>
<fpage>424</fpage>
<lpage>434</lpage>
<pub-id pub-id-type="doi">10.1038/nrneph.2010.69</pub-id>
<pub-id pub-id-type="pmid">20517292</pub-id>
</element-citation>
</ref>
<ref id="B80-ijms-21-00119">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Font-Llitjos</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jimenez-Vidal</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bisceglia</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Di Perna</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>de Sanctis</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rousaud</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zelante</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Palacín</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nunes</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>New insights into cystinuria: 40 new mutations, genotype–phenotype correlation, and digenic inheritance causing partial phenotype</article-title>
<source/>J. Med. Genet.
          <year>2005</year>
<volume>42</volume>
<fpage>58</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2004.022244</pub-id>
<pub-id pub-id-type="pmid">15635077</pub-id>
</element-citation>
</ref>
<ref id="B81-ijms-21-00119">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaildrat</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lebbah</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tebani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sudrie-Arnaud</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Tostivint</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Bollee</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Tubeuf</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Charles</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bertholet-Thomas</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Goldenberg</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical and molecular characterization of cystinuria in a French cohort: Relevance of assessing large-scale rearrangements and splicing variants</article-title>
<source/>Mol. Genet. Genom. Med.
          <year>2017</year>
<volume>5</volume>
<fpage>373</fpage>
<lpage>389</lpage>
<pub-id pub-id-type="doi">10.1002/mgg3.294</pub-id>
<pub-id pub-id-type="pmid">28717662</pub-id>
</element-citation>
</ref>
<ref id="B82-ijms-21-00119">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dello Strologo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pras</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pontesilli</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Beccia</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ricci-Barbini</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>de Sanctis</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ponzone</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gallucci</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bisceglia</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zelante</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Comparison between SLC3A1 and SLC7A9 cystinuria patients and carriers: A need for a new classification</article-title>
<source/>J. Am. Soc. Nephrol.
          <year>2002</year>
<volume>13</volume>
<fpage>2547</fpage>
<lpage>2553</lpage>
<pub-id pub-id-type="doi">10.1097/01.ASN.0000029586.17680.E5</pub-id>
<pub-id pub-id-type="pmid">12239244</pub-id>
</element-citation>
</ref>
<ref id="B83-ijms-21-00119">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Camargo</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Bockenhauer</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kleta</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Aminoacidurias: Clinical and molecular aspects</article-title>
<source/>Kidney Int.
          <year>2008</year>
<volume>73</volume>
<fpage>918</fpage>
<lpage>925</lpage>
<pub-id pub-id-type="doi">10.1038/sj.ki.5002790</pub-id>
<pub-id pub-id-type="pmid">18200002</pub-id>
</element-citation>
</ref>
<ref id="B84-ijms-21-00119">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barbosa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lopes</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mota</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Martins</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Alves</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>De Bonis</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>do Ceu Mota</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dias</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rodrigues-Santos</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical, biochemical and molecular characterization of cystinuria in a cohort of 12 patients</article-title>
<source/>Clin. Genet.
          <year>2012</year>
<volume>81</volume>
<fpage>47</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="doi">10.1111/j.1399-0004.2011.01638.x</pub-id>
<pub-id pub-id-type="pmid">21255007</pub-id>
</element-citation>
</ref>
<ref id="B85-ijms-21-00119">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harnevik</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fjellstedt</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Molbaek</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Denneberg</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Soderkvist</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Mutation analysis of SLC7A9 in cystinuria patients in Sweden</article-title>
<source/>Genet. Test.
          <year>2003</year>
<volume>7</volume>
<fpage>13</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="doi">10.1089/109065703321560886</pub-id>
<pub-id pub-id-type="pmid">12820697</pub-id>
</element-citation>
</ref>
<ref id="B86-ijms-21-00119">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Font</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Feliubadalo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Estivill</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Nunes</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Golomb</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kreiss</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Pras</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bisceglia</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>D’Adamo</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Zelante</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Functional analysis of mutations in SLC7A9, and genotype–phenotype correlation in non-type I cystinuria</article-title>
<source/>Hum. Mol. Genet.
          <year>2001</year>
<volume>10</volume>
<fpage>305</fpage>
<lpage>316</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/10.4.305</pub-id>
<pub-id pub-id-type="pmid">11157794</pub-id>
</element-citation>
</ref>
<ref id="B87-ijms-21-00119">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stenson</surname>
<given-names>P.D.</given-names>
</name>
<name>
<surname>Mort</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ball</surname>
<given-names>E.V.</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hayden</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Heywood</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hussain</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>D.N.</given-names>
</name>
</person-group>
<article-title>The human gene mutation database: Towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies</article-title>
<source/>Hum. Genet.
          <year>2017</year>
<volume>136</volume>
<fpage>665</fpage>
<lpage>677</lpage>
<pub-id pub-id-type="doi">10.1007/s00439-017-1779-6</pub-id>
<pub-id pub-id-type="pmid">28349240</pub-id>
</element-citation>
</ref>
<ref id="B88-ijms-21-00119">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goodyer</surname>
<given-names>P.R.</given-names>
</name>
<name>
<surname>Clow</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Reade</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Girardin</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Prospective analysis and classification of patients with cystinuria identified in a newborn screening program</article-title>
<source/>J. Pediatr.
          <year>1993</year>
<volume>122</volume>
<fpage>568</fpage>
<lpage>572</lpage>
<pub-id pub-id-type="doi">10.1016/S0022-3476(05)83537-1</pub-id>
<pub-id pub-id-type="pmid">8463902</pub-id>
</element-citation>
</ref>
<ref id="B89-ijms-21-00119">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goodyer</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Saadi</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ong</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Elkas</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Rozen</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Cystinuria subtype and the risk of nephrolithiasis</article-title>
<source/>Kidney Int.
          <year>1998</year>
<volume>54</volume>
<fpage>56</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="doi">10.1046/j.1523-1755.1998.00957.x</pub-id>
<pub-id pub-id-type="pmid">9648063</pub-id>
</element-citation>
</ref>
<ref id="B90-ijms-21-00119">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldfarb</surname>
<given-names>D.S.</given-names>
</name>
</person-group>
<article-title>Potential pharmacologic treatments for cystinuria and for calcium stones associated with hyperuricosuria</article-title>
<source/>Clin. J. Am. Soc. Nephrol.
          <year>2011</year>
<volume>6</volume>
<fpage>2093</fpage>
<lpage>2097</lpage>
<pub-id pub-id-type="doi">10.2215/CJN.00320111</pub-id>
<pub-id pub-id-type="pmid">21757641</pub-id>
</element-citation>
</ref>
<ref id="B91-ijms-21-00119">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DeBerardinis</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Coughlin</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Penicillamine therapy for pediatric cystinuria: Experience from a cohort of American children</article-title>
<source/>J. Urol.
          <year>2008</year>
<volume>180</volume>
<fpage>2620</fpage>
<lpage>2623</lpage>
<pub-id pub-id-type="doi">10.1016/j.juro.2008.08.057</pub-id>
<pub-id pub-id-type="pmid">18951580</pub-id>
</element-citation>
</ref>
<ref id="B92-ijms-21-00119">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fattah</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hambaroush</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Goldfarb</surname>
<given-names>D.S.</given-names>
</name>
</person-group>
<article-title>Cystine nephrolithiasis</article-title>
<source/>Transl. Androl. Urol.
          <year>2014</year>
<volume>3</volume>
<fpage>228</fpage>
<lpage>233</lpage>
<pub-id pub-id-type="pmid">25383320</pub-id>
</element-citation>
</ref>
<ref id="B93-ijms-21-00119">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Asplin</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Penniston</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Goldfarb</surname>
<given-names>D.S.</given-names>
</name>
</person-group>
<article-title>Monosodium urate stones are rare, and urine pH is not low in cystinuria</article-title>
<source/>Am. J. Kidney Dis.
          <year>2013</year>
<volume>62</volume>
<fpage>179</fpage>
<lpage>180</lpage>
<pub-id pub-id-type="doi">10.1053/j.ajkd.2013.03.041</pub-id>
<pub-id pub-id-type="pmid">23773841</pub-id>
</element-citation>
</ref>
<ref id="B94-ijms-21-00119">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parvari</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Brodyansky</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Elpeleg</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Moses</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Landau</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hershkovitz</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>A recessive contiguous gene deletion of chromosome 2p16 associated with cystinuria and a mitochondrial disease</article-title>
<source/>Am. J. Hum. Genet.
          <year>2001</year>
<volume>69</volume>
<fpage>869</fpage>
<lpage>875</lpage>
<pub-id pub-id-type="doi">10.1086/323624</pub-id>
<pub-id pub-id-type="pmid">11524703</pub-id>
</element-citation>
</ref>
<ref id="B95-ijms-21-00119">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jaeken</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Martens</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Francois</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Eyskens</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lecointre</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Derua</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Meulemans</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Slootstra</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Waelkens</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>de Zegher</surname>
<given-names>F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Deletion of PREPL, a gene encoding a putative serine oligopeptidase, in patients with hypotonia–cystinuria syndrome</article-title>
<source/>Am. J. Hum. Genet.
          <year>2006</year>
<volume>78</volume>
<fpage>38</fpage>
<lpage>51</lpage>
<pub-id pub-id-type="doi">10.1086/498852</pub-id>
<pub-id pub-id-type="pmid">16385448</pub-id>
</element-citation>
</ref>
<ref id="B96-ijms-21-00119">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chabrol</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Martens</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Meulemans</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jaeken</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Matthijs</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Creemers</surname>
<given-names>J.W.</given-names>
</name>
</person-group>
<article-title>Deletion of C2orf34, PREPL and SLC3A1 causes atypical hypotonia–cystinuria syndrome</article-title>
<source/>J. Med. Genet.
          <year>2008</year>
<volume>45</volume>
<fpage>314</fpage>
<lpage>318</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2007.055475</pub-id>
<pub-id pub-id-type="pmid">18234729</pub-id>
</element-citation>
</ref>
<ref id="B97-ijms-21-00119">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martens</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Heulens</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Meulemans</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zaffanello</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tilstra</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hes</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Rooman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Francois</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>de Zegher</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Jaeken</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Global distribution of the most prevalent deletions causing hypotonia-cystinuria syndrome</article-title>
<source/>Eur. J. Hum. Genet.
          <year>2007</year>
<volume>15</volume>
<fpage>1029</fpage>
<lpage>1033</lpage>
<pub-id pub-id-type="doi">10.1038/sj.ejhg.5201881</pub-id>
<pub-id pub-id-type="pmid">17579669</pub-id>
</element-citation>
</ref>
<ref id="B98-ijms-21-00119">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Regal</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>X.M.</given-names>
</name>
<name>
<surname>Selcen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Verhille</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Meulemans</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Creemers</surname>
<given-names>J.W.M.</given-names>
</name>
<name>
<surname>Engel</surname>
<given-names>A.G.</given-names>
</name>
</person-group>
<article-title>PREPL deficiency with or without cystinuria causes a novel myasthenic syndrome</article-title>
<source/>Neurology
          <year>2014</year>
<volume>82</volume>
<fpage>1254</fpage>
<lpage>1260</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0000000000000295</pub-id>
<pub-id pub-id-type="pmid">24610330</pub-id>
</element-citation>
</ref>
<ref id="B99-ijms-21-00119">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taroni</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Capone</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Berrettini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>De Marco</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Manzoni</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Montini</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>A Case of Hypotonia-Cystinuria Syndrome with Genito-Urinary Malformations and Extrarenal Involvement</article-title>
<source/>Front. Pediatr.
          <year>2019</year>
<volume>7</volume>
<fpage>127</fpage>
<pub-id pub-id-type="doi">10.3389/fped.2019.00127</pub-id>
<pub-id pub-id-type="pmid">31024870</pub-id>
</element-citation>
</ref>
<ref id="B100-ijms-21-00119">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nagamori</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wiriyasermkul</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Guarch</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Okuyama</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nakagomi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tadagaki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nishinaka</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Bodoy</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Takafuji</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Okuda</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Novel cystine transporter in renal proximal tubule identified as a missing partner of cystinuria-related plasma membrane protein rBAT/SLC3A1</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2016</year>
<volume>113</volume>
<fpage>775</fpage>
<lpage>780</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1519959113</pub-id>
<pub-id pub-id-type="pmid">26739563</pub-id>
</element-citation>
</ref>
<ref id="B101-ijms-21-00119">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olschok</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Vester</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Lahme</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kurth</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Eggermann</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>No evidence for point mutations in the novel renal cystine transporter AGT1/SLC7A13 contributing to the etiology of cystinuria</article-title>
<source/>BMC Nephrol.
          <year>2018</year>
<volume>19</volume>
<elocation-id>278</elocation-id>
<pub-id pub-id-type="doi">10.1186/s12882-018-1080-5</pub-id>
<pub-id pub-id-type="pmid">30342472</pub-id>
</element-citation>
</ref>
<ref id="B102-ijms-21-00119">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rees</surname>
<given-names>M.I.</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pearce</surname>
<given-names>B.R.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Duguid</surname>
<given-names>I.C.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Beatty</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>Armstrong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shiang</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in the gene encoding GlyT2 (SLC6A5) define a presynaptic component of human startle disease</article-title>
<source/>Nat. Genet.
          <year>2006</year>
<volume>38</volume>
<fpage>801</fpage>
<lpage>806</lpage>
<pub-id pub-id-type="doi">10.1038/ng1814</pub-id>
<pub-id pub-id-type="pmid">16751771</pub-id>
</element-citation>
</ref>
<ref id="B103-ijms-21-00119">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dafsari</surname>
<given-names>H.S.</given-names>
</name>
<name>
<surname>Kawalia</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sprute</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Karakaya</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Malenica</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Herkenrath</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Nuernberg</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Motameny</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Thiele</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Cirak</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Novel mutations in SLC6A5 with benign course in hyperekplexia</article-title>
<source/>Cold Spring. Harb. Mol. Case Stud.
          <year>2019</year>
<volume>5</volume>
<fpage>a004465</fpage>
<pub-id pub-id-type="doi">10.1101/mcs.a004465</pub-id>
<pub-id pub-id-type="pmid">31604777</pub-id>
</element-citation>
</ref>
<ref id="B104-ijms-21-00119">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davies</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hammond</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Mullins</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Carta</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Rees</surname>
<given-names>M.I.</given-names>
</name>
</person-group>
<article-title>The glycinergic system in human startle disease: A genetic screening approach</article-title>
<source/>Front. Mol. Neurosci.
          <year>2010</year>
<volume>3</volume>
<fpage>8</fpage>
<pub-id pub-id-type="doi">10.3389/fnmol.2010.00008</pub-id>
<pub-id pub-id-type="pmid">20407582</pub-id>
</element-citation>
</ref>
<ref id="B105-ijms-21-00119">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harvey</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Topf</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Rees</surname>
<given-names>M.I.</given-names>
</name>
</person-group>
<article-title>The genetics of hyperekplexia: More than startle!</article-title>
<source/>Trends Genet.
          <year>2008</year>
<volume>24</volume>
<fpage>439</fpage>
<lpage>447</lpage>
<pub-id pub-id-type="doi">10.1016/j.tig.2008.06.005</pub-id>
<pub-id pub-id-type="pmid">18707791</pub-id>
</element-citation>
</ref>
<ref id="B106-ijms-21-00119">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bode</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>J.W.</given-names>
</name>
</person-group>
<article-title>The impact of human hyperekplexia mutations on glycine receptor structure and function</article-title>
<source/>Mol. Brain
          <year>2014</year>
<volume>7</volume>
<fpage>2</fpage>
<pub-id pub-id-type="doi">10.1186/1756-6606-7-2</pub-id>
<pub-id pub-id-type="pmid">24405574</pub-id>
</element-citation>
</ref>
<ref id="B107-ijms-21-00119">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomas</surname>
<given-names>R.H.</given-names>
</name>
</person-group>
<article-title>Hyperekplexia: Overexcitable and underdiagnosed</article-title>
<source/>Dev. Med. Child Neurol.
          <year>2015</year>
<volume>57</volume>
<fpage>313</fpage>
<pub-id pub-id-type="doi">10.1111/dmcn.12638</pub-id>
<pub-id pub-id-type="pmid">25407752</pub-id>
</element-citation>
</ref>
<ref id="B108-ijms-21-00119">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Villarejo-Lopez</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jimenez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bartolome-Martin</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zafra</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lapunzina</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Aragon</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lopez-Corcuera</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>P2X receptors up-regulate the cell-surface expression of the neuronal glycine transporter GlyT2</article-title>
<source/>Neuropharmacology
          <year>2017</year>
<volume>125</volume>
<fpage>99</fpage>
<lpage>116</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2017.07.018</pub-id>
<pub-id pub-id-type="pmid">28734869</pub-id>
</element-citation>
</ref>
<ref id="B109-ijms-21-00119">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Preising</surname>
<given-names>M.N.</given-names>
</name>
<name>
<surname>Görg</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Friedburg</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Qvartskhava</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Budde</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Bonus</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Toliat</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Pfleger</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Altmüller</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Herebian</surname>
<given-names>D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Biallelic mutation of human SLC6A6 encoding the taurine transporter TAUT is linked to early retinal degeneration</article-title>
<source/>FASEB J.
          <year>2019</year>
<volume>33</volume>
<fpage>11507</fpage>
<lpage>11527</lpage>
<pub-id pub-id-type="doi">10.1096/fj.201900914RR</pub-id>
<pub-id pub-id-type="pmid">31345061</pub-id>
</element-citation>
</ref>
<ref id="B110-ijms-21-00119">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vinnakota</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Egal</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sarthy</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Sarkar</surname>
<given-names>H.K.</given-names>
</name>
</person-group>
<article-title>Molecular characterization and in situ localization of a mouse retinal taurine transporter</article-title>
<source/>J. Neurochem.
          <year>1997</year>
<volume>69</volume>
<fpage>2238</fpage>
<lpage>2250</lpage>
<pub-id pub-id-type="doi">10.1046/j.1471-4159.1997.69062238.x</pub-id>
<pub-id pub-id-type="pmid">9375654</pub-id>
</element-citation>
</ref>
<ref id="B111-ijms-21-00119">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alfadhel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nashabat</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Al Qahtani</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Alfares</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Al Mutairi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Al Shaalan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Douglas</surname>
<given-names>G.V.</given-names>
</name>
<name>
<surname>Wierenga</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Juusola</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Alrifai</surname>
<given-names>M.T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutation in SLC6A9 encoding a glycine transporter causes a novel form of non-ketotic hyperglycinemia in humans</article-title>
<source/>Hum. Genet.
          <year>2016</year>
<volume>135</volume>
<fpage>1263</fpage>
<lpage>1268</lpage>
<pub-id pub-id-type="doi">10.1007/s00439-016-1719-x</pub-id>
<pub-id pub-id-type="pmid">27481395</pub-id>
</element-citation>
</ref>
<ref id="B112-ijms-21-00119">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alfallaj</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Alfadhel</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Glycine Transporter 1 Encephalopathy from Biochemical Pathway to Clinical Disease: Review</article-title>
<source/>Child Neurol. Open
          <year>2019</year>
<volume>6</volume>
<fpage>2329048x19831486</fpage>
<pub-id pub-id-type="doi">10.1177/2329048X19831486</pub-id>
<pub-id pub-id-type="pmid">30815509</pub-id>
</element-citation>
</ref>
<ref id="B113-ijms-21-00119">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harvey</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Carta</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pearce</surname>
<given-names>B.R.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Supplisson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rees</surname>
<given-names>M.I.</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>A critical role for glycine transporters in hyperexcitability disorders</article-title>
<source/>Front. Mol. Neurosci.
          <year>2008</year>
<volume>1</volume>
<fpage>1</fpage>
<pub-id pub-id-type="doi">10.3389/neuro.02.001.2008</pub-id>
<pub-id pub-id-type="pmid">18946534</pub-id>
</element-citation>
</ref>
<ref id="B114-ijms-21-00119">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harvey</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Yee</surname>
<given-names>B.K.</given-names>
</name>
</person-group>
<article-title>Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain</article-title>
<source/>Nat. Rev. Drug Discov.
          <year>2013</year>
<volume>12</volume>
<fpage>866</fpage>
<lpage>885</lpage>
<pub-id pub-id-type="doi">10.1038/nrd3893</pub-id>
<pub-id pub-id-type="pmid">24172334</pub-id>
</element-citation>
</ref>
<ref id="B115-ijms-21-00119">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurolap</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Armbruster</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hershkovitz</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hauf</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mory</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Paperna</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hannappel</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Tal</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Nijem</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sella</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Loss of glycine transporter 1 causes a subtype of glycine encephalopathy with arthrogryposis and mildly elevated cerebrospinal fluid glycine</article-title>
<source/>Am. J. Hum. Genet.
          <year>2016</year>
<volume>99</volume>
<fpage>1172</fpage>
<lpage>1180</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2016.09.004</pub-id>
<pub-id pub-id-type="pmid">27773429</pub-id>
</element-citation>
</ref>
<ref id="B116-ijms-21-00119">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iqbal</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Willemsen</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Papon</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Musante</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Benevento</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Venselaar</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wissink-Lindhout</surname>
<given-names>W.M.</given-names>
</name>
<name>
<surname>Vulto-van Silfhout</surname>
<given-names>A.T.</given-names>
</name>
<name>
<surname>Vissers</surname>
<given-names>L.E.L.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Homozygous SLC6A17 mutations cause autosomal-recessive intellectual disability with progressive tremor, speech impairment, and behavioral problems</article-title>
<source/>Am. J. Hum. Genet.
          <year>2015</year>
<volume>96</volume>
<fpage>386</fpage>
<lpage>396</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2015.01.010</pub-id>
<pub-id pub-id-type="pmid">25704603</pub-id>
</element-citation>
</ref>
<ref id="B117-ijms-21-00119">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>N.H.</given-names>
</name>
<name>
<surname>Reith</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Quick</surname>
<given-names>M.W.</given-names>
</name>
</person-group>
<article-title>Synaptic uptake and beyond: The sodium- and chloride-dependent neurotransmitter transporter family SLC6</article-title>
<source/>Pflugers Arch.
          <year>2004</year>
<volume>447</volume>
<fpage>519</fpage>
<lpage>531</lpage>
<pub-id pub-id-type="doi">10.1007/s00424-003-1064-5</pub-id>
<pub-id pub-id-type="pmid">12719981</pub-id>
</element-citation>
</ref>
<ref id="B118-ijms-21-00119">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bröer</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>The SLC6 orphans are forming a family of amino acid transporters</article-title>
<source/>Neurochem. Int.
          <year>2006</year>
<volume>48</volume>
<fpage>559</fpage>
<lpage>567</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuint.2005.11.021</pub-id>
<pub-id pub-id-type="pmid">16540203</pub-id>
</element-citation>
</ref>
<ref id="B119-ijms-21-00119">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Q.R.</given-names>
</name>
<name>
<surname>Mandiyan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>López-Corcuera</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>A rat brain cDNA encoding the neurotransmitter transporter with an unusual structure</article-title>
<source/>FEBS Lett.
          <year>1993</year>
<volume>315</volume>
<fpage>114</fpage>
<lpage>118</lpage>
<pub-id pub-id-type="doi">10.1016/0014-5793(93)81145-P</pub-id>
<pub-id pub-id-type="pmid">8093354</pub-id>
</element-citation>
</ref>
<ref id="B120-ijms-21-00119">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parra</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Baust</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>El Mestikawy</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Quiroz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hoffman</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Haflett</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Torres</surname>
<given-names>G.E.</given-names>
</name>
</person-group>
<article-title>The orphan transporter Rxt1/NTT4 (SLC6A17) functions as a synaptic vesicle amino acid transporter selective for proline, glycine, leucine, and alanine</article-title>
<source/>Mol. Pharmacol.
          <year>2008</year>
<volume>74</volume>
<fpage>1521</fpage>
<lpage>1532</lpage>
<pub-id pub-id-type="doi">10.1124/mol.108.050005</pub-id>
<pub-id pub-id-type="pmid">18768736</pub-id>
</element-citation>
</ref>
<ref id="B121-ijms-21-00119">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zaia</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Reimer</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Synaptic vesicle protein NTT4/XT1 (SLC6A17) catalyzes Naþ-coupled neutral amino acid transport</article-title>
<source/>J. Biol. Chem.
          <year>2009</year>
<volume>284</volume>
<fpage>8439</fpage>
<lpage>8448</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M806407200</pub-id>
<pub-id pub-id-type="pmid">19147495</pub-id>
</element-citation>
</ref>
<ref id="B122-ijms-21-00119">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seow</surname>
<given-names>H.F.</given-names>
</name>
<name>
<surname>Bröer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bröer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>Potter</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Cavanaugh</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Rasko</surname>
<given-names>J.E.</given-names>
</name>
</person-group>
<article-title>Hartnup disorder is caused by mutations in the gene encoding the neutral amino acid transporter SLC6A19</article-title>
<source/>Nat. Genet.
          <year>2004</year>
<volume>36</volume>
<fpage>1003</fpage>
<lpage>1007</lpage>
<pub-id pub-id-type="doi">10.1038/ng1406</pub-id>
<pub-id pub-id-type="pmid">15286788</pub-id>
</element-citation>
</ref>
<ref id="B123-ijms-21-00119">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kleta</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Romeo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ristic</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Ohura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Stuart</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Arcos-Burgos</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dave</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Camargo</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in SLC6A19, encoding B0AT1, cause Hartnup disorder</article-title>
<source/>Nat. Genet.
          <year>2004</year>
<volume>36</volume>
<fpage>999</fpage>
<lpage>1002</lpage>
<pub-id pub-id-type="doi">10.1038/ng1405</pub-id>
<pub-id pub-id-type="pmid">15286787</pub-id>
</element-citation>
</ref>
<ref id="B124-ijms-21-00119">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bröer</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Apical transporters for neutral amino acids: Physiology and pathophysiology</article-title>
<source/>Physiology (Bethesda)
          <year>2008</year>
<volume>23</volume>
<fpage>95</fpage>
<lpage>103</lpage>
<pub-id pub-id-type="doi">10.1152/physiol.00045.2007</pub-id>
<pub-id pub-id-type="pmid">18400692</pub-id>
</element-citation>
</ref>
<ref id="B125-ijms-21-00119">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bröer</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>The role of the neutral amino acid transporter B0AT1 (SLC6A19) in Hartnup disorder and protein nutrition</article-title>
<source/>IUBMB. Life
          <year>2009</year>
<volume>61</volume>
<fpage>591</fpage>
<lpage>599</lpage>
<pub-id pub-id-type="doi">10.1002/iub.210</pub-id>
<pub-id pub-id-type="pmid">19472175</pub-id>
</element-citation>
</ref>
<ref id="B126-ijms-21-00119">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singer</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Camargo</surname>
<given-names>S.M.</given-names>
</name>
</person-group>
<article-title>Collectrin and ACE2 in renal and intestinal amino acid transport</article-title>
<source/>Channels (Austin)
          <year>2011</year>
<volume>5</volume>
<fpage>410</fpage>
<lpage>423</lpage>
<pub-id pub-id-type="doi">10.4161/chan.5.5.16470</pub-id>
<pub-id pub-id-type="pmid">21814048</pub-id>
</element-citation>
</ref>
<ref id="B127-ijms-21-00119">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scriver</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Mahon</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>H.L.</given-names>
</name>
<name>
<surname>Clow</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Reade</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Kronick</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lemieux</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Laberge</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>The Hartnup phenotype: Mendelian transport disorder, multifactorial disease</article-title>
<source/>Am. J. Hum. Genet.
          <year>1987</year>
<volume>40</volume>
<fpage>401</fpage>
<lpage>412</lpage>
<pub-id pub-id-type="pmid">3578280</pub-id>
</element-citation>
</ref>
<ref id="B128-ijms-21-00119">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baron</surname>
<given-names>D.N.</given-names>
</name>
<name>
<surname>Dent</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hart</surname>
<given-names>E.W.</given-names>
</name>
<name>
<surname>Jepson</surname>
<given-names>J.B.</given-names>
</name>
</person-group>
<article-title>Hereditary pellagra-like skin rash with temporary cerebellar ataxia, constant renal aminoaciduria and other bizarre biochemical features</article-title>
<source/>Lancet
          <year>1956</year>
<volume>268</volume>
<fpage>421</fpage>
<lpage>428</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(56)91914-6</pub-id>
</element-citation>
</ref>
<ref id="B129-ijms-21-00119">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheon</surname>
<given-names>C.K.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>B.H.</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Yoo</surname>
<given-names>H.W.</given-names>
</name>
</person-group>
<article-title>Novel mutation in SLC6A19 causing late-onset seizures in Hartnup disorder</article-title>
<source/>Pediatr. Neurol.
          <year>2010</year>
<volume>42</volume>
<fpage>369</fpage>
<lpage>371</lpage>
<pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2010.01.009</pub-id>
<pub-id pub-id-type="pmid">20399395</pub-id>
</element-citation>
</ref>
<ref id="B130-ijms-21-00119">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pillai</surname>
<given-names>N.R.</given-names>
</name>
<name>
<surname>Yubero</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Shayota</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Oyarzábal</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Azamian</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Arjona</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Brandi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Palau</surname>
<given-names>F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Loss of CLTRN function produces a neuropsychiatric disorder and a biochemical phenotype that mimics Hartnup disease</article-title>
<source/>Am. J. Med. Genet. A
          <year>2019</year>
<volume>179</volume>
<fpage>2459</fpage>
<lpage>2468</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.61357</pub-id>
<pub-id pub-id-type="pmid">31520464</pub-id>
</element-citation>
</ref>
<ref id="B131-ijms-21-00119">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bröer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>Kowalczuk</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Vanslambrouck</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Rodgers</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Auray-Blais</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cavanaugh</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Bröer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rasko</surname>
<given-names>J.E.</given-names>
</name>
</person-group>
<article-title>Iminoglycinuria and hyperglycinuria are discrete human phenotypes resulting from complex mutations in proline and glycine transporters</article-title>
<source/>J. Clin. Investig.
          <year>2008</year>
<volume>118</volume>
<fpage>3881</fpage>
<lpage>3892</lpage>
<pub-id pub-id-type="doi">10.1172/JCI36625</pub-id>
<pub-id pub-id-type="pmid">19033659</pub-id>
</element-citation>
</ref>
<ref id="B132-ijms-21-00119">
<label>132.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Chesney</surname>
<given-names>R.W.</given-names>
</name>
</person-group>
<article-title>Iminoglycinuria</article-title>
<source/>The Metabolic and Molecular Bases of Inherited Disease. Vol. III
          <edition>8th ed.</edition>
<person-group person-group-type="editor">
<name>
<surname>Scriver</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Beaudet</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Sly</surname>
<given-names>W.S.</given-names>
</name>
<name>
<surname>Valle</surname>
<given-names>D.</given-names>
</name>
</person-group>
<publisher-name>McGraw-Hill</publisher-name>
<publisher-loc>New York, NY, USA</publisher-loc>
<year>2001</year>
<fpage>4971</fpage>
<lpage>4981</lpage>
</element-citation>
</ref>
<ref id="B133-ijms-21-00119">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yahyaoui</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Blasco-Alonso</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Benito</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rodríguez-García</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Andrade</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Aldámiz-Echevarría</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Muñoz-Hernández</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Vega</surname>
<given-names>A.I.</given-names>
</name>
<name>
<surname>Pérez-Cerdá</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>García-Martín</surname>
<given-names>M.L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A new metabolic disorder in human cationic amino acid transporter-2 that mimics arginase 1 deficiency in newborn screening</article-title>
<source/>J. Inherit. Metab. Dis.
          <year>2019</year>
<volume>42</volume>
<fpage>407</fpage>
<lpage>413</lpage>
<pub-id pub-id-type="doi">10.1002/jimd.12063</pub-id>
<pub-id pub-id-type="pmid">30671984</pub-id>
</element-citation>
</ref>
<ref id="B134-ijms-21-00119">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoshide</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ikeda</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Karashima</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Matsuura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Komaki</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kishino</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Niikawa</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Endo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Matsuda</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Molecular cloning, tissue distribution, and chromosomal localization of human cationic amino acid transporter 2 (HCAT2)</article-title>
<source/>Genomics
          <year>1996</year>
<volume>38</volume>
<fpage>174</fpage>
<lpage>178</lpage>
<pub-id pub-id-type="doi">10.1006/geno.1996.0613</pub-id>
<pub-id pub-id-type="pmid">8954799</pub-id>
</element-citation>
</ref>
<ref id="B135-ijms-21-00119">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toivonen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tringham</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kurko</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Terho</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Simell</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Heiskanen</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Mykkänen</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Interactions of y+LAT1 and 4F2hc in the y+l amino acid transporter complex: Consequences of lysinuric protein intolerance-causing mutations</article-title>
<source/>Gen. Physiol. Biophys.
          <year>2013</year>
<volume>32</volume>
<fpage>479</fpage>
<lpage>488</lpage>
<pub-id pub-id-type="doi">10.4149/gpb_2013050</pub-id>
<pub-id pub-id-type="pmid">23940088</pub-id>
</element-citation>
</ref>
<ref id="B136-ijms-21-00119">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perheentupa</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Visakorpi</surname>
<given-names>J.K.</given-names>
</name>
</person-group>
<article-title>Protein intolerance with deficient transport of basic aminoacids. Another inborn error of metabolism</article-title>
<source/>Lancet
          <year>1965</year>
<volume>2</volume>
<fpage>813</fpage>
<lpage>816</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(65)92446-3</pub-id>
<pub-id pub-id-type="pmid">4158034</pub-id>
</element-citation>
</ref>
<ref id="B137-ijms-21-00119">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noguchi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Overview of symptoms and treatment for lysinuric protein intolerance</article-title>
<source/>J. Hum. Genet.
          <year>2019</year>
<volume>64</volume>
<fpage>849</fpage>
<lpage>858</lpage>
<pub-id pub-id-type="doi">10.1038/s10038-019-0620-6</pub-id>
<pub-id pub-id-type="pmid">31213652</pub-id>
</element-citation>
</ref>
<ref id="B138-ijms-21-00119">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Posey</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Burrage</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Hardison</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Elsea</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Willis</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Schlesinger</surname>
<given-names>A.E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lysinuric protein intolerance presenting with multiple fractures</article-title>
<source/>Mol. Genet. Metab. Rep.
          <year>2014</year>
<volume>1</volume>
<fpage>176</fpage>
<lpage>183</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgmr.2014.03.004</pub-id>
<pub-id pub-id-type="pmid">25419514</pub-id>
</element-citation>
</ref>
<ref id="B139-ijms-21-00119">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Svedström</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Parto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Marttinen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Virtama</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Simell</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Skeletal manifestations of lysinuric protein intolerance. A follow-up study of 29 patients</article-title>
<source/>Skelet. Radiol.
          <year>1993</year>
<volume>22</volume>
<fpage>11</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1007/BF00191519</pub-id>
</element-citation>
</ref>
<ref id="B140-ijms-21-00119">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Güzel-Ozantürk</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ozgül</surname>
<given-names>R.K.</given-names>
</name>
<name>
<surname>Unal</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Hişmi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Aydın</surname>
<given-names>H.İ.</given-names>
</name>
<name>
<surname>Sivri</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Molecular and clinical evaluation of Turkish patients with lysinuric protein intolerance</article-title>
<source/>Gene
          <year>2013</year>
<volume>521</volume>
<fpage>293</fpage>
<lpage>295</lpage>
<pub-id pub-id-type="doi">10.1016/j.gene.2013.03.033</pub-id>
<pub-id pub-id-type="pmid">23542076</pub-id>
</element-citation>
</ref>
<ref id="B141-ijms-21-00119">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bijarnia-Mahay</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jain</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Bansal</surname>
<given-names>R.K.</given-names>
</name>
<name>
<surname>Reddy</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Haberle</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Lysinuric protein intolerance presenting with recurrent hyperammonemic encephalopathy</article-title>
<source/>Indian Pediatr.
          <year>2016</year>
<volume>53</volume>
<fpage>732</fpage>
<lpage>734</lpage>
<pub-id pub-id-type="doi">10.1007/s13312-016-0920-2</pub-id>
<pub-id pub-id-type="pmid">27567650</pub-id>
</element-citation>
</ref>
<ref id="B142-ijms-21-00119">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lukkarinen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Näntö-Salonen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ruuskanen</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Lauteala</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Säkö</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nuutinen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Simell</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Varicella and varicella immunity in patients with lysinuric protein intolerance</article-title>
<source/>J. Inherit. Metab. Dis.
          <year>1998</year>
<volume>21</volume>
<fpage>103</fpage>
<lpage>111</lpage>
<pub-id pub-id-type="doi">10.1023/A:1005335423939</pub-id>
<pub-id pub-id-type="pmid">9584261</pub-id>
</element-citation>
</ref>
<ref id="B143-ijms-21-00119">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tanner</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Näntö-Salonen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Niinikoski</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jahnukainen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Keskinen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Saha</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kananen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Helanterä</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Metso</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Linnanvuo</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Nephropathy advancing to end-stage renal disease: A novel complication of lysinuric protein intolerance</article-title>
<source/>J. Pediatr.
          <year>2007</year>
<volume>150</volume>
<fpage>631</fpage>
<lpage>634</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpeds.2007.01.043</pub-id>
<pub-id pub-id-type="pmid">17517249</pub-id>
</element-citation>
</ref>
<ref id="B144-ijms-21-00119">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicolas</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bednarek</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Vuiblet</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Boyer</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Brassier</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>De Lonlay</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Galmiche</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Krug</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Baudouin</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Pichard</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Renal involvement in a French paediatric cohort of patients with lysinuric protein intolerance</article-title>
<source/>JIMD. Rep.
          <year>2016</year>
<volume>29</volume>
<fpage>11</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="pmid">26608393</pub-id>
</element-citation>
</ref>
<ref id="B145-ijms-21-00119">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kärki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Näntö-Salonen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Niinikoski</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tanner</surname>
<given-names>L.M.</given-names>
</name>
</person-group>
<article-title>Urine beta2-microglobulin is an early marker of renal involvement in LPI</article-title>
<source/>JIMD Rep.
          <year>2016</year>
<volume>25</volume>
<fpage>47</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="pmid">26122628</pub-id>
</element-citation>
</ref>
<ref id="B146-ijms-21-00119">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valimahamed-Mitha</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Berteloot</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ducoin</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ottolenghi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>de Lonlay</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>de Blic</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Lung involvement in children with lysinuric protein intolerance</article-title>
<source/>J. Inherit. Metab. Dis.
          <year>2015</year>
<volume>38</volume>
<fpage>257</fpage>
<lpage>263</lpage>
<pub-id pub-id-type="doi">10.1007/s10545-014-9777-5</pub-id>
<pub-id pub-id-type="pmid">25335805</pub-id>
</element-citation>
</ref>
<ref id="B147-ijms-21-00119">
<label>147.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parenti</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sebastio</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Strisciuglio</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Incerti</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Pecoraro</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Terracciano</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Andria</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Lysinuric protein intolerance characterized by bone marrow abnormalities and severe clinical course</article-title>
<source/>J. Pediatr.
          <year>1995</year>
<volume>126</volume>
<fpage>246</fpage>
<lpage>251</lpage>
<pub-id pub-id-type="doi">10.1016/S0022-3476(95)70552-X</pub-id>
<pub-id pub-id-type="pmid">7844671</pub-id>
</element-citation>
</ref>
<ref id="B148-ijms-21-00119">
<label>148.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Simell</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Lysinuric protein intolerance and other cationic aminoacidurias</article-title>
<source/>The Metabolic and Molecular Basis of Inherited Disease
          <person-group person-group-type="editor">
<name>
<surname>Scriver</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Beaudet</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Sly</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Valle</surname>
<given-names>D.</given-names>
</name>
</person-group>
<publisher-name>McGraw-Hill</publisher-name>
<publisher-loc>New York, NY, USA</publisher-loc>
<year>2001</year>
<fpage>4933</fpage>
<lpage>4956</lpage>
</element-citation>
</ref>
<ref id="B149-ijms-21-00119">
<label>149.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palacin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Borsani</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sebastio</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>The molecular bases of cystinuria and lysinuric protein intolerance</article-title>
<source/>Curr. Opin. Genet. Dev.
          <year>2001</year>
<volume>11</volume>
<fpage>328</fpage>
<lpage>335</lpage>
<pub-id pub-id-type="doi">10.1016/S0959-437X(00)00198-2</pub-id>
<pub-id pub-id-type="pmid">11377971</pub-id>
</element-citation>
</ref>
<ref id="B150-ijms-21-00119">
<label>150.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tringham</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kurko</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tanner</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tuikkala</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nevalainen</surname>
<given-names>O.S.</given-names>
</name>
<name>
<surname>Niinikoski</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Näntö-Salonen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hietala</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Simell</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Mykkänen</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Exploring the transcriptomic variation caused by the Finnish founder mutation of lysinuric protein intolerance (LPI)</article-title>
<source/>Mol. Genet. Metab.
          <year>2012</year>
<volume>105</volume>
<fpage>408</fpage>
<lpage>415</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgme.2011.12.007</pub-id>
<pub-id pub-id-type="pmid">22221392</pub-id>
</element-citation>
</ref>
<ref id="B151-ijms-21-00119">
<label>151.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>Z.B.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X.F.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>J.N.</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D.Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>SLC7A14 linked to autosomal recessive retinitis pigmentosa</article-title>
<source/>Nat. Commun.
          <year>2014</year>
<volume>5</volume>
<fpage>3517</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms4517</pub-id>
<pub-id pub-id-type="pmid">24670872</pub-id>
</element-citation>
</ref>
<ref id="B152-ijms-21-00119">
<label>152.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>L.Y.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>W.H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y.T.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Phenotypic variability of SLC7A14 mutations in patients with inherited retinal dystrophy</article-title>
<source/>Ophthalmic Genet.
          <year>2019</year>
<volume>40</volume>
<fpage>118</fpage>
<lpage>123</lpage>
<pub-id pub-id-type="doi">10.1080/13816810.2019.1586964</pub-id>
<pub-id pub-id-type="pmid">30924391</pub-id>
</element-citation>
</ref>
<ref id="B153-ijms-21-00119">
<label>153.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greene</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>McMillan</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Barker</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Kurnool</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lomax</surname>
<given-names>M.I.</given-names>
</name>
<name>
<surname>Burmeister</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lesperance</surname>
<given-names>M.M.</given-names>
</name>
</person-group>
<article-title>DFNA25, a novel locus for dominant nonsyndromic hereditary hearing impairment, maps to 12q21-24</article-title>
<source/>Am. J. Hum. Genet.
          <year>2001</year>
<volume>68</volume>
<fpage>254</fpage>
<lpage>260</lpage>
<pub-id pub-id-type="doi">10.1086/316925</pub-id>
<pub-id pub-id-type="pmid">11115382</pub-id>
</element-citation>
</ref>
<ref id="B154-ijms-21-00119">
<label>154.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruel</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Emery</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nouvian</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bersot</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Amilhon</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Van Rybroek</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Rebillard</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lenoir</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Eybalin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Delprat</surname>
<given-names>B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice</article-title>
<source/>Am. J. Hum. Genet.
          <year>2008</year>
<volume>83</volume>
<fpage>278</fpage>
<lpage>292</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2008.07.008</pub-id>
<pub-id pub-id-type="pmid">18674745</pub-id>
</element-citation>
</ref>
<ref id="B155-ijms-21-00119">
<label>155.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ryu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Bok</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>C.I.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>K.Y.</given-names>
</name>
<name>
<surname>Baek</surname>
<given-names>J.I.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>U.K.</given-names>
</name>
</person-group>
<article-title>Identification of a novel splicing mutation within SLC17A8 in a Korean family with hearing loss by whole-exome sequencing</article-title>
<source/>Gene
          <year>2017</year>
<volume>627</volume>
<fpage>233</fpage>
<lpage>238</lpage>
<pub-id pub-id-type="doi">10.1016/j.gene.2017.06.040</pub-id>
<pub-id pub-id-type="pmid">28647561</pub-id>
</element-citation>
</ref>
<ref id="B156-ijms-21-00119">
<label>156.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seal</surname>
<given-names>R.P.</given-names>
</name>
<name>
<surname>Akil</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yoo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Clause</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kandler</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Noebels</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Glowatzki</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sensorineural deafness and seizures in mice lacking vesicular glutamate transporter 3</article-title>
<source/>Neuron
          <year>2008</year>
<volume>57</volume>
<fpage>263</fpage>
<lpage>275</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2007.11.032</pub-id>
<pub-id pub-id-type="pmid">18215623</pub-id>
</element-citation>
</ref>
<ref id="B157-ijms-21-00119">
<label>157.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akil</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Seal</surname>
<given-names>R.P.</given-names>
</name>
<name>
<surname>Burke</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Alemi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>During</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Edwards</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Lustig</surname>
<given-names>L.R.</given-names>
</name>
</person-group>
<article-title>Restoration of hearing in the VGLUT3 knockout mouse using virally mediated gene therapy</article-title>
<source/>Neuron
          <year>2012</year>
<volume>75</volume>
<fpage>283</fpage>
<lpage>293</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2012.05.019</pub-id>
<pub-id pub-id-type="pmid">22841313</pub-id>
</element-citation>
</ref>
<ref id="B158-ijms-21-00119">
<label>158.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amoedo</surname>
<given-names>N.D.</given-names>
</name>
<name>
<surname>Punzi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Obre</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lacombe</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>De Grassi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pierri</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Rossignol</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>AGC1/2, the mitochondrial aspartate-glutamate carriers</article-title>
<source/>Biochim. Biophys. Acta.
          <year>2016</year>
<volume>1863</volume>
<fpage>2394</fpage>
<lpage>2412</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbamcr.2016.04.011</pub-id>
<pub-id pub-id-type="pmid">27132995</pub-id>
</element-citation>
</ref>
<ref id="B159-ijms-21-00119">
<label>159.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alkan</surname>
<given-names>H.F.</given-names>
</name>
<name>
<surname>Walter</surname>
<given-names>K.E.</given-names>
</name>
<name>
<surname>Luengo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Madreiter-Sokolowski</surname>
<given-names>C.T.</given-names>
</name>
<name>
<surname>Stryeck</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lau</surname>
<given-names>A.N.</given-names>
</name>
<name>
<surname>Al-Zoughbi</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Hoefler</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cytosolic aspartate availability determines cell survival when glutamine is limiting</article-title>
<source/>Cell Metab.
          <year>2018</year>
<volume>28</volume>
<fpage>706</fpage>
<lpage>720</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2018.07.021</pub-id>
<pub-id pub-id-type="pmid">30122555</pub-id>
</element-citation>
</ref>
<ref id="B160-ijms-21-00119">
<label>160.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Falk</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gai</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>McCormick</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Place</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lasorsa</surname>
<given-names>F.M.</given-names>
</name>
<name>
<surname>Otieno</surname>
<given-names>F.G.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Abdel-Magid</surname>
<given-names>N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>AGC1 deficiency causes infantile epilepsy, abnormal myelination, and reduced N-acetylaspartate</article-title>
<source/>JIMD Rep.
          <year>2014</year>
<volume>14</volume>
<fpage>77</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="pmid">24515575</pub-id>
</element-citation>
</ref>
<ref id="B161-ijms-21-00119">
<label>161.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wibom</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lasorsa</surname>
<given-names>F.M.</given-names>
</name>
<name>
<surname>Tohonen</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Barbaro</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sterky</surname>
<given-names>F.H.</given-names>
</name>
<name>
<surname>Kucinski</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Naess</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Jonsson</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pierri</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Palmieri</surname>
<given-names>F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>AGC1 deficiency associated with global cerebral hypomyelination</article-title>
<source/>N. Engl. J. Med.
          <year>2009</year>
<volume>361</volume>
<fpage>489</fpage>
<lpage>495</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa0900591</pub-id>
<pub-id pub-id-type="pmid">19641205</pub-id>
</element-citation>
</ref>
<ref id="B162-ijms-21-00119">
<label>162.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dahlin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Hedlund</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Jonsson</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>von Dobeln</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Wedell</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>The ketogenic diet compensates for AGC1 deficiency and improves myelination</article-title>
<source/>Epilepsia
          <year>2015</year>
<volume>56</volume>
<fpage>e176</fpage>
<lpage>e181</lpage>
<pub-id pub-id-type="doi">10.1111/epi.13193</pub-id>
<pub-id pub-id-type="pmid">26401995</pub-id>
</element-citation>
</ref>
<ref id="B163-ijms-21-00119">
<label>163.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kavanaugh</surname>
<given-names>B.C.</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>E.B.</given-names>
</name>
<name>
<surname>Baytas</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Merck</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Buch</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Phornphutkul</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Caruso</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Morrow</surname>
<given-names>E.M.</given-names>
</name>
</person-group>
<article-title>Longitudinal MRI findings in patient with SLC25A12 pathogenic variants inform disease progression and classification</article-title>
<source/>Am. J. Med. Genet. A
          <year>2019</year>
<volume>179</volume>
<fpage>2284</fpage>
<lpage>2291</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.61322</pub-id>
<pub-id pub-id-type="pmid">31403263</pub-id>
</element-citation>
</ref>
<ref id="B164-ijms-21-00119">
<label>164.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saheki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Mitochondrial aspartate glutamate carrier (citrin) deficiency as the cause of adult-onset type II citrullinemia (CTLN2) and idiopathic neonatal hepatitis (NICCD)</article-title>
<source/>J. Hum. Genet.
          <year>2002</year>
<volume>47</volume>
<fpage>333</fpage>
<lpage>341</lpage>
<pub-id pub-id-type="doi">10.1007/s100380200046</pub-id>
<pub-id pub-id-type="pmid">12111366</pub-id>
</element-citation>
</ref>
<ref id="B165-ijms-21-00119">
<label>165.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saheki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Iijima</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Moriyama</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yazaki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Takei</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ikeda</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Metabolic derangements in deficiency of citrin, a liver-type mitochondrial aspartate–glutamate carrier</article-title>
<source/>Hepatol. Res.
          <year>2005</year>
<volume>33</volume>
<fpage>181</fpage>
<lpage>184</lpage>
<pub-id pub-id-type="doi">10.1016/j.hepres.2005.09.031</pub-id>
<pub-id pub-id-type="pmid">16199199</pub-id>
</element-citation>
</ref>
<ref id="B166-ijms-21-00119">
<label>166.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>W.X.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>H.S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.H.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Q.Q.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>S.T.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>F.P.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>W.R.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Y.Z.</given-names>
</name>
</person-group>
<article-title>Molecular diagnosis of pediatric patients with citrin deficiency in China: SLC25A13 mutation spectrum and the geographic distribution</article-title>
<source/>Sci. Rep.
          <year>2016</year>
<volume>6</volume>
<fpage>29732</fpage>
<pub-id pub-id-type="doi">10.1038/srep29732</pub-id>
<pub-id pub-id-type="pmid">27405544</pub-id>
</element-citation>
</ref>
<ref id="B167-ijms-21-00119">
<label>167.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>Y.Z.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.L.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>L.S.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Saheki</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Failure to thrive and dyslipidemia caused by citrin deficiency. A novel clinical phenotype</article-title>
<source/>Chin. J. Contemp. Pediatr.
          <year>2009</year>
<volume>11</volume>
<fpage>328</fpage>
<lpage>332</lpage>
</element-citation>
</ref>
<ref id="B168-ijms-21-00119">
<label>168.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tazawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nishi</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Abukawa</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sakamoto</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Iinuma</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Saheki</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Neonatal presentation of adult-onset type II citrullinemia</article-title>
<source/>Hum. Genet.
          <year>2001</year>
<volume>108</volume>
<fpage>87</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="doi">10.1007/s004390000448</pub-id>
<pub-id pub-id-type="pmid">11281457</pub-id>
</element-citation>
</ref>
<ref id="B169-ijms-21-00119">
<label>169.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tazawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ohura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Abukawa</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Nishinomiya</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hosoda</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yamashita</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nagata</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Kono</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yasuda</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Infantile cholestatic jaundice associated with adult-onset type II citrullinemia</article-title>
<source/>J. Pediatr.
          <year>2001</year>
<volume>138</volume>
<fpage>735</fpage>
<lpage>740</lpage>
<pub-id pub-id-type="doi">10.1067/mpd.2001.113264</pub-id>
<pub-id pub-id-type="pmid">11343052</pub-id>
</element-citation>
</ref>
<ref id="B170-ijms-21-00119">
<label>170.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tamamori</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Okano</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ozaki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Fujimoto</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kajiwara</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fukuda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Saheki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tagami</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yamano</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Neonatal intrahepatic cholestasis caused by citrin deficiency: Severe hepatic dysfunction in an infant requiring liver transplantation</article-title>
<source/>Eur. J. Pediatr.
          <year>2002</year>
<volume>161</volume>
<fpage>609</fpage>
<lpage>613</lpage>
<pub-id pub-id-type="doi">10.1007/s00431-002-1045-2</pub-id>
<pub-id pub-id-type="pmid">12424587</pub-id>
</element-citation>
</ref>
<ref id="B171-ijms-21-00119">
<label>171.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tazawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Abukawa</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sakamoto</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Tsuchiya</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Saheki</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Clinical pictures of 75 patients with neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD)</article-title>
<source/>J. Inherit. Metab. Dis.
          <year>2007</year>
<volume>30</volume>
<fpage>139</fpage>
<lpage>144</lpage>
<pub-id pub-id-type="doi">10.1007/s10545-007-0506-1</pub-id>
<pub-id pub-id-type="pmid">17323144</pub-id>
</element-citation>
</ref>
<ref id="B172-ijms-21-00119">
<label>172.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>C.F.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Mei</surname>
<given-names>H.F.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.P.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>L.X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>G.Q.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.L.</given-names>
</name>
</person-group>
<article-title>Newborn screening program and blood amino acid profiling in early neonates with citrin deficiency</article-title>
<source/>Zhonghua Er Ke Za Zhi
          <year>2019</year>
<volume>57</volume>
<fpage>797</fpage>
<lpage>801</lpage>
<pub-id pub-id-type="pmid">31594068</pub-id>
</element-citation>
</ref>
<ref id="B173-ijms-21-00119">
<label>173.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iijima</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jalil</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Begum</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yasuda</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yamaguchi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Xian Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kawada</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Endou</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Saheki</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Pathogenesis of adult-onset type II citrullinemia caused by deficiency of citrin, a mitochondrial solute carrier protein: Tissue and subcellular localization of citrin</article-title>
<source/>Adv. Enzym. Regul.
          <year>2001</year>
<volume>41</volume>
<fpage>325</fpage>
<lpage>342</lpage>
<pub-id pub-id-type="doi">10.1016/S0065-2571(00)00022-4</pub-id>
</element-citation>
</ref>
<ref id="B174-ijms-21-00119">
<label>174.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okano</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ohura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sakamoto</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Inui</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Current treatment for citrin deficiency during NICCD and adaptation/compensation stages: Strategy to prevent CTLN2</article-title>
<source/>Mol. Genet. Metab.
          <year>2019</year>
<volume>127</volume>
<fpage>175</fpage>
<lpage>183</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgme.2019.06.004</pub-id>
<pub-id pub-id-type="pmid">31255436</pub-id>
</element-citation>
</ref>
<ref id="B175-ijms-21-00119">
<label>175.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Häberle</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Boddaert</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Burlina</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chakrapani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dixon</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Huemer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Karall</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Martinelli</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Crespo</surname>
<given-names>P.S.</given-names>
</name>
<name>
<surname>Santer</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Suggested guidelines for the diagnosis and management of urea cycle disorders</article-title>
<source/>Orphanet J. Rare Dis.
          <year>2012</year>
<volume>7</volume>
<fpage>32</fpage>
<pub-id pub-id-type="doi">10.1186/1750-1172-7-32</pub-id>
<pub-id pub-id-type="pmid">22642880</pub-id>
</element-citation>
</ref>
<ref id="B176-ijms-21-00119">
<label>176.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Camacho</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Obie</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Biery</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Goodman</surname>
<given-names>B.K.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Almashanu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Steel</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Casey</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>G.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Hyperornithinaemia-hyperammonaemia-homocitrullinuria syndrome is caused by mutations in a gene encoding a mitochondrial ornithine transporter</article-title>
<source/>Nat. Genet.
          <year>1999</year>
<volume>22</volume>
<fpage>151</fpage>
<lpage>158</lpage>
<pub-id pub-id-type="doi">10.1038/9658</pub-id>
<pub-id pub-id-type="pmid">10369256</pub-id>
</element-citation>
</ref>
<ref id="B177-ijms-21-00119">
<label>177.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tessa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fiermonte</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Dionisi-Vici</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Paradies</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Baumgartner</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Chien</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Loguercio</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>de Baulny</surname>
<given-names>H.O.</given-names>
</name>
<name>
<surname>Nassogne</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Schiff</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of novel mutations in the SLC25A15 gene in hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome: A clinical, molecular, and functional study</article-title>
<source/>Hum. Mutat.
          <year>2009</year>
<volume>30</volume>
<fpage>741</fpage>
<lpage>748</lpage>
<pub-id pub-id-type="doi">10.1002/humu.20930</pub-id>
<pub-id pub-id-type="pmid">19242930</pub-id>
</element-citation>
</ref>
<ref id="B178-ijms-21-00119">
<label>178.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyamoto</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kanazawa</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kawakami</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kuhara</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Takeshita</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tsujino</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Diagnosis of Japanese patients with HHH syndrome by molecular genetic analysis: A common mutation, R179X</article-title>
<source/>J. Hum. Genet.
          <year>2001</year>
<volume>46</volume>
<fpage>260</fpage>
<lpage>262</lpage>
<pub-id pub-id-type="doi">10.1007/s100380170075</pub-id>
<pub-id pub-id-type="pmid">11355015</pub-id>
</element-citation>
</ref>
<ref id="B179-ijms-21-00119">
<label>179.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinelli</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Diodato</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ponzi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Monné</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Boenzi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bertini</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Fiermonte</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Dionisi-Vici</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome</article-title>
<source/>Orphanet J. Rare Dis.
          <year>2015</year>
<volume>10</volume>
<fpage>29</fpage>
<pub-id pub-id-type="doi">10.1186/s13023-015-0242-9</pub-id>
<pub-id pub-id-type="pmid">25874378</pub-id>
</element-citation>
</ref>
<ref id="B180-ijms-21-00119">
<label>180.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salvi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Santorelli</surname>
<given-names>F.M.</given-names>
</name>
<name>
<surname>Bertini</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Boldrini</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Meli</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Donati</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Burlina</surname>
<given-names>A.B.</given-names>
</name>
<name>
<surname>Rizzo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Di Capua</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fariello</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical and molecular findings in hyperornithinemia-hyperammonemia-homocitrullinuria syndrome</article-title>
<source/>Neurology
          <year>2001</year>
<volume>57</volume>
<fpage>911</fpage>
<lpage>914</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.57.5.911</pub-id>
<pub-id pub-id-type="pmid">11552031</pub-id>
</element-citation>
</ref>
<ref id="B181-ijms-21-00119">
<label>181.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olivieri</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pro</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Diodato</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Di Capua</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Longo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Martinelli</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bertini</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Dionisi-Vici</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Corticospinal tract damage in HHH syndrome: A metabolic cause of hereditary spastic paraplegia</article-title>
<source/>Orphanet J. Rare Dis.
          <year>2019</year>
<volume>14</volume>
<fpage>208</fpage>
<pub-id pub-id-type="doi">10.1186/s13023-019-1181-7</pub-id>
<pub-id pub-id-type="pmid">31443672</pub-id>
</element-citation>
</ref>
<ref id="B182-ijms-21-00119">
<label>182.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Molinari</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Raas-Rothschild</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rio</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fiermonte</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Encha-Razavi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Palmieri</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Palmieri</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ben-Neriah</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Kadhom</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Vekemans</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Impaired mitochondrial glutamate transport in autosomal recessive neonatal myoclonic epilepsy</article-title>
<source/>Am. J. Hum. Genet.
          <year>2005</year>
<volume>76</volume>
<fpage>334</fpage>
<lpage>339</lpage>
<pub-id pub-id-type="doi">10.1086/427564</pub-id>
<pub-id pub-id-type="pmid">15592994</pub-id>
</element-citation>
</ref>
<ref id="B183-ijms-21-00119">
<label>183.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Molinari</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kaminska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fiermonte</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Boddaert</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Raas-Rothschild</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Plouin</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Palmieri</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Brunelle</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Palmieri</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Dulac</surname>
<given-names>O.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in the mitochondrial glutamate carrier SLC25A22 in neonatal epileptic encephalopathy with suppression bursts</article-title>
<source/>Clin. Genet.
          <year>2009</year>
<volume>76</volume>
<fpage>188</fpage>
<lpage>194</lpage>
<pub-id pub-id-type="doi">10.1111/j.1399-0004.2009.01236.x</pub-id>
<pub-id pub-id-type="pmid">19780765</pub-id>
</element-citation>
</ref>
<ref id="B184-ijms-21-00119">
<label>184.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lemattre</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Imbert-Bouteille</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gatinois</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Benit</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sanchez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Guignard</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tran Mau-Them</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Haquet</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Rivier</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Carme</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Report on three additional patients and genotype-phenotype correlation in SLC25A22-related disorders group</article-title>
<source/>Eur. J. Hum. Genet.
          <year>2019</year>
<volume>27</volume>
<fpage>1692</fpage>
<lpage>1700</lpage>
<pub-id pub-id-type="doi">10.1038/s41431-019-0433-2</pub-id>
<pub-id pub-id-type="pmid">31285529</pub-id>
</element-citation>
</ref>
<ref id="B185-ijms-21-00119">
<label>185.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goubert</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mircheva</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lasorsa</surname>
<given-names>F.M.</given-names>
</name>
<name>
<surname>Melon</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Profilo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sutera</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Becq</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Palmieri</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Palmieri</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Aniksztejn</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Inhibition of the mitochondrial glutamate carrier SLC25A22 in astrocytes leads to intracellular glutamate accumulation</article-title>
<source/>Front. Cell. Neurosci.
          <year>2017</year>
<volume>11</volume>
<fpage>149</fpage>
<pub-id pub-id-type="doi">10.3389/fncel.2017.00149</pub-id>
<pub-id pub-id-type="pmid">28620281</pub-id>
</element-citation>
</ref>
<ref id="B186-ijms-21-00119">
<label>186.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giacomini</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pisciotta</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Prato</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Meola</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Zara</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Fiorillo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Baratto</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Severino</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>De Grandis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mancardi</surname>
<given-names>M.M.</given-names>
</name>
</person-group>
<article-title>Severe early-onset developmental and epileptic encephalopathy (DEE) associated with novel compound heterozygous pathogenic variants in SLC25A22: Case report and literature review</article-title>
<source/>Seizure
          <year>2019</year>
<volume>70</volume>
<fpage>56</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="doi">10.1016/j.seizure.2019.06.029</pub-id>
<pub-id pub-id-type="pmid">31279168</pub-id>
</element-citation>
</ref>
<ref id="B187-ijms-21-00119">
<label>187.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reid</surname>
<given-names>E.S.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Benatti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chong</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>James</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ocaka</surname>
<given-names>L.</given-names>
</name>
<collab>GOSgene</collab>
<name>
<surname>Hemingway</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Little</surname>
<given-names>D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in SLC25A22: Hyperprolinaemia, vacuolated fibroblasts and presentation with developmental delay</article-title>
<source/>J. Inherit. Metab. Dis.
          <year>2017</year>
<volume>40</volume>
<fpage>385</fpage>
<lpage>394</lpage>
<pub-id pub-id-type="doi">10.1007/s10545-017-0025-7</pub-id>
<pub-id pub-id-type="pmid">28255779</pub-id>
</element-citation>
</ref>
<ref id="B188-ijms-21-00119">
<label>188.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scheffer</surname>
<given-names>I.E.</given-names>
</name>
<name>
<surname>Berkovic</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Capovilla</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Connolly</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>French</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Guilhoto</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hirsch</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Jain</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mathern</surname>
<given-names>G.W.</given-names>
</name>
<name>
<surname>Moshé</surname>
<given-names>S.L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology</article-title>
<source/>Epilepsia
          <year>2017</year>
<volume>58</volume>
<fpage>512</fpage>
<lpage>521</lpage>
<pub-id pub-id-type="doi">10.1111/epi.13709</pub-id>
<pub-id pub-id-type="pmid">28276062</pub-id>
</element-citation>
</ref>
<ref id="B189-ijms-21-00119">
<label>189.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poduri</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Heinzen</surname>
<given-names>E.L.</given-names>
</name>
<name>
<surname>Chitsazzadeh</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Lasorsa</surname>
<given-names>F.M.</given-names>
</name>
<name>
<surname>Elhosary</surname>
<given-names>P.C.</given-names>
</name>
<name>
<surname>LaCoursiere</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Yuskaitis</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Atabay</surname>
<given-names>K.D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>SLC25A22 is a novel gene for migrating partial seizures in infancy</article-title>
<source/>Ann. Neurol.
          <year>2013</year>
<volume>74</volume>
<fpage>873</fpage>
<lpage>882</lpage>
<pub-id pub-id-type="doi">10.1002/ana.23998</pub-id>
<pub-id pub-id-type="pmid">24596948</pub-id>
</element-citation>
</ref>
<ref id="B190-ijms-21-00119">
<label>190.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toral</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Velez</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Boudreault</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Schaefer</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Saffra</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Bassuk</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>Tsang</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Mahajan</surname>
<given-names>V.B.</given-names>
</name>
</person-group>
<article-title>Structural modeling of a novel SLC38A8 mutation that causes foveal hypoplasia</article-title>
<source/>Mol. Genet. Genom. Med.
          <year>2017</year>
<volume>5</volume>
<fpage>202</fpage>
<lpage>209</lpage>
<pub-id pub-id-type="doi">10.1002/mgg3.266</pub-id>
</element-citation>
</ref>
<ref id="B191-ijms-21-00119">
<label>191.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Araimi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pal</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Poulter</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>van Genderen</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Carr</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Cudrnak</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sheridan</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mohamed</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Bradbury</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A new recessively inherited disorder composed of foveal hypoplasia, optic nerve decussation defects and anterior segment dysgenesis maps to chromosome 16q23.3-24.1</article-title>
<source/>Mol. Vis.
          <year>2013</year>
<volume>19</volume>
<fpage>2165</fpage>
<lpage>2172</lpage>
<pub-id pub-id-type="pmid">24194637</pub-id>
</element-citation>
</ref>
<ref id="B192-ijms-21-00119">
<label>192.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poulter</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Al-Araimi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Conte</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>van Genderen</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Sheridan</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Carr</surname>
<given-names>I.M.</given-names>
</name>
<name>
<surname>Parry</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Shires</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Carrella</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bradbury</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Recessive mutations in SLC38A8 cause foveal hypoplasia and optic nerve misrouting without albinism</article-title>
<source/>Am. J. Hum. Genet.
          <year>2013</year>
<volume>93</volume>
<fpage>1143</fpage>
<lpage>1150</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2013.11.002</pub-id>
<pub-id pub-id-type="pmid">24290379</pub-id>
</element-citation>
</ref>
<ref id="B193-ijms-21-00119">
<label>193.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perez</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gradstein</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Flusser</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Markus</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Langer</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Marcus</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lifshitz</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kadir</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Birk</surname>
<given-names>O.S.</given-names>
</name>
</person-group>
<article-title>Isolated foveal hypoplasia with secondary nystagmus and low vision is associated with a homozygous SLC38A8 mutation</article-title>
<source/>Eur. J. Hum. Genet.
          <year>2014</year>
<volume>22</volume>
<fpage>703</fpage>
<lpage>706</lpage>
<pub-id pub-id-type="doi">10.1038/ejhg.2013.212</pub-id>
<pub-id pub-id-type="pmid">24045842</pub-id>
</element-citation>
</ref>
<ref id="B194-ijms-21-00119">
<label>194.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gahl</surname>
<given-names>W.A.</given-names>
</name>
<name>
<surname>Thoene</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Cystinosis</article-title>
<source/>N. Engl. J. Med.
          <year>2002</year>
<volume>347</volume>
<fpage>111</fpage>
<lpage>121</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMra020552</pub-id>
<pub-id pub-id-type="pmid">12110740</pub-id>
</element-citation>
</ref>
<ref id="B195-ijms-21-00119">
<label>195.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalatzis</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Cherqui</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Antignac</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gasnier</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Cystinosin, the protein defective in cystinosis, is a H(+)-driven lysosomal cystine transporter</article-title>
<source/>EMBO J.
          <year>2001</year>
<volume>20</volume>
<fpage>5940</fpage>
<lpage>5949</lpage>
<pub-id pub-id-type="doi">10.1093/emboj/20.21.5940</pub-id>
<pub-id pub-id-type="pmid">11689434</pub-id>
</element-citation>
</ref>
<ref id="B196-ijms-21-00119">
<label>196.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nesterova</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gahl</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Nephropathic cystinosis: Late complications of a multisystemic disease</article-title>
<source/>Pediatr. Nephrol.
          <year>2008</year>
<volume>23</volume>
<fpage>863</fpage>
<lpage>878</lpage>
<pub-id pub-id-type="doi">10.1007/s00467-007-0650-8</pub-id>
<pub-id pub-id-type="pmid">18008091</pub-id>
</element-citation>
</ref>
<ref id="B197-ijms-21-00119">
<label>197.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cherqui</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Courtoy</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>The renal Fanconi syndrome in cystinosis: Pathogenic insights and therapeutic perspectives</article-title>
<source/>Nat. Rev. Nephrol.
          <year>2017</year>
<volume>13</volume>
<fpage>115</fpage>
<lpage>131</lpage>
<pub-id pub-id-type="doi">10.1038/nrneph.2016.182</pub-id>
<pub-id pub-id-type="pmid">27990015</pub-id>
</element-citation>
</ref>
<ref id="B198-ijms-21-00119">
<label>198.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Haggar</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Cystinosis as a lysosomal storage disease with multiple mutant alleles: Phenotypic-genotypic correlations</article-title>
<source/>World J. Nephrol.
          <year>2013</year>
<volume>2</volume>
<fpage>94</fpage>
<lpage>102</lpage>
<pub-id pub-id-type="pmid">24255892</pub-id>
</element-citation>
</ref>
<ref id="B199-ijms-21-00119">
<label>199.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Servais</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Morinière</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Grünfeld</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Noel</surname>
<given-names>L.H.</given-names>
</name>
<name>
<surname>Goujon</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>ChadefauxVekemans</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Antignac</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Late-onset nephropathic cystinosis: Clinical presentation, outcome, and genotyping</article-title>
<source/>Clin. J. Am. Soc. Nephrol.
          <year>2008</year>
<volume>3</volume>
<fpage>27</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="doi">10.2215/CJN.01740407</pub-id>
<pub-id pub-id-type="pmid">18178779</pub-id>
</element-citation>
</ref>
<ref id="B200-ijms-21-00119">
<label>200.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anikster</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lucero</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huizing</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shotelersuk</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Bernardini</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>McDowell</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Iwata</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kaiser-Kupfer</surname>
<given-names>M.I.</given-names>
</name>
<name>
<surname>Jaffe</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ocular nonnephropathic cystinosis: Clinical, biochemical, and molecular correlations</article-title>
<source/>Pediatr. Res.
          <year>2000</year>
<volume>47</volume>
<fpage>17</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="doi">10.1203/00006450-200001000-00007</pub-id>
<pub-id pub-id-type="pmid">10625078</pub-id>
</element-citation>
</ref>
<ref id="B201-ijms-21-00119">
<label>201.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Labbé</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Niaudet</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Loirat</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Charbit</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Guest</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Baudouin</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>In vivo confocal microscopy and anterior segment optical coherence tomography analysis of the cornea in nephropathic cystinosis</article-title>
<source/>Ophthalmology
          <year>2009</year>
<volume>116</volume>
<fpage>870</fpage>
<lpage>876</lpage>
<pub-id pub-id-type="doi">10.1016/j.ophtha.2008.11.021</pub-id>
<pub-id pub-id-type="pmid">19410944</pub-id>
</element-citation>
</ref>
<ref id="B202-ijms-21-00119">
<label>202.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Emma</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Nesterova</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Langman</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Labbé</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cherqui</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Goodyer</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Janssen</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Greco</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Topaloglu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Elenberg</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Nephropathic cystinosis: An international consensus document</article-title>
<source/>Nephrol. Dial. Transplant.
          <year>2014</year>
<volume>29</volume>
<issue>Suppl. 4</issue>
<fpage>iv87</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="doi">10.1093/ndt/gfu090</pub-id>
<pub-id pub-id-type="pmid">25165189</pub-id>
</element-citation>
</ref>
<ref id="B203-ijms-21-00119">
<label>203.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bäumner</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>L.T.</given-names>
</name>
</person-group>
<article-title>Nephropathic Cystinosis: Symptoms, Treatment, and Perspectives of a Systemic Disease</article-title>
<source/>Front. Pediatr.
          <year>2018</year>
<volume>6</volume>
<fpage>58</fpage>
<pub-id pub-id-type="doi">10.3389/fped.2018.00058</pub-id>
<pub-id pub-id-type="pmid">29594088</pub-id>
</element-citation>
</ref>
<ref id="B204-ijms-21-00119">
<label>204.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Servais</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Saitovitch</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hummel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Boisgontier</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Scemla</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sberro-Soussan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Snanoudj</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lemaitre</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Legendre</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pontoizeau</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Central nervous system complications in adult cystinosis patients</article-title>
<source/>J. Inherit. Metab. Dis.
          <year>2019</year>
<fpage>1</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1002/jimd.12164</pub-id>
</element-citation>
</ref>
<ref id="B205-ijms-21-00119">
<label>205.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harrison</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Yeagy</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Rocca</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Kohn</surname>
<given-names>D.B.</given-names>
</name>
<name>
<surname>Salomon</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Cherqui</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Hematopoietic stem cell gene therapy for the multisystemic lysosomal storage disorder cystinosis</article-title>
<source/>Mol. Ther.
          <year>2013</year>
<volume>21</volume>
<fpage>433</fpage>
<lpage>444</lpage>
<pub-id pub-id-type="doi">10.1038/mt.2012.214</pub-id>
<pub-id pub-id-type="pmid">23089735</pub-id>
</element-citation>
</ref>
<ref id="B206-ijms-21-00119">
<label>206.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cascio</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.F.</given-names>
</name>
<name>
<surname>Pauly</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Srikanth</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Skinner</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Stevenson</surname>
<given-names>R.E.</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Boccuto</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Abnormalities in the genes that encode large amino acid transporters increase the risk of autism spectrum disorder</article-title>
<source/>Mol. Genet. Genomic. Med.
          <year>2019</year>
<fpage>e1036</fpage>
<pub-id pub-id-type="doi">10.1002/mgg3.1036</pub-id>
<pub-id pub-id-type="pmid">31701662</pub-id>
</element-citation>
</ref>
<ref id="B207-ijms-21-00119">
<label>207.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Bergeron</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Scriver</surname>
<given-names>C.R.</given-names>
</name>
</person-group>
<article-title>Mechanisms of aminoaciduria</article-title>
<source/>The Kidney: Physiology and Pathophysiology
          <person-group person-group-type="editor">
<name>
<surname>Seldin</surname>
<given-names>D.W.</given-names>
</name>
<name>
<surname>Giebisch</surname>
<given-names>G.</given-names>
</name>
</person-group>
<publisher-name>Raven Press</publisher-name>
<publisher-loc>New York, NY, USA</publisher-loc>
<year>1985</year>
</element-citation>
</ref>
<ref id="B208-ijms-21-00119">
<label>208.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kihara</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Valente</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Fluharty</surname>
<given-names>A.L.</given-names>
</name>
</person-group>
<article-title>Hyperdibasicaminoaciduria in a mentally retarded homozygote with a peculiar response to phenothiazines</article-title>
<source/>Pediatrics
          <year>1973</year>
<volume>51</volume>
<fpage>223</fpage>
<lpage>229</lpage>
<pub-id pub-id-type="pmid">4144453</pub-id>
</element-citation>
</ref>
<ref id="B209-ijms-21-00119">
<label>209.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Whelan</surname>
<given-names>D.T.</given-names>
</name>
<name>
<surname>Scriver</surname>
<given-names>C.R.</given-names>
</name>
</person-group>
<article-title>Hyperdibasicaminoaciduria: An inherited disorder of amino acid transport</article-title>
<source/>Pediat. Res.
          <year>1968</year>
<volume>2</volume>
<fpage>525</fpage>
<lpage>534</lpage>
<pub-id pub-id-type="doi">10.1203/00006450-196811000-00011</pub-id>
<pub-id pub-id-type="pmid">5727921</pub-id>
</element-citation>
</ref>
<ref id="B210-ijms-21-00119">
<label>210.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santarelli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>K.V.</given-names>
</name>
<name>
<surname>Labermaier</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Uribe</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dournes</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Balsevich</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hartmann</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Masana</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Holsboer</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>SLC6A15, a novel stress vulnerability candidate, modulates anxiety and depressive-like behavior: Involvement of the glutamatergic system</article-title>
<source/>Stress
          <year>2016</year>
<volume>19</volume>
<fpage>83</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="doi">10.3109/10253890.2015.1105211</pub-id>
<pub-id pub-id-type="pmid">26585320</pub-id>
</element-citation>
</ref>
<ref id="B211-ijms-21-00119">
<label>211.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santarelli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Namendorf</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Anderzhanova</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Gerlach</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bedenk</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kaltwasser</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Labermaier</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Reichel</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Drgonova</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The amino acid transporter SLC6A15 is a regulator of hippocampal neurochemistry and behavior</article-title>
<source/>J. Psychiatr. Res.
          <year>2015</year>
<volume>68</volume>
<fpage>261</fpage>
<lpage>269</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychires.2015.07.012</pub-id>
<pub-id pub-id-type="pmid">26228428</pub-id>
</element-citation>
</ref>
<ref id="B212-ijms-21-00119">
<label>212.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knöpfel</surname>
<given-names>E.B.</given-names>
</name>
<name>
<surname>Vilches</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Camargo</surname>
<given-names>S.M.R.</given-names>
</name>
<name>
<surname>Errasti-Murugarren</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Stäubli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mayayo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Munier</surname>
<given-names>F.L.</given-names>
</name>
<name>
<surname>Miroshnikova</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Poncet</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Junza</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Dysfunctional LAT2 Amino Acid Transporter Is Associated with Cataract in Mouse and Humans</article-title>
<source/>Front. Physiol.
          <year>2019</year>
<volume>10</volume>
<fpage>688</fpage>
<pub-id pub-id-type="doi">10.3389/fphys.2019.00688</pub-id>
<pub-id pub-id-type="pmid">31231240</pub-id>
</element-citation>
</ref>
<ref id="B213-ijms-21-00119">
<label>213.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vilches</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Boiadjieva-Knöpfel</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bodoy</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Camargo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>López de Heredia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Prat</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ormazabal</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Artuch</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zorzano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Verrey</surname>
<given-names>F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cooperation of Antiporter LAT2/CD98hc with Uniporter TAT1 for Renal Reabsorption of Neutral Amino Acids</article-title>
<source/>J. Am. Soc. Nephrol.
          <year>2018</year>
<volume>29</volume>
<fpage>1624</fpage>
<lpage>1635</lpage>
<pub-id pub-id-type="doi">10.1681/ASN.2017111205</pub-id>
<pub-id pub-id-type="pmid">29610403</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<table-wrap id="ijms-21-00119-t001" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-21-00119-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>Amino acid transporters included in this review, their function, and involvement in inherited metabolic disease.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">SLC</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Substrate(s)</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Function</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Associated Inherited Metabolic Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC1A1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Glu, Asp, Cys</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System XAG</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Dicarboxylic aminoaciduria </td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC1A2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Glu, Asp</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System XAG</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Early infantile epileptic encephalopathy</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC1A3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Glu, Asp</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System XAG</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Episodic ataxia type 6</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC1A4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Glu, neutral AA</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System ASC</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Spastic tetraplegia, thin corpus callosum, and progressive microcephaly</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC1A5</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Neutral AA</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System ASC</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC1A6</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Glu, Asp</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System XAG</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC1A7</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Glu, Asp</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System XAG</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC3A1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cys, dibasic, and neutral AA</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Heavy chains of heterodimeric AAT</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cystinuria</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC3A2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Dibasic and neutral AA</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Heavy chains of heterodimeric AAT</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC6A5</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gly</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gly transporter</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hyperekplexia 3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC6A6</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Tau</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Tau transporter</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Retinal dystrophy</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC6A7</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Pro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Pro transporter</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC6A9</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gly</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gly transporter</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Glycine encephalopathy with normal serum glycine</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC6A14</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cationic and neutral AA</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System B<sup>0,+</sup></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC6A15</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Pro, Met, BCAAs</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System B<sup>0</sup></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC6A17</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Pro, Gly, Leu, Ala, Glu</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System B<sup>0</sup></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mental retardation, autosomal recessive 48</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC6A18</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gly, Ala</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System Gly</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hyperglycinuria</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC6A19</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Neutral AA</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System B<sup>0</sup></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hartnup disorder, iminoglycinuria, hyperglycinuria</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC6A20</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Pro</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System IMINO</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Iminoglycinuria, hyperglycinuria</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC7A1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Lys, Arg, Orn</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System y<sup>+</sup></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC7A2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Lys, Arg, Orn</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System y<sup>+</sup></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC7A2-related argininemia </td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC7A3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Lys, Arg, Orn</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System y<sup>+</sup></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC7A4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cationic AA</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System y<sup>+</sup></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC7A5</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Leu, Hys, Met, Ile, Val, Phe, Tyr, Trp</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System L</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC7A6</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Lys, Arg, Orn, Hys, Met, Leu</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System y<sup>+</sup>L</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC7A7</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Lys, Arg, Orn, Hys, Met, Leu, Ala, Cys</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System y<sup>+</sup>L</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Lysinuric protein intolerance</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC7A8</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Neutral AA</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System L</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC7A9</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cys, dibasic and neutral AA</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System b<sup>0,+</sup></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cystinuria</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC7A10</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gly, Ala, Ser, Cys, Thr</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System ASC</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC7A11</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Glu, Asp, Cys</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System y<sup>+</sup></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC7A12</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gly, Ala, Ser, Cys, Thr</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System ASC</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC7A13</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Glu, Asp, Cys</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Glu/Asp/Cys transporter</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cystinuria</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC7A14</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Arg, Lys, Orn</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System C</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Retinitis pigmentosa 68</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC16A10</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Trp, Tyr, Phe</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System T</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC17A6</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Glu</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Vesicular Glu transporter</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC17A7</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Glu</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Vesicular Glu transporter</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC17A8</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Glu</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Vesicular Glu transporter</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Deafness, autosomal dominant 25</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC25A2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Lys, Arg, Hys, Orn, Cit, ADMA</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Orn/Cit carrier</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC25A12</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Asp, Glu</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Asp/Glu carrier</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Early infantile epileptic encephalopathy, 39</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC25A13</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Asp, Glu</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Asp/Glu carrier</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AGC2 deficiency</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC25A15</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Lys, Arg, Hys, Orn, Cit</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Orn/Cit carrier</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hyperornithinemia-hyperammonemia- homocitrullinuria (HHH) syndrome</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC25A18</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Glu</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Glu carrier</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC25A22</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Glu</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Glu carrier</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Early infantile epileptic encephalopathy, 3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC25A29</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Arg, Lys, Orn, Hys</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Basic AA transporter</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC32A1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gly, GABA</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Vesicular Gly/GABA transporter</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC36A1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gly, Pro, Ala</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Proton AA symporter</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC36A2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gly, Pro, Ala</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Proton AA symporter</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Iminoglycinuria, hyperglycinuria</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC36A3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gly, Pro, Ala?</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Proton AA symporter</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC36A4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Pro, Trp, Ala</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Proton AA symporter</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC38A1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gly, Alan, Ser, Cys, Gln, Asn, Hys, Met, Thr, Pro, Tyr, Val</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC38A2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gly, Pro, Ala, Ser, Cys, Gln, Asn, Hys, Met</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC38A3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gly, Pro, Ala, Ser, Cys, Gln, Met, Hys, Lys, Arg</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System N</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC38A4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gly, Ala, Ser, Cys, Gln, Asn, Met</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC38A5</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gln, Asn, Hys, Ala</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System N</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC38A7</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gln, Ala, Hys, Asn, Ser</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System N</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC38A8</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gln, Ala, Arg, Hys, Asp</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Foveal hypoplasia, 2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC38A9</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gln</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Lysosomal Gln transceptor</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC38A10</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gln, Ala, Glu, Asp, Ser</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC43A1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Leu, Ile, Met, Phe, Val</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System L</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC43A2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Leu, Ile, Met, Phe, Val</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">System L</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC66A4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cys and cystathionine</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Lysosomal Cys transporter</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cystinosis</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="ijms-21-00119-t002" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-21-00119-t002_Table 2</object-id>
<label>Table 2</label>
<caption>
<p>Amino acid transporters with associated inherited metabolic disease: name of the amino acid transporter, gene/locus, location, phenotype MIM number, inheritance, and main clinical manifestations.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Amino Acid Transporter</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Gene/Locus</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Location</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Associated Inherited Metabolic Disease</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Phenotype MIM Number</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Inheritance</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Clinical Manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">EAAT3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>SLC1A1</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">9p24.2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Dicarboxylic aminoaciduria</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">222730</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AR</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Possibly benign in most cases. Associated with OCD and schizophrenia</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">EAAT2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>SLC1A2</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">11p13</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Early infantile epileptic encephalopathy</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">617105</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AR/AD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Severe early-onset epileptic encephalopathy</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">EAAT1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>SLC1A3</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">5p13.2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Episodic ataxia type 6</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">612656</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Episodic ataxia, seizures, migraine, alternating hemiplegia</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ASCT1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>SLC1A4</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2p14</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Spastic tetraplegia, thin corpus callosum, and progressive microcephaly</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">616657</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AR</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Spastic tetraplegia, thin corpus callosum, and progressive microcephaly</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rBAT</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>SLC3A1</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2p21</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cystinuria</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">220100</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AR/AD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cystine stones</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">GLYT2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>SLC6A5</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">11p15.1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hyperekplexia 3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">614618</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AR/AD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Startle reflex, generalized muscle stiffness, sudden infant death</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">TAUT</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>SLC6A6</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3p25.1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Retinal dystrophy</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">-</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AR</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Early-onset atypical panretinal degeneration</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">GLYT1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>SLC6A9</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1p34.1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Glycine encephalopathy with normal serum glycine</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">617301</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AR</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Early-onset encephalopathy with severe hypotonia, dysmorphic features, and abnormal antenatal findings</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">NTT4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>SLC6A17</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1p13.3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mental retardation, autosomal recessive 48</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">616269</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AR</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Intellectual disability with progressive tremor, speech impairment, facial dysmorphism, and behavioral problems</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">B<sup>0</sup>AT1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>SLC6A19</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">5p.15.33</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hartnup disorder<break></break><break></break><break></break><break></break>Hyperglycinuria<break></break>Iminoglycinuria</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">234500<break></break><break></break><break></break><break></break>138500<break></break>242600</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AR<break></break><break></break><break></break><break></break>AD<break></break>AR/AD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Pellagra-like dermatitis, intermittent cerebellar ataxia, neuropsychiatric symptoms<break></break>Possibly benign<break></break>Possibly benign</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SIT1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>SLC6A20</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3p21.31</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Iminoglycinuria<break></break>Hyperglycinuria</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">242600<break></break>138500</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AR/AD<break></break>AD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Possibly benign<break></break>Possibly benign</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">CAT-2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>SLC7A2</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">8p22</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Argininemia SLC7A2-related</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">-</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AR</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Unknown</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">y<sup>+</sup>LAT1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>SLC7A7</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">14q11.2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Lysinuric protein intolerance</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">222700</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AR</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hyperammonemia, protein intolerance, growth failure, renal disease, lung disease, immunological alterations</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">b<sup>0,+</sup> AT</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>SLC7A9</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">19q13.11</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cystinuria</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">220100</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AR/AD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cystine stones</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC7A14</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>SLC7A14</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3q26.2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Retinitis pigmentosa 68</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">615725</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AR</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Retinitis pigmentosa/Leber congenital amaurosis</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">VGLUT3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>SLC17A8</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">12q23.1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Deafness, autosomal dominant 25</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">605583</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Slowly progressive high frequency sensorineural hearing loss</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AGC1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>SLC25A12</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2q31.1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Early infantile epileptic encephalopathy, 39</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">612949</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AR</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Progressive encephalopathy, hypotonia, microcephaly, myoclonic epilepsy </td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AGC2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>SLC25A13</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">7q21.3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Neonatal intrahepatic cholestasis Citrullinemia type II</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">605814<break></break><break></break>603471</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AR</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Neonatal intrahepatic cholestasis with persistent jaundice<break></break>Neuropsychiatric symptoms, ammonia intoxication</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ORC1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>SLC25A15</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">13q14.11</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hyperornithinemia-hyperammonemia- homocitrullinuria syndrome</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">238970</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AR</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Episodic hyperammonemia and neurological symptoms</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">GC1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>SLC25A22</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">11p15.5</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Early infantile epileptic encephalopathy, 3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">609304</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AR</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Myoclonic epilepsy, progressive microcephaly, hypotonia</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">PAT2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>SLC36A2</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">5q33.1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">IminoglycinuriaHyperglycinuria</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">242600<break></break>138500</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AR/ADAD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Possibly benignPossibly benign</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SNAT8</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>SLC38A8</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">16q23.3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Foveal hypoplasia, 2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">609218</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AR</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Low vision, secondary nystagmus</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">CTNS</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>SLC66A4 (CTNS)</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">17p13.2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cystinosis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">219800<break></break>219900<break></break>219750</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AR</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Fanconi syndrome, photophobia, neurological deterioration</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>